INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (1, 'rs10306114', 'PTGS1 (PA24346)', '2B', 'Efficacy', 'aspirin (PA448497)', 'Cardiovascular', 'Coronary Artery Disease (PA443796),"Myocardial Infarction (PA445019)"', '"AA:Patients with the AA genotype who are treated with aspirin may have a decreased, but not absent, risk for non-response to aspirin as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient''s response to aspirin.,"AG:Patients with the AG genotype who are treated with aspirin may have an increased risk for non-response to aspirin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient''s response to aspirin.","GG:Patients with the GG genotype who are treated with aspirin may have an increased risk for non-response to aspirin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient''s response to aspirin."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (2, 'rs1041983', 'NAT2 (PA18)', '2A', 'Toxicity/ADR', 'ethambutol (PA164784021),"isoniazid (PA450112)","pyrazinamide (PA451182)","rifampin (PA451250)"', 'Pulmonology', 'Tuberculosis (PA445941)', '"CC:Patients with the CC genotype and tuberculosis (TB) may have a decreased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the CT genotype. Other genetic and clinical factors may also influence risk for hepatotoxicity.,"CT:Patients with the CT genotype and tuberculosis (TB) may have a decreased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the TT genotype, or an increased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for hepatotoxicity.","TT:Patients with the TT genotype and tuberculosis (TB) may have an increased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for hepatotoxicity."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (3, 'rs1042522', 'TP53 (PA36679)', '2B', 'Efficacy,"Toxicity/ADR"', 'antineoplastic agents (PA452621)', 'Oncology', 'Neoplasms (PA445062)', '"CC:Patients with the CC genotype may have 1) decreased but not absent risk for toxicity 2) increased response when treated with antineoplastic agents as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patient''s response to antineoplastic agents.,"CG:Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased response when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient''s response to antineoplastic agents.","GG:Patients with the GG genotype may have 1) increased risk for toxicity 2) decreased response when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient''s response to antineoplastic agents."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (4, 'rs1042713', 'ADRB2 (PA39)', '2A', 'Efficacy', 'salbutamol (PA448068),"salmeterol (PA451300)"', 'Pulmonology', 'Asthma (PA443450)', '"AA:Children with the AA genotype with asthma who are treated with salmeterol or salbutamol may have a decreased response to treatment (as measured by increased risk of asthma excerbations and lower quality of life scores) as compared to children with the GG genotype. This association does not seem to apply to lung function measurements such as peak expiratory flow rate or FEV1. Other genetic and clinical factors may also influence a patient''s response to treatment. ,"AG:Children with the AG genotype with asthma who are treated with salmeterol or salbutamol may have a decreased response to treatment (as measured by increased risk of asthma excerbations and lower quality of life scores) as compared to children with the GG genotype or may have a better response to treatment (as measured by increased risk of asthma excerbations and lower quality of life scores) as compared to patients with the AA genotype. This association does not seem to apply to lung function measurements such as peak expiratory flow rate or FEV1. Other genetic and clinical factors may also influence a patient''s response to treatment. ","GG:Children with the GG genotype with asthma who are treated with salmeterol or salbutamol may have a better response to treatment (as measured by a decreased risk of asthma excerbations and higher quality of life scores) as compared to children with the AA genotype. This association does not seem to apply to lung function measurements. This association does not seem to apply to lung function measurements such as peak expiratory flow rate or FEV1. Other genetic and clinical factors may also influence a patient''s response to treatment. "');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (5, 'rs10455872', 'LPA (PA30432)', '2B', 'Efficacy,"Toxicity/ADR"', 'hmg coa reductase inhibitors (PA133950441)', 'Cardiovascular', 'Coronary Artery Disease (PA443796)', '"AA:Patients with the AA genotype may have an improved response to hmg coa reductase inhibitors and a decreased risk of coronary artery disease as compared to patients with the AG and GG genotypes. Other clinical and genetic factors may also influence response to hmg coa reductase inhibitors. ,"AG:Patients with the AG genotype may have an improved response to hmg coa reductase inhibitors and a decreased risk of coronary artery disease as compared to patients with the GG genotypes and a decreased response to hmg coa reductase inhibitors and increased risk of coronary artery disease as compared to patients with the AA genotype. Other clinical and genetic factors may also influence response to hmg coa reductase inhibitors. ","GG:Patients with the GG genotype may have a worse response to hmg coa reductase inhibitors and an increased risk of coronary artery disease as compared to patients with the AG and AA genotypes. However, in one study the GG genotype was associated with worse response to rosuvastatin as compared to the AA genotype (not AG). Other clinical and genetic factors may also influence response to hmg coa reductase inhibitors. "');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (6, 'rs1045642', 'ABCB1 (PA267)', '2A', 'Efficacy', 'ondansetron (PA450705)', 'Drug Response effects/ toxicity', '', '"AA:Patients with genotype AA may have decreased likelihood of nausea and vomiting shortly after being treated with ondansetron as compared to patients with genotype AG or GG. Other genetic and clinical factors may also influence a patient''s response to ondansetron.,"AG:Patients with genotype AG may have increased likelihood of nausea and vomiting shortly after being treated with treated with ondansetron as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient''s response to ondansetron.","GG:Patients with genotype GG may have increased likelihood of nausea and vomiting shortly after being treated with treated with ondansetron as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient''s response to ondansetron."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (20, 'rs1057910', 'CYP2C9 (PA126)', '2A', 'Dosage', 'celecoxib (PA448871)', 'variant implication on drug metabolism', '', '"AA:Patients with the AA (CYP2C9 *1/*1) genotype may have increased metabolism of celecoxib as compared to patients with the AC or CC (*1/*3 or *3/*3) genotype. Other genetic and clinical factors may also influence a metabolism of celecoxib. ,"AC:Patients with the AC (CYP2C9 *1/*3) genotype may have reduced metabolism of celecoxib as compared to patients with the AA (*1/*1) genotype, and increased metabolism as compared to patients with the CC (*3/*3) genotype. Other genetic and clinical factors may also influence metabolism of celecoxib. ","CC:Patients with the CC (CYP2C9 *3/*3) genotype may have reduced metabolism of celecoxib as compared to patients with the AA or AC (*1/*1 or *1/*3) genotype. Other genetic and clinical factors may also influence metabolism of celecoxib. "');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (7, 'rs1045642', 'ABCB1 (PA267)', '2A', 'Toxicity/ADR', 'nevirapine (PA450616)', 'Infectious Diseases', 'HIV Infections (PA446213)', '"AA:Patients with the AA genotype and HIV-1 infection who are treated with nevirapine may have a decreased, but not absent, risk for nevirapine hepatotoxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient''s risk for hepatotoxicity with nevirapine treatment.,"AG:While patients with the AA genotype and HIV-1 infection who are treated with nevirapine may have a decreased, but not absent, risk for nevirapine hepatotoxicity as compared to patients with the GG genotype, it is not clear what the influence of one A allele with the G allele is. Other genetic and clinical factors may also influence a patient''s risk for hepatotoxicity with nevirapine treatment.","GG:Patients with the GG genotype and HIV-1 infection who are treated with nevirapine may have an increased risk for nevirapine hepatotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient''s risk for hepatotoxicity with nevirapine treatment."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (8, 'rs1045642', 'ABCB1 (PA267)', '2A', 'Other', 'digoxin (PA449319)', 'Drug Response effects/ toxicity', '', '"AA:Patients with AA genotype may have decreased metabolism and increased serum concentration of digoxin as compared to patients with the GG genotype. Other genetic and clinical factors may also impact the metabolism of digoxin.,"AG:Patients with AG genotype may have decreased metabolism and increased serum concentration of digoxin as compared to patients with the GG genotype. Other genetic and clinical factors may also impact the metabolism of digoxin.","GG:Patients with GG genotype may have increased metabolism and decreased serum concentration of digoxin as compared to patients with the AA genotype. Other genetic and clinical factors may also impact the metabolism of digoxin."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (9, 'rs1045642', 'ABCB1 (PA267)', '2A', 'Dosage,"Efficacy"', 'methotrexate (PA450428)', 'Oncology', 'Burkitt Lymphoma (PA443580),"Drug Toxicity (PA443937)","Lymphoma, T-Cell (PA446309)","Precursor Cell Lymphoblastic Leukemia-Lymphoma (PA446155)","Toxic liver disease (PA164925725)"', '"AA:Patients with the AA genotype and lymphoma or leukemia who are treated with methotrexate may have increased concentrations of the drug and may have an increased risk of toxicity as compared to patients with the GG genotype, although this is contradicted in some studies. Other genetic and clinical factors may also influence a patient''s risk of methotrexate-induced toxicities. ,"AG:Patients with the AG genotype and lymphoma or leukemia who are treated with methotrexate may have an increased risk of toxicity as compared to patients with the GG genotype, or a decreased risk of toxicity as compared to patients with the AA genotype, although this is contradicted in some studies. Other genetic and clinical factors may also influence a patient''s risk of methotrexate-induced toxicities. ","GG:Patients with the GG genotype and lymphoma or leukemia who are treated with methotrexate may have lower concentrations of the drug and may have a reduced, but not absent, risk of toxicity as compared to patients with the AA genotype, although this is contradicted in some studies. Other genetic and clinical factors may also influence a patient''s risk of methotrexate-induced toxicities. "');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (10, 'rs1045642', 'ABCB1 (PA267)', '2B', '', 'fentanyl (PA449599),"methadone (PA450401)","morphine (PA450550)","opioids (PA452618)","oxycodone (PA450741)","tramadol (PA451735)"', 'Pain Medicine', 'Pain (PA445208),"Pain, Postoperative (PA445210)"', '"AA:Patients with the AA genotype may experience improved efficacy of opioids and may require a decreased dose as compared to patients with the GG and possiblly AG genotypes, although this is contradicted in most studies, which report no association between the allele with dose or efficacy of opioids for pain. Other genetic and clinical factors may also influence a dose and efficacy of opioids for pain.,"AG:Patients with the AG genotype may experience improved efficacy of opioids and may require a decreased dose as compared to patients with the GG genotypes, although this is contradicted in most studies, which report no association between the allele with dose or efficacy of opioids for pain. Other genetic and clinical factors may also influence a dose and efficacy of opioids for pain.","GG:Patients with the GG genotype may experience decreased efficacy of opioids and may require an increased dose as compared to patients with the AA and possibly AG genotypes, although this is contradicted in most studies, which report no association between the allele with dose or efficacy of opioids for pain. Other genetic and clinical factors may also influence a dose and efficacy of opioids for pain."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (11, 'rs10497203', 'TANC1 (PA142670838)', '2B', 'Toxicity/ADR', 'radiotherapy (PA166122986)', 'Oncology', 'Prostatic Neoplasms (PA445425)', '"AA:Patients with the AA genotype and prostate cancer who are treated with radiotherapy may have a reduced risk of late stage toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient''s risk of radiotherapy-induced toxicity. ,"AC:Patients with the AC genotype and prostate cancer who are treated with radiotherapy may have an increased risk of late stage toxicity as compared to patients with the AA genotype, or may have a reduced risk of late stage toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient''s risk of radiotherapy-induced toxicity. ","CC:Patients with the CC genotype and prostate cancer who are treated with radiotherapy may have an increased risk of late stage toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient''s risk of radiotherapy-induced toxicity. "');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (12, 'rs1050828', 'G6PD (PA28469)', '1B', 'Toxicity/ADR', 'chlorproguanil (PA165857067),"dapsone (PA449211)"', 'Infectious Diseases', 'Malaria (PA444859)', '"CC:Patients with the CC genotype with Malaria who are treated with artesunate, chlorproguanil and dapsone may have 1) a decreased, but not absent, risk of hemolysis and severe/ unsafe hemoglobin decreases 2) decreased, but not absent, risk of requiring a blood transfusion as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient''s response to artesunate, chlorproguanil and dapsone.,"CT:Patients with the CT genotype with Malaria who are treated with artesunate, chlorproguanil and dapsone may have an increased risk of requiring a blood transfusion as compared to patients with the CC genotype. This association was contradicted in another study showing no association of the CT genotype with increased risk of unsafe hemoglobin decreases or requirement for a blood transfusion when treated with artesunate, chlorproguanil and dapsone compared to to patients with the CC genotype. Other genetic and clinical factors may also influence a patient''s response to artesunate, chlorproguanil and dapsone.","TT:Patients with the TT genotype with Malaria who are treated with artesunate, chlorproguanil and dapsone may have 1) an increased risk of hemolysis and severe/ unsafe hemoglobin decreases 2) an increased risk of requiring a blood transfusion as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient''s response to artesunate, chlorproguanil and dapsone."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (13, 'rs10509681', 'CYP2C8 (PA125)', '2A', 'Metabolism/PK', 'rosiglitazone (PA451283)', 'variant implication on drug metabolism', '', '"CC:Patients with the CC genotype (CYP2C8*3/*3) may have increased metabolism of rosiglitazone, a smaller change in HbA1c, and a decreased risk of edema as compared to patients with the TT genotype (CYP2C8*1/*1). One study found no association with blood glucose levels. Other genetic and clinical factors may also influence metabolism of rosiglitazone, risk of edema and blood glucose levels.,"CT:Patients with the CT (CYP2C8*3/*1) genotype may have increased metabolism of rosiglitazone and a decreased risk of edema compared to patients with the TT genotype (CYP2C8*1/*1). No association was found when considering blood glucose levels. Other genetic and clinical factors may also influence metabolism of rosiglitazone, risk of edema and blood glucose levels.","TT:Patients with the TT (CYP2C8*1/*1) genotype may have decreased metabolism of rosiglitazone, a larger change in HbA1c, and an increased risk of edema as compared to patients with the CC (CYP2C8*3/*3) or CT (CYP2C8*3/*1) genotype. One study found no association with blood glucose levels. Other genetic and clinical factors may also influence metabolism of rosiglitazone, risk of edema and blood glucose levels."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (14, 'rs1051730', 'CHRNA3 (PA113)', '2B', 'Toxicity/ADR', 'nicotine (PA450626)', 'Drug Response effects/ toxicity', '', '"AA:Patients with the AA genotype may have an increased risk for nicotine dependency, decreased lung function when exposed to nicotine, but may experience an increased chance of achieving 6 month abstinence if prescribed nicotine replacement therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient''s response to nicotine.,"AG:Patients with the AG genotype may have an increased risk for nicotine dependency, decreased lung function when exposed to nicotine, but may experience an increased chance of achieving 6 month abstinence if prescribed nicotine replacement therapy as compared to patients with the GG genotype or a decreased risk for nicotine dependency and decreased chance of achieving 6 month abstinence if prescribed nicotine replacement therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient''s response to nicotine.","GG:Patients with the GG genotype may have an decreased risk for nicotine dependency, increased lung function when exposed to nicotine, but may experience decreased chance of achieving 6 month abstinence if prescribed nicotine replacement therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient''s response to nicotine."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (15, 'rs1051740', 'EPHX1 (PA27829)', '2B', 'Dosage', 'carbamazepine (PA448785)', 'Neurology', 'Epilepsy (PA444065)', '"CC:Patients with the CC genotype and Epilepsy may have higher metabolism of carbamazepine and may require an increased dose of carbamazepine as compared to patients with the the CT or TT genotypes, although this is contradicted in some studies. Other genetic and clinical factors may also influence metabolism and dose of carbamazepine.,"CT:Patients with the CT genotype and Epilepsy may have higher metabolism of carbamazepine and may require an increased dose of carbamazepine as compared to patients with the the TT genotype, although this is contradicted in some studies. Other genetic and clinical factors may also influence metabolism and dose of carbamazepine.","TT:Patients with the TT genotype and Epilepsy may have lower metabolism of carbamazepine and may require a decreased dose of carbamazepine as compared to patients with the the CC or CT genotypes, although this is contradicted in some studies. Other genetic and clinical factors may also influence metabolism and dose of carbamazepine."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (16, 'rs1056892', 'CBR3 (PA26122)', '2B', 'Toxicity/ADR', 'anthracyclines and related substances (PA130620651)', 'Cardiovascular; Oncology', 'Heart Failure (PA444370),"Neoplasms (PA445062)"', '"AA:Patients with the AA genotype may have decreased risk of cardiac damage after anthracycline exposure as compared to patients with the GG genotype. Patients with the AA genotype may still be at risk for adverse events when exposed to anthracyclines based on their genotype. Other genetic and clinical factors may also influence a patient''s risk for adverse events.,"AG:Patients with the AG genotype may have increased risk of cardiac damage after anthracycline exposure as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient''s risk for adverse events.","GG:Patients with the GG genotype may have increased risk of cardiac damage after anthracycline exposure as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient''s risk for adverse events."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (17, 'rs1057910', 'CYP2C9 (PA126)', '2A', 'Toxicity/ADR', 'Antiinflammatory agents, non-steroids (PA164712462),"celecoxib (PA448871)","diclofenac (PA449293)"', 'Drug Response effects/ toxicity', '', '"AA:Patients with the AA genotype who are treated with non-steroid antiinflammatory agents, celecoxib or diclofenac may have a decreased, but not absent, risk of gastrointestinal bleeding as compared to patients with the AC and CC genotype. Other genetic and clinical factors may also influence a patient''s response to Antiinflammatory agents, non-steroids, celecoxib or diclofenac.,"AC:Patients with the AC genotype who are treated with non-steroids antiinflammatory agents, celecoxib or diclofenac may have an increased risk of gastrointestinal bleeding as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient''s response to Antiinflammatory agents, non-steroids, celecoxib or diclofenac.","CC:Patients with the CC genotype who are treated with non-steroids antiinflammatory agents, celecoxib or diclofenac may have an increased risk of gastrointestinal bleeding as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient''s response to Antiinflammatory agents, non-steroids, celecoxib or diclofenac."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (18, 'rs1057910', 'CYP2C9 (PA126)', '2A', 'Dosage,"Toxicity/ADR"', 'acenocoumarol (PA452632)', 'variant implication on Dosing', '', '"AA:Patients with the AA genotype may require increased dose of acenocoumarol as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence acenocoumarol dose.,"AC:Patients with the AC genotype may require decreased dose of acenocoumarol or closer INR monitoring as compared to patients with the AA genotype. Other genetic and clinical factors may also influence acenocoumarol dose.","CC:Patients with the CC genotype may require decreased dose of acenocoumarol or closer INR monitoring as compared to patients with the AA genotype. Other genetic and clinical factors may also influence acenocoumarol dose."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (19, 'rs1057910', 'CYP2C9 (PA126)', '1A', 'Dosage', 'warfarin (PA451906)', 'variant implication on Dosing', '', '"AA:Patients with the AA genotype may require an increased dose of warfarin as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient''s risk for adverse events.,"AC:Patients with the AC genotype may require a decreased dose of warfarin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient''s risk for adverse events.","CC:Patients with the CC genotype may require a decreased dose of warfarin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient''s risk for adverse events."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (21, 'rs1057910', 'CYP2C9 (PA126)', '2A', 'Toxicity/ADR', 'acenocoumarol (PA452632),"warfarin (PA451906)"', 'Hematology', 'Hemorrhage (PA444417)', '"AA:The AA (CYP2C9 *1/*1) genotype may be associated with a decreased risk of hemorrhage when treated with acenocoumarol or warfarin as compared to the CC or AC genotypes, although this is contradicted in most studies. Other clinical and genetic factors may also influence risk of hemorrhage in patients treated with acenocoumarol or warfarin. ,"AC:The AC (CYP2C9 *1/*3) genotype may be associated with a decreased risk of hemorrhage when treated with acenocoumarol or warfarin as compared to the CC and an increased risk as compared to the AA genotype, although this is contradicted in most studies. Other clinical and genetic factors may also influence risk of hemorrhage in patients treated with acenocoumarol or warfarin. ","CC:The CC (CYP2C9 *3/*3) genotype may be associated with an increased risk of hemorrhage when treated with acenocoumarol or warfarin as compared to the AA or AC genotypes, although this may be contradicted in most studies. Other clinical and genetic factors may also influence risk of hemorrhage in patients treated with acenocoumarol or warfarin. "');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (22, 'rs1076560', 'DRD2 (PA27478)', '2B', 'Toxicity/ADR', 'cocaine (PA449072)', 'Psychiatry', 'Cocaine-Related Disorders (PA446878)', '"AA:Patients with the AA genotype who abused cocaine may have an increased risk of death from cocaine intoxication as compared to patients with the CC genotype. Other genetic and clinical factors may also influence cocaine-related death.,"AC:Patients with the AC genotype who abused cocaine may have an increased risk of death from cocaine intoxication as compared to patients with the CC genotype, or a decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence cocaine-related death.","CC:Patients with the CC genotype who abused cocaine may have a decreased risk of death from cocaine intoxication as compared to patients with the AA genotype. Other genetic and clinical factors may also influence cocaine-related death."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (23, 'rs11045879', 'SLCO1B1 (PA134865839)', '2A', 'Toxicity/ADR', 'methotrexate (PA450428)', 'Oncology', 'Precursor Cell Lymphoblastic Leukemia-Lymphoma (PA446155)', '"CC:Patients with the CC genotype and precursor cell lymphoblastic leukemia-lymphoma who are treated with methotrexate: 1) may have decreased clearance of methotrexate as compared to patients with the CT or TT genotype 2) may have a decreased, but not absent, risk for GI toxicity as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient''s risk for GI toxicity when treated with methotrexate.,"CT:Patients with the CT genotype and precursor cell lymphoblastic leukemia-lymphoma who are treated with methotrexate: 1) may have increased clearance of methotrexate as compared to patients with the CC genotype and decreased clearance as compared to the TT genotype 2) may have an increased risk for GI toxicity when treated with methotrexate as compared to patients with the CC genotype and decreased risk as compared to the TT genotype.","TT:Patients with the TT genotype and precursor cell lymphoblastic leukemia-lymphoma who are treated with methotrexate: 1) may have increased clearance of methotrexate as compared to patients with the CC or CT genotype 2) may have an increased risk for GI toxicity when treated with methotrexate as compared to patients with the CC or CT genotype."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (24, 'rs111888148', 'RYR1 (PA34896)', '1A', 'Toxicity/ADR', 'desflurane (PA164749136),"enflurane (PA449461)","halothane (PA449845)","isoflurane (PA450106)","methoxyflurane (PA450434)","sevoflurane (PA451341)","succinylcholine (PA451522)"', 'Pharmacogenetic disorder', 'Malignant Hyperthermia (PA444863)', '"AA:Patients with the AA genotype may develop Malignant Hyperthermia (MH) when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG. Please note: the A allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes therefore the phenotype of an individual with AA genotype is not known. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).,"AG:Patients with the AG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG. Other genetic or clinical factors may also influence whether a patient develop Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).","GG:Patients with the GG genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype AG or AA. Other genetic or clinical factors may put a patient at risk for developing malignant hyperthermia."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (25, 'rs11212617', 'C11orf65 (PA144596484)', '2B', 'Efficacy', 'metformin (PA450395)', 'Metabolic disorder', 'Diabetes Mellitus, Type 2 (PA443890)', '"AA:Patients with the AA genotype with Diabetes Mellitus, Type 2 who are treated with metformin may have a decreased response to metformin as compared to patients with the CC genotype. An association with increased/decreased response to metformin was not seen in people with impaired glucose tolerance. Other genetic and clinical factors may also influence a patient''s response to metformin.,"AC:Patients with the AC genotype with Diabetes Mellitus, Type 2 who are treated with metformin may have an increased response to metformin as compared to patients with the AA genotype or may have a decreased response to metformin as compared to patients with the CC genotype. An association with increased/decreased response to metformin was not seen in people with impaired glucose tolerance. Other genetic and clinical factors may also influence a patient''s response to metformin.","CC:Patients with the CC genotype with Diabetes Mellitus, Type 2 who are treated with metformin may have an increased response to metformin as compared to patients with the AA genotype. An association with increased/decreased response to metformin was not seen in people with impaired glucose tolerance. Other genetic and clinical factors may also influence a patient''s response to metformin."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (26, 'rs112445441', 'KRAS (PA30196)', '2B', 'Dosage', 'cetuximab (PA10040),"panitumumab (PA162373091)"', 'Oncology', 'Colorectal Neoplasms (PA446108)', '"AC:Patients with colorectal cancer with the AC genotype (G13V) may have similar response when treated with cetuximab or panitumumab as compared to patients with the CC genotype (wild type KRAS") and improved response as compared to patients with other KRAS mutations although some studies did not observe this benefit and fewer studies have looked at this genotype as compared to CT (G13D). However current guidelines still recommend not using anti-EGFR treatments in these patients. Other genetic and clinical factors may also influence response to cetuximab or panitumumab.","CC:Patients with the colorectal cancer with the CC genotype ("wild type KRAS") and no other KRAS mutations may have increased response when treated with cetuximab or panitumumab as compared to patients with KRAS mutations although some studies suggest that the CT genotype at this locus has similar response to CC. Other genetic and clinical factors may also influence response to cetuximab or panitumumab.","CT:Patients with colorectal cancer with the CT genotype (G13D) may have similar response when treated with cetuximab or panitumumab as compared to patients with the CC genotype ("wild type KRAS") and improved response as compared to patients with other KRAS mutations although some studies did not observe this benefit. However current guidelines still recommend not using anti-EGFR treatments in these patients. Other genetic and clinical factors may also influence response to cetuximab or panitumumab."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (27, 'rs112563513', 'RYR1 (PA34896)', '1A', 'Toxicity/ADR', 'desflurane (PA164749136),"enflurane (PA449461)","halothane (PA449845)","isoflurane (PA450106)","methoxyflurane (PA450434)","sevoflurane (PA451341)","succinylcholine (PA451522)"', 'Pharmacogenetic disorder', 'Malignant Hyperthermia (PA444863)', '"AA:Patients with the AA genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the GG genotype. Please note: the A allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).,"AG:Patients with the AG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the GG genotype. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).","GG:Patients with the GG genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the AG or AA genotype. Other genetic or clinical factors may put a patient at risk for developing Malignant Hyperthermia."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (28, 'rs1127354', 'ITPA (PA29973)', '2B', 'Dosage', 'interferon alfa-2b, recombinant (PA164783990),"ribavirin (PA451241)"', 'Infectious Diseases', 'Hepatitis C, Chronic (PA446863)', '"AA:Patients with the AA genotype and chronic hepatitis C may not require a dose reduction of ribavirin when treated with recombinant interferon alfa-2b and ribavirin, or recombinant interferon alfa-2b, ribavirin and telaprevir, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient''s risk for response to ribavirin.,"AC:Patients with the AC genotype and chronic hepatitis C may not require a dose reduction or ribavirin when treated with recombinant interferon alfa-2b and ribavirin, or recombinant interferon alfa-2b, ribavirin and telaprevir, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient''s risk for response to ribavirin.","CC:Patients with the CC genotype and chronic hepatitis C may require a dose reduction of ribavirin when treated with recombinant interferon alfa-2b and ribavirin, or recombinant interferon alfa-2b, ribavirin and telaprevir, as compared to patients with the AC and AA genotype. Other genetic and clinical factors may also influence a patient''s risk for response to ribavirin."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (29, 'rs1127354', 'ITPA (PA29973)', '2B', 'Toxicity/ADR', 'peginterferon alfa-2b (PA164784024),"ribavirin (PA451241)"', 'Infectious Diseases', 'Hepatitis C, Chronic (PA446863)', '"AA:Patients with chronic hepatitis C and the AA genotype may have a decreased risk of anemia but an increased risk of thrombocytopenia when compared to patients with the CC genotype who are taking peg interferon alfa-2b and ribavirin. Other clinical and genetic factors may influence risk of anemia in patients with hepatitis C who are taking peg interferon alfa-2b and ribavirin.,"AC:Patients with chronic hepatitis C and the AC genotype may have a decreased risk of anemia but an increased risk of thrombocytopenia when compared to patients with the CC genotype who are taking peg interferon alfa-2b and ribavirin. Other clinical and genetic factors may influence risk of anemia in patients with hepatitis C who are taking peg interferon alfa-2b and ribavirin.","CC:Patients with chronic hepatitis C and the CC genotype, may have an increased risk of anemia but a decreased risk of thrombocytopenia as compared to patients with the AA or AC genotype who are taking peg interferon alfa-2b and ribavirin. Other clinical and genetic factors may influence risk of anemia in patients with hepatitis C who are taking peg interferon alfa-2b and ribavirin."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (30, 'rs113993958', 'CFTR (PA109)', '1A', 'Efficacy', 'ivacaftor (PA165950341)', 'Pulmonology', 'Cystic Fibrosis (PA443829)', '"CC:Patients with the CC genotype (two copies of the CFTR D110H variant) and cystic fibrosis may respond to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including D110H. Other genetic and clinical factors may also influence a patient''s response to ivacaftor.,"CG:Patients with the CG genotype (one copy of the CFTR D110H variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including D110H. Other genetic and clinical factors may also influence a patient''s response to ivacaftor.","GG:Patients with the GG genotype (do not have a copy of the CFTR D110H variant) and cystic fibrosis have an unknown response to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including D110H. Other genetic and clinical factors may also influence a patient''s response to ivacaftor."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (31, 'rs113993959', 'CFTR (PA109)', '2A', 'Efficacy', 'ataluren (PA166151864)', 'Pulmonology', 'Cystic Fibrosis (PA443829)', '"GG:Patients with the GG genotype and cystic fibrosis may not respond to treatment with ataluren. Randomized clinical trials did not find improvement in chloride transport or improved pulmonary function after 2 rounds of 2 weeks of treatment. Other genetic and clinical factors may also influence changes in chloride transport and improvement of pulmonary symptoms in patients with cystic fibrosis.,"GT:Patients with the GT genotype and cystic fibrosis may have increased response when treated with ataluren as compared to patients with the GG genotype. Randomized clinical trials found improvement in chloride transport, but did not find evidence for improved pulmonary function after 2 rounds of 2 weeks of treatment. Other genetic and clinical factors may also influence changes in chloride transport and improvement of pulmonary symptoms in patients with cystic fibrosis.","TT:Patients with the TT genotype and cystic fibrosis may have increased response when treated with ataluren as compared to patients with the GG genotype. Randomized clinical trials found improvement in chloride transport, but did not find evidence for improved pulmonary function after 2 weeks of treatment. Other genetic and clinical factors may also influence changes in chloride transport and improvement of pulmonary symptoms in patients with cystic fibrosis."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (37, 'rs11615', 'ERCC1 (PA155)', '2B', 'Efficacy,"Toxicity/ADR"', 'carboplatin (PA448803),"cisplatin (PA449014)","oxaliplatin (PA131285527)","platinum (PA150595617)","Platinum compounds (PA164713176)"', 'Oncology', 'Carcinoma, Non-Small-Cell Lung (PA443622),"Colorectal Neoplasms (PA446108)","Esophageal Neoplasms (PA444101)","Mesothelioma (PA444937)","Neoplasms (PA445062)","Ovarian Neoplasms (PA445204)","Pancreatic Neoplasms (PA445218)"', '"AA:Patients with the AA genotype may have 1) an increased risk for nephrotoxicity 2) decreased survival and 3) a poorer response when treated with platinum-based chemotherapy as compared to patients with the AG or GG genotype. However, some studies find no association with drug toxicity, and one study found a better response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient''s response to platinum-based chemotherapy.,"AG:Patients with the AG genotype who are treated with platinum-based chemotherapy may have an increased risk for nephrotoxicity as compared to patients with the GG genotype. The findings for response and overall survival are inconclusive. Patients with the AG genotype may have an increased response compared to patients with the AA genotype. However, another study showed an increased response compared to patients with the GG genotype. Additionally, some studies find no association with drug toxicity or survival. Other genetic and clinical factors may also influence a patient''s response to platinum-based chemotherapy.","GG:Patients with the GG genotype may have 1) decreased but not absent risk for toxicity, 2) increased survival and 3) a better response when treated with platinum-based chemotherapy as compared to patients with the AA or AG genotype. However, some studies find no association with drug toxicity, and one study found a poorer response as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient''s response to platinum-based chemotherapy."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (32, 'rs113993960', 'CFTR (PA109)', '1A', 'Efficacy', 'ivacaftor (PA165950341)', 'Pulmonology', 'Cystic Fibrosis (PA443829)', '"CTT/CTT:Indication of ivacaftor in cystic fibrosis patients with the CTT/CTT genotype (no copies of the CFTR F508del variant) is dependent on the presence of other variants within the CFTR gene. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants. Other genetic and clinical factors may also influence a patient''s response to ivacaftor. ,"CTT/del:Indication of ivacaftor in cystic fibrosis patients with the CTT/del genotype (one copy of the CFTR F508del variant) is dependent on the presence of other variants within the CFTR gene. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants. Other genetic and clinical factors may also influence a patient''s response to ivacaftor. ","del/del:Ivacaftor is not recommended in cystic fibrosis patients with the del/del genotype (two copies of the F508del variant). A clinical trial of ivacaftor in patients with the del/del genotype showed ivacaftor was ineffective in these patients, though this study was not powered to examine efficacy. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants. Other genetic and clinical factors may also influence a patient''s response to ivacaftor. "');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (33, 'rs113993960', 'CFTR (PA109)', '1B', 'Efficacy', 'ivacaftor / lumacaftor (PA166152935)', 'Pulmonology', 'Cystic Fibrosis (PA443829)', '"CTT/CTT:The CTT/CTT genotype (no copies of the CFTR F508del variant) is not an indication for the combination drug of ivacaftor plus lumacaftor in patients with cystic fibrosis. ,"CTT/del:Patients with cystic fibrosis and the CTT/del genotype (one copy of the CFTR F508del variant)may experience a limited benefit from treatment with the combination drug of ivacaftor plus lumacaftor, as shown by improvement in sweat chloride concentrations CFQ-R questionnaire scores when compared to treatment with placebo. However, ppFEV1, BMI or body weight did not show a significant improvement following ivacaftor/lumacaftor treatment. This genotype is not an indication for use of the combination drug of ivacaftor plus lumacaftor according to the FDA-approved drug label for this drug combination. Other genetic and clinical factors may also influence a patient''s response to the combination drug of ivacaftor plus lumacaftor. ","del/del:Patients with the del/del genotype (two copies of the F508del variant) may benefit from treatment with the combination drug of ivacaftor plus lumacaftor, as shown by improvement in sweat chloride concentrations and/or forced expiratory volume in 1 second (FEV1) when compared to treatment with placebo. This genotype is an indication for use of the combination drug of ivacaftor plus lumacaftor according to the FDA-approved drug label for this drug combination. Other genetic and clinical factors may also influence a patient''s response to the combination drug of ivacaftor plus lumacaftor. "');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (34, 'rs115545701', 'CFTR (PA109)', '1A', 'Efficacy', 'ivacaftor (PA165950341)', 'Pulmonology', 'Cystic Fibrosis (PA443829)', '"CC:Patients with the CC genotype (do not carry a copy of the CFTR R74W variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R74W. Other genetic and clinical factors may also influence a patient''s response to ivacaftor.,"CT:Patients with the CT genotype (one copy of the CFTR R74W variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R74W. Other genetic and clinical factors may also influence a patient''s response to ivacaftor.","TT:Patients with the TT genotype (two copies of the CFTR R74W variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R74W. Other genetic and clinical factors may also influence a patient''s response to ivacaftor."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (35, 'rs11568315', 'EGFR (PA7360)', '2B', 'Efficacy', 'gefitinib (PA131301952)', 'Oncology', 'Carcinoma, Non-Small-Cell Lung (PA443622)', '"(CA)16/(CA)16:Advanced non-small-cell lung cancer patients patients with (CA)16/(CA)16 + (CA)16/(CA)17 genotype are more likely to have better clinical response (increased response rate (RR), increased progression-free survival (PFS) and increased survival time) when treated with gefitinib as compared to patients with (CA)17/(CA)17 genotype. NOTE:The rs11568315 is (CA)n repeat in intron 1 of EGFR. 16 or fewer CA repeats were considered short, were combined together and named as (CA)16, and; 17 or more CA repeats were considered long, were combined together and named as (CA)17.,"(CA)16/(CA)17:Advanced non-small-cell lung cancer patients patients with (CA)16/(CA)16 + (CA)16/(CA)17 genotype are more likely to have better clinical response (increased response rate (RR), increased progression-free survival (PFS) and increased survival time) when treated with gefitinib as compared to patients with (CA)17/(CA)17 genotype. NOTE:The rs11568315 is (CA)n repeat in intron 1 of EGFR. 16 or fewer CA repeats were considered short, were combined together and named as (CA)16, and; 17 or more CA repeats were considered long, were combined together and named as (CA)17.","(CA)17/(CA)17:Advanced non-small-cell lung cancer patients patients with (CA)17/(CA)17 genotype are more likely to have worse clinical response (decreased response rate (RR), decreased progression-free survival (PFS) and decreased survival time) when treated with gefitinib as compared to (CA)16/(CA)16 + (CA)16/(CA)17 genotype. NOTE:The rs11568315 is (CA)n repeat in intron 1 of EGFR. 16 or fewer CA repeats were considered short, were combined together and named as (CA)16, and; 17 or more CA repeats were considered long, were combined together and named as (CA)17."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (36, 'rs11598702', 'NT5C2 (PA31801)', '2B', 'Other', 'gemcitabine (PA449748)', 'Oncology', 'Neoplasms (PA445062)', '"CC:Patients with the CC genotype may have increased clearance of gemcitabine as compared to patients with the TT genotype. Other genetic and clinical factors may also affect clearance of gemcitabine.,"CT:Patients with the CT genotype may have increased clearance of gemcitabine as compared to patients with the TT genotype. Other genetic and clinical factors may also affect clearance of gemcitabine.","TT:Patients with the TT genotype may have decreased clearance of gemcitabine as compared to patients with the CT and CC genotypes. Other genetic and clinical factors may also affect clearance of gemcitabine."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (38, 'rs11676382', 'GGCX (PA28660)', '2B', 'Dosage', 'warfarin (PA451906)', 'variant implication on Dosing', '', '"CC:Patients with the CC genotype may need an increased dose of warfarin as compared to patients with the CG and GG genotypes, however this has been contradicted in some studies. Other clinical and genetic factors may also influence dose of warfarin. ,"CG:Patients with the CG genotype may need a decreased dose of warfarin as compared to patients with the CC genotype, however this has been contradicted in some studies. Other clinical and genetic factors may also influence dose of warfarin. ","GG:Patients with the GG genotype may need a decreased dose of warfarin as compared to patients with the CC genotype, however this has been contradicted in some studies. Other clinical and genetic factors may also influence dose of warfarin. "');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (39, 'rs116855232', 'NUDT15 (PA134963132)', '1A', 'Dosage,"Toxicity/ADR"', 'azathioprine (PA448515),"mercaptopurine (PA450379)"', 'Oncology', 'Inflammatory Bowel Diseases (PA446116),"Precursor Cell Lymphoblastic Leukemia-Lymphoma (PA446155)"', '"CC:Patients with the CC genotype who are treated with thiopurines for inflammatory bowel diseases (IBD) or acute lymphoblastic leukemia (ALL) may have a reduced, but not absent risk of developing leukopenia, neutropenia or alopecia as compared to patients with the CT or TT genotype. Patients may also tolerate higher doses of thiopurines and be less likely to discontinue thiopurine treatment as compared to patients with the CT or TT genotype, possibly due to the reduced risk for adverse effects. Other genetic and clinical factors may also influence a patient''s risk for leukopenia, alopecia or treatment discontinuation.,"CT:Patients with the CT genotype who are treated with thiopurines for inflammatory bowel diseases (IBD) or acute lymphoblastic leukemia (ALL) may have an increased risk of developing leukopenia, neutropenia or alopecia as compared to patients with the CC genotype. Patients may also require lower doses of thiopurines and be more likely to discontinue thiopurine treatment as compared to patients with the CC genotype, possibly due to the increased risk for adverse effects. Other genetic and clinical factors may also influence a patient''s risk for leukopenia, alopecia or treatment discontinuation.","TT:Patients with the TT genotype who are treated with thiopurines for inflammatory bowel diseases (IBD) or acute lymphoblastic leukemia (ALL) may have an increased risk of developing leukopenia, neutropenia or alopecia as compared to patients with the CC genotype. Patients may also require lower doses of thiopurines and be more likely to discontinue thiopurine treatment as compared to patients with the CC genotype, possibly due to the increased risk for adverse effects. Other genetic and clinical factors may also influence a patient''s risk for leukopenia, alopecia or treatment discontinuation."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (40, 'rs118192116', 'RYR1 (PA34896)', '1A', 'Toxicity/ADR', 'desflurane (PA164749136),"enflurane (PA449461)","halothane (PA449845)","isoflurane (PA450106)","methoxyflurane (PA450434)","sevoflurane (PA451341)","succinylcholine (PA451522)"', 'Pharmacogenetic disorder', 'Malignant Hyperthermia (PA444863),"Myopathy, Central Core (PA447048)"', '"CC:Individuals with the CC genotype and central core myopathy may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with CG or GG genotype. Other genetic or clinical factors may put a patient at risk for developing malignant hyperthermia.,"CG:Individuals with the CG genotype and central core myopathy may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with CC genotype. Other clinical and genetic factors may also influence whether a patient develops Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).","GG:Individuals with the GG genotype and central core myopathy may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with CC genotype. Other clinical and genetic factors may also influence whether a patient of develops Malignant Hyperthermia. Please note: the G allele is thought to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations)."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (41, 'rs118192122', 'RYR1 (PA34896)', '1A', 'Toxicity/ADR', 'desflurane (PA164749136),"enflurane (PA449461)","halothane (PA449845)","isoflurane (PA450106)","methoxyflurane (PA450434)","sevoflurane (PA451341)","succinylcholine (PA451522)"', 'Pharmacogenetic disorder', 'Malignant Hyperthermia (PA444863)', '"AA:Patients with the AA genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the GG genotype. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. Please note: the A allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).,"AG:Patients with the AG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the GG genotype. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).","GG:Patients with the GG genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the AG or GG genotype. Other genetic or clinical factors may put a patient at risk for developing Malignant Hyperthermia."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (42, 'rs118192124', 'RYR1 (PA34896)', '1A', 'Toxicity/ADR', 'desflurane (PA164749136),"enflurane (PA449461)","halothane (PA449845)","isoflurane (PA450106)","methoxyflurane (PA450434)","sevoflurane (PA451341)","succinylcholine (PA451522)"', 'Pharmacogenetic disorder', 'Malignant Hyperthermia (PA444863)', '"CC:Patients with the CC genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the TT or CT genotype. Other genetic or clinical factors may put a patient at risk for developing Malignant Hyperthermia.,"CT:Patients with the CT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CC genotype Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).","TT:Patients with the TT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CC genotype. Please note: the T allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations)."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (43, 'rs118192161', 'RYR1 (PA34896)', '1A', 'Toxicity/ADR', 'desflurane (PA164749136),"enflurane (PA449461)","halothane (PA449845)","isoflurane (PA450106)","methoxyflurane (PA450434)","sevoflurane (PA451341)","succinylcholine (PA451522)"', 'Pharmacogenetic disorder', 'Malignant Hyperthermia (PA444863),"Myopathy, Central Core (PA447048)"', '"CC:Patients with the CC genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype TT or CT. Other genetic or clinical factors may put a patient at risk for developing Malignant Hyperthermia.,"CT:Patients with the CT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype CC. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).","TT:Patients with the TT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype CC. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. Please note: the T allele confers susceptibility to MH in an autosomal dominant manner and is almost always reported in heterozygotes therefore. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations)."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (44, 'rs118192162', 'RYR1 (PA34896)', '1A', 'Toxicity/ADR', 'desflurane (PA164749136),"enflurane (PA449461)","halothane (PA449845)","isoflurane (PA450106)","methoxyflurane (PA450434)","sevoflurane (PA451341)","succinylcholine (PA451522)"', 'Pharmacogenetic disorder', 'Malignant Hyperthermia (PA444863)', '"AA:Patients with the AA genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype AC or CC. Other genetic or clinical factors may put a patient at risk for developing malignant hyperthermia.,"AC:Patients with the AC genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype AA. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).","CC:Patients with the CC genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype AA. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. Please note: the C allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations)."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (45, 'rs118192163', 'RYR1 (PA34896)', '1A', 'Toxicity/ADR', 'desflurane (PA164749136),"enflurane (PA449461)","halothane (PA449845)","isoflurane (PA450106)","methoxyflurane (PA450434)","sevoflurane (PA451341)","succinylcholine (PA451522)"', 'Pharmacogenetic disorder', 'Malignant Hyperthermia (PA444863),"Myopathy, Central Core (PA447048)"', '"AA:Patients with the AA genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the GG genotype. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. Please note: the A allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).,"AG:Patients with the AG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the GG genotype. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).","GG:Patients with the GG genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the AA or AG genotype. Other genetic or clinical factors may put a patient at risk for developing malignant hyperthermia."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (46, 'rs118192167', 'RYR1 (PA34896)', '1A', 'Toxicity/ADR', 'desflurane (PA164749136),"enflurane (PA449461)","halothane (PA449845)","isoflurane (PA450106)","methoxyflurane (PA450434)","sevoflurane (PA451341)","succinylcholine (PA451522)"', 'Pharmacogenetic disorder', 'Malignant Hyperthermia (PA444863),"Myopathy, Central Core (PA447048)"', '"AA:Patients with the AA genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the GG or AG genotype. Other genetic or clinical factors may put a patient at risk for developing Malignant Hyperthermia.,"AG:Patients with the AG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the AA genotype. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).","GG:Patients with the GG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the AA genotype. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. Please note: the G allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations)."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (47, 'rs118192168', 'RYR1 (PA34896)', '1A', 'Toxicity/ADR', 'desflurane (PA164749136),"enflurane (PA449461)","halothane (PA449845)","isoflurane (PA450106)","methoxyflurane (PA450434)","sevoflurane (PA451341)","succinylcholine (PA451522)","volatile anesthetics (PA166131630)"', 'Pharmacogenetic disorder', 'Malignant Hyperthermia (PA444863)', '"AA:Patients with the AA genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the GG genotype. Please note: the A allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes.Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).,"AG:Patients with the AG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the GG genotype. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).","GG:Patients with the GG genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the AA or AG genotype. Other genetic or clinical factors may put a patient at risk for developing Malignant Hyperthermia."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (48, 'rs118192170', 'RYR1 (PA34896)', '1A', 'Toxicity/ADR', 'desflurane (PA164749136),"enflurane (PA449461)","halothane (PA449845)","isoflurane (PA450106)","methoxyflurane (PA450434)","sevoflurane (PA451341)","succinylcholine (PA451522)"', 'Pharmacogenetic disorder', 'Malignant Hyperthermia (PA444863),"Myopathy, Central Core (PA447048)"', '"CC:Patients with the CC genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the TT genotype. Please note: the C allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).,"CT:Patients with the CT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the TT genotype. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).","TT:Patients with the TT genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CC or CT genotype. Other genetic or clinical factors may put a patient at risk for developing Malignant Hyperthermia."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (49, 'rs118192172', 'RYR1 (PA34896)', '1A', 'Toxicity/ADR', 'desflurane (PA164749136),"enflurane (PA449461)","halothane (PA449845)","isoflurane (PA450106)","methoxyflurane (PA450434)","sevoflurane (PA451341)","succinylcholine (PA451522)"', 'Pharmacogenetic disorder', 'Malignant Hyperthermia (PA444863)', '"CC:Patients with the CC genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the TT or CT genotype. Other genetic or clinical factors may put a patient at risk for developing malignant hyperthermia.,"CT:Patients with the CT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CC genotype. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).","TT:Patients with the TT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CC genotype. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations)."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (50, 'rs118192175', 'RYR1 (PA34896)', '1A', 'Toxicity/ADR', 'desflurane (PA164749136),"enflurane (PA449461)","halothane (PA449845)","isoflurane (PA450106)","methoxyflurane (PA450434)","sevoflurane (PA451341)","succinylcholine (PA451522)"', 'Pharmacogenetic disorder', 'Malignant Hyperthermia (PA444863)', '"CC:Patients with the CC genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the TT or CT genotype. Other genetic or clinical factors may put a patient at risk for developing malignant hyperthermia.,"CT:Patients with the CT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CC genotype. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).","TT:Patients with the TT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CC genotype. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. Please note: the T allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations)."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (51, 'rs118192176', 'RYR1 (PA34896)', '1A', 'Toxicity/ADR', 'desflurane (PA164749136),"enflurane (PA449461)","halothane (PA449845)","isoflurane (PA450106)","methoxyflurane (PA450434)","sevoflurane (PA451341)","succinylcholine (PA451522)"', 'Pharmacogenetic disorder', 'Malignant Hyperthermia (PA444863)', '"AA:Patients with the AA genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the GG genotype. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. Please note: the A allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).,"AG:Patients with the AG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the GG genotype. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).","GG:Patients with the GG genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the AA or AG genotype. Other genetic or clinical factors may put a patient at risk for developing malignant hyperthermia."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (52, 'rs118192177', 'RYR1 (PA34896)', '1A', 'Toxicity/ADR', 'desflurane (PA164749136),"enflurane (PA449461)","halothane (PA449845)","isoflurane (PA450106)","methoxyflurane (PA450434)","sevoflurane (PA451341)","succinylcholine (PA451522)"', 'Pharmacogenetic disorder', 'Malignant Hyperthermia (PA444863)', '"CC:Patients with the CC genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the TT, CT, CG, or GG genotype. Other genetic or clinical factors may put a patient at risk for developing malignant hyperthermia.,"CG:Patients with the CG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CC genotype. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).","CT:Patients with the CT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CC genotype. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).","GG:Patients with the GG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CC genotype. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. Please note: the G allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).","TT:Patients with the TT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CC genotype. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. Please note: the T allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations)."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (53, 'rs118192178', 'RYR1 (PA34896)', '1A', 'Toxicity/ADR', 'desflurane (PA164749136),"enflurane (PA449461)","halothane (PA449845)","isoflurane (PA450106)","methoxyflurane (PA450434)","sevoflurane (PA451341)","succinylcholine (PA451522)"', 'Pharmacogenetic disorder', 'Malignant Hyperthermia (PA444863)', '"CC:Patients with the CC genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CT, CG, GG or TT genotype. Other genetic or clinical factors may put a patient at risk for developing Malignant Hyperthermia.,"CG:Patients with the CG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CC genotype. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).","CT:Patients with the CT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CC genotype. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).","GG:Patients with the GG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CC genotype. Please note: the G allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).","TT:Patients with the TT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CC genotype. Please note: the T allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations)."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (54, 'rs11881222', 'IFNL3 (PA134952671)', '2A', 'Efficacy', 'peginterferon alfa-2a (PA164749390),"peginterferon alfa-2b (PA164784024)","ribavirin (PA451241)"', 'Infectious Diseases', 'Hepatitis C (PA444445),"HIV (PA447230)"', '"AA:Patients with the AA genotype and hepatitis C or HIV may have a better response to treatment with peginterferon-alpha and ribavirin as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.,"AG:Patients with the AG genotype and hepatitis C or HIV may have a poorer response to treatment with peginterferon-alpha and ribavirin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.","GG:Patients with the GG genotype and hepatitis C or HIV may have a poorer response to treatment with peginterferon-alpha and ribavirin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (55, 'rs11971167', 'CFTR (PA109)', '1A', 'Efficacy', 'ivacaftor (PA165950341)', 'Pulmonology', 'Cystic Fibrosis (PA443829)', '"GG:Patients with the GG genotype (do not have a copy of the CFTR D1270N variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including D1270N. Other genetic and clinical factors may also influence a patient''s response to ivacaftor.,"GT:Patients with the GT genotype (one copy of the CFTR D1270N variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including D1270N. Other genetic and clinical factors may also influence a patient''s response to ivacaftor.","TT:Patients with the TT genotype (two copies of the CFTR D1270N variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including D1270N. Other genetic and clinical factors may also influence a patient''s response to ivacaftor."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (56, 'rs121434568', 'EGFR (PA7360)', '1B', 'Efficacy', 'erlotinib (PA134687924)', 'Oncology', 'Carcinoma, Non-Small-Cell Lung (PA443622)', '"GG:Patients with an activating somatic EGFR mutation who have advanced non-small-cell lung cancer and who are treated with erlotinib may be more likely have increased response rate (RR) and increased progression-free survival (PFS) time compared to patients who have no somatic mutation. The manuscripts where this annotation derived from, presented the results according to activating somatic EGFR mutation status, regardless of the mutation type, therefore, the rs121434568 (L858R), exon 19 deletion(s), and other activating somatic mutations were included in mutation positive group and combined under rs121434568, mutation bearing patients are presented here as GG genotype. Very few of the patients have more than one type of somatic mutation. None of the studies mentioned status for heterozygosity or homozygocity. Other genetic, demographic and environmental parameters may affect the treatment outcome. ,"GT:Patients with an activating somatic EGFR mutation who have advanced non-small-cell lung cancer and who are treated with erlotinib may be more likely have increased response rate (RR) and increased progression-free survival (PFS) time compared to patients who have no somatic mutation. The manuscripts where this annotation derived from, presented the results according to activating somatic EGFR mutation status, regardless of the mutation type, therefore, the rs121434568 (L858R), exon 19 deletion(s), and other activating somatic mutations were included in mutation positive group and combined under rs121434568, mutation bearing patients are presented here as GT genotype. Very few of the patients have more than one type of somatic mutation. None of the studies mentioned status for heterozygosity or homozygocity. Other genetic, demographic and environmental parameters may affect the treatment outcome.","TT:Patients without an activating somatic EGFR mutation who have advanced non-small-cell lung cancer and who are treated with erlotinib may be more likely have decreased response rate (RR) and decreased progression-free survival (PFS) time compared to patients who have activating somatic mutation. The manuscripts where this annotation derived from, presented the results according to activating somatic EGFR mutation status, regardless of the mutation type, therefore, the rs121434568 (L858R), exon 19 deletion(s), and other activating somatic mutations were included in mutation positive group and combined under rs121434568. Patients who have no mutation are presented here as TT genotype. Very few of the patients have more than one type of somatic mutation. None of the studies mentioned status for heterozygosity or homozygocity. Other genetic, demographic and environmental parameters may affect the treatment outcome."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (57, 'rs121434568', 'EGFR (PA7360)', '2A', 'Efficacy', 'carboplatin (PA448803),"gefitinib (PA131301952)","paclitaxel (PA450761)"', 'Oncology', 'Carcinoma, Non-Small-Cell Lung (PA443622)', '"GG:Patients with an activating somatic EGFR mutation are presented in this annotation and effects of gefitinib vs paclitaxel plus carboplatin were compared in non-small-cell lung cancer patients. Patients with an activating somatic EGFR mutation had increased progression-free survival (PFS) time and increased response rate (RR) when treated with gefitinib vs paclitaxel plus carboplatin. Genotypes are not compared in this annotation. The manuscripts where this annotation derived from, presented the results according to activating somatic EGFR mutation status, regardless of the mutation type, therefore, the rs121434568 (L858R), exon 19 deletion(s), and other activating somatic mutations were included in mutation positive group and combined under rs121434568, mutation bearing patients are presented here as GG genotype. Very few of the patients have more than one type of somatic mutation. None of the studies mentioned status for heterozygosity or homozygocity. Other genetic, demographic and environmental parameters may affect the treatment outcome. ,"GT:Patients with an activating somatic EGFR mutation are presented in this annotation and effects of gefitinib vs paclitaxel plus carboplatin were compared in non-small-cell lung cancer patients. Patients with an activating somatic EGFR mutation had increased progression-free survival (PFS) time and increased response rate (RR) when treated with gefitinib vs paclitaxel plus carboplatin. Genotypes are not compared in this annotation. The manuscripts where this annotation derived from, presented the results according to activating somatic EGFR mutation status, regardless of the mutation type, therefore, the rs121434568 (L858R), exon 19 deletion(s), and other activating somatic mutations were included in mutation positive group and combined under rs121434568, mutation bearing patients are presented here as GT genotype. Very few of the patients have more than one type of somatic mutation. None of the studies mentioned status for heterozygosity or homozygocity. Other genetic, demographic and environmental parameters may affect the treatment outcome. ","TT:Patients who have no activating somatic EGFR mutation were NOT included in these studies where this annotation is derived from. In this annotation and effects of gefitinib vs vs paclitaxel plus carboplatin were compared in non-small-cell lung cancer patients who have somatic mutation. Genotypes are not compared in this annotation."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (58, 'rs121434568', 'EGFR (PA7360)', '2A', 'Efficacy', 'carboplatin (PA448803),"docetaxel (PA449383)","erlotinib (PA134687924)","gemcitabine (PA449748)","paclitaxel (PA450761)"', 'Oncology', 'Carcinoma, Non-Small-Cell Lung (PA443622)', '"GG:Patients with an activating somatic EGFR mutation are presented in this annotation and effects of erlotinib vs standard chemotherapy [i) paclitaxel plus carboplatin, ii) cisplatin plus gemcitabine or docetaxel] were compared in non-small-cell lung cancer patients. Patients with an activating somatic EGFR mutation had increased progression-free survival (PFS) time, decreased toxic effects and decreased serious adverse events when treated with erlotinib vs standard chemotherapy. Genotypes are not compared in this annotation. The manuscripts where this annotation derived from, presented the results according to activating somatic EGFR mutation status, regardless of the mutation type, therefore, the rs121434568 (L858R), exon 19 deletion(s), and other activating somatic mutations were included in mutation positive group and combined under rs121434568, mutation bearing patients are presented here as GG genotype. Very few of the patients have more than one type of somatic mutation. None of the studies mentioned status for heterozygosity or homozygocity. Other genetic, demographic and environmental parameters may affect the treatment outcome. ,"GT:Patients with an activating somatic EGFR mutation are presented in this annotation and effects of erlotinib vs standard chemotherapy [i) paclitaxel plus carboplatin, ii) cisplatin plus gemcitabine or docetaxel] were compared in non-small-cell lung cancer patients. Patients with an activating somatic EGFR mutation had increased progression-free survival (PFS) time, decreased toxic effects and decreased serious adverse events when treated with erlotinib vs standard chemotherapy. Genotypes are not compared in this annotation. The manuscripts where this annotation derived from, presented the results according to activating somatic EGFR mutation status, regardless of the mutation type, therefore, the rs121434568 (L858R), exon 19 deletion(s), and other activating somatic mutations were included in mutation positive group and combined under rs121434568, mutation bearing patients are presented here as GT genotype. Very few of the patients have more than one type of somatic mutation. None of the studies mentioned status for heterozygosity or homozygocity. Other genetic, demographic and environmental parameters may affect the treatment outcome. ","TT:Patients who have no activating somatic EGFR mutation were NOT included in these studies where this annotation is derived from. In this annotation and effects of erlotinib vs standard chemotherapy [i) paclitaxel plus carboplatin, ii) cisplatin plus gemcitabine or docetaxel] were compared in non-small-cell lung cancer patients who have somatic mutation. Genotypes are not compared in this annotation."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (59, 'rs121434568', 'EGFR (PA7360)', '1B', 'Efficacy', 'gefitinib (PA131301952)', 'Oncology', 'Carcinoma, Non-Small-Cell Lung (PA443622)', '"GG:Patients with an activating somatic EGFR mutation who have advanced non-small-cell lung cancer and who are treated with gefitinib may be more likely to have increased response rate (RR) and increased progression-free survival (PFS) time compared to patients who have no somatic mutation. The manuscripts where this annotation derived from, presented the results according to activating somatic EGFR mutation status, regardless of the mutation type, therefore, the rs121434568 (L858R), exon 19 deletion(s), and other activating somatic mutations were included in mutation positive group and combined under rs121434568, mutation bearing patients are presented here as GG genotype. Very few of the patients have more than one type of somatic mutation. None of the studies mentioned status for heterozygosity or homozygosity. Other genetic, demographic and environmental parameters may affect the treatment outcome. ,"GT:Patients with an activating somatic EGFR mutation who have advanced non-small-cell lung cancer and who are treated with gefitinib may be more likely to have increased response rate (RR) and increased progression-free survival (PFS) time compared to patients who have no somatic mutation. The manuscripts where this annotation derived from, presented the results according to activating somatic EGFR mutation status, regardless of the mutation type, therefore, the rs121434568 (L858R), exon 19 deletion(s), and other activating somatic mutations were included in mutation positive group and combined under rs121434568, mutation bearing patients are presented here as GT genotype. Very few of the patients have more than one type of somatic mutation. None of the studies mentioned status for heterozygosity or homozygosity. Other genetic, demographic and environmental parameters may affect the treatment outcome. ","TT:Patients without an activating somatic EGFR mutation who have advanced non-small-cell lung cancer and who are treated with gefitinib may be more likely to have decreased response rate (RR) and decreased progression-free survival (PFS) time compared to patients who have activating somatic mutation. The manuscripts where this annotation derived from, presented the results according to activating somatic EGFR mutation status, regardless of the mutation type, therefore, the rs121434568 (L858R), exon 19 deletion(s), and other activating somatic mutations were included in mutation positive group and combined under rs121434568. Patients who have no mutation are presented here as TT genotype. Very few of the patients have more than one type of somatic mutation. None of the studies mentioned status for heterozygosity or homozygosity. Other genetic, demographic and environmental parameters may affect the treatment outcome."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (60, 'rs121434569', 'EGFR (PA7360)', '2A', 'Efficacy', 'erlotinib (PA134687924),"gefitinib (PA131301952)"', 'Oncology', 'Carcinoma, Non-Small-Cell Lung (PA443622)', '"CC:Advanced non-small-cell lung cancer patients with CC genotype may less likely develop acquired resistance and more likely have increased progression-free survival (PFS) time when treated with erlotinib or gefitinib compared to patients with CT or TT genotypes. In these studies, patients who have EGFR activating mutations [e.g. L858R or exon 19 deletion] are treated with erlotinib or gefitinib. The T790M mutation (rs121434569) was not detected or detected in very low frequency in patients who remained sensitive to erlotinib or gefitinib treatment or in nonresponders to these drugs. This is a somatic mutation, occurred in one cell then go for clonal expansion under some circumstances. None of the studies mentioned status for heterozygosity or homozygocity.,"CT:Advanced non-small-cell lung cancer patients with CT genotype may more likely develop acquired resistance and less likely have increased progression-free survival (PFS) time when treated with erlotinib or gefitinib compared to patients with CC genotypes. In these studies, patients who have EGFR activating mutations [e.g. L858R or exon 19 deletion] are treated with erlotinib or gefitinib. The T790M mutation (rs121434569) was not detected or detected in very low frequency in patients who remained sensitive to erlotinib or gefitinib treatment or in nonresponders to these drugs. This is a somatic mutation, occurred in one cell then go for clonal expansion under some circumstances. None of the studies mentioned status for heterozygosity or homozygocity. ","TT:Advanced non-small-cell lung cancer patients with TT genotype may more likely develop acquired resistance and less likely have increased progression-free survival (PFS) time when treated with erlotinib or gefitinib compared to patients with CC genotypes. In these studies, patients who have EGFR activating mutations [e.g. L858R or exon 19 deletion] are treated with erlotinib or gefitinib. The T790M mutation (rs121434569) was not detected or detected in very low frequency in patients who remained sensitive to erlotinib or gefitinib treatment or in nonresponders to these drugs. This is a somatic mutation, occurred in one cell then go for clonal expansion under some circumstances. None of the studies mentioned status for heterozygosity or homozygocity. "');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (61, 'rs121908752', 'CFTR (PA109)', '1A', 'Efficacy', 'ivacaftor (PA165950341)', 'Pulmonology', 'Cystic Fibrosis (PA443829)', '"GG:Patients with the GG genotype (two copies of the CFTR L206W variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including L206W. Other genetic and clinical factors may also influence a patient''s response to ivacaftor.,"GT:Patients with the GT genotype (one copy of the CFTR L206W variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including L206W. Other genetic and clinical factors may also influence a patient''s response to ivacaftor.","TT:Patients with the TT genotype (do not have a copy of the CFTR L206W variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including L206W. Other genetic and clinical factors may also influence a patient''s response to ivacaftor."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (62, 'rs121908753', 'CFTR (PA109)', '1A', 'Efficacy', 'ivacaftor (PA165950341)', 'Pulmonology', 'Cystic Fibrosis (PA443829)', '"AA:Patients with the AA genotype (two copies of the CFTR R352Q variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R352Q. Other genetic and clinical factors may also influence a patient''s response to ivacaftor.,"AG:Patients with the AG genotype (one copy of the CFTR R352Q variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R352Q. Other genetic and clinical factors may also influence a patient''s response to ivacaftor.","GG:Patients with the GG genotype (do not have a copy of the CFTR R352Q variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R352Q. Other genetic and clinical factors may also influence a patient''s response to ivacaftor."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (63, 'rs121908755', 'CFTR (PA109)', '1A', 'Efficacy', 'ivacaftor (PA165950341)', 'Pulmonology', 'Cystic Fibrosis (PA443829)', '"AA:Patients with the AA genotype (two copies of the CFTR S549N variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S549N. Other genetic and clinical factors may also influence a patient''s response to ivacaftor. ,"AG:Patients with the AG genotype (one copy of the CFTR S549N variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S549N. Other genetic and clinical factors may also influence a patient''s response to ivacaftor. ","GG:Patients with the GG genotype (do not have a copy of the CFTR S549N variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S549N. Other genetic and clinical factors may also influence a patient''s response to ivacaftor. "');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (64, 'rs121908757', 'CFTR (PA109)', '1A', 'Efficacy', 'ivacaftor (PA165950341)', 'Pulmonology', 'Cystic Fibrosis (PA443829)', '"AA:Patients with the AA genotype (do not have a copy of the CFTR S549R variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S549R. Other genetic and clinical factors may also influence a patient''s response to ivacaftor.,"AC:Patients with the AC genotype (one copy of the CFTR S549R variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S549R. Other genetic and clinical factors may also influence a patient''s response to ivacaftor. ","CC:Patients with the CC genotype (two copies of the CFTR S549R variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S549R. Other genetic and clinical factors may also influence a patient''s response to ivacaftor. "');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (65, 'rs121909005', 'CFTR (PA109)', '1A', 'Efficacy', 'ivacaftor (PA165950341)', 'Pulmonology', 'Cystic Fibrosis (PA443829)', '"GG:Patients with the GG genotype (two copies of the CFTR S549R variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S549R. Other genetic and clinical factors may also influence a patient''s response to ivacaftor. ,"GT:Patients with the GT genotype (one copy of the CFTR S549R variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S549R. Other genetic and clinical factors may also influence a patient''s response to ivacaftor. ","TT:Patients with the TT genotype (do not have a copy of the CFTR S549R variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S549R. Other genetic and clinical factors may also influence a patient''s response to ivacaftor."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (66, 'rs121909013', 'CFTR (PA109)', '1A', 'Efficacy', 'ivacaftor (PA165950341)', 'Pulmonology', 'Cystic Fibrosis (PA443829)', '"AA:Patients with the AA genotype (two copies of the CFTR G551S variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including G551S. Other genetic and clinical factors may also influence a patient''s response to ivacaftor. ,"AG:Patients with the AG genotype (one copy of the CFTR G551S variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including G551S. Other genetic and clinical factors may also influence a patient''s response to ivacaftor. ","GG:Patients with the GG genotype (do not have a copy of the CFTR G551S variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including G551S. Other genetic and clinical factors may also influence a patient''s response to ivacaftor."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (67, 'rs121909020', 'CFTR (PA109)', '1A', 'Efficacy', 'ivacaftor (PA165950341)', 'Pulmonology', 'Cystic Fibrosis (PA443829)', '"AA:Patients with the AA genotype (two copies of the CFTR A1067T variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including A1067T. Other genetic and clinical factors may also influence a patient''s response to ivacaftor.,"AG:Patients with the AG genotype (one copy of the CFTR A1067T variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including A1067T. Other genetic and clinical factors may also influence a patient''s response to ivacaftor.","GG:Patients with the GG genotype (do not have a copy of the CFTR A1067T variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including A1067T. Other genetic and clinical factors may also influence a patient''s response to ivacaftor."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (68, 'rs121909041', 'CFTR (PA109)', '1A', '', 'ivacaftor (PA165950341)', 'Pulmonology', 'Cystic Fibrosis (PA443829)', '"CC:Patients with the CC genotype (two copies of the CFTR S1255P variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S1255P. Other genetic and clinical factors may also influence a patient''s response to ivacaftor. ,"CT:Patients with the CT genotype (one copy of the CFTR S1255P variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S1255P. Other genetic and clinical factors may also influence a patient''s response to ivacaftor. ","TT:Patients with the TT genotype (do not have a copy of the CFTR S1255P variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S1255P. Other genetic and clinical factors may also influence a patient''s response to ivacaftor."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (69, 'rs121918592', 'RYR1 (PA34896)', '1A', 'Toxicity/ADR', 'desflurane (PA164749136),"enflurane (PA449461)","halothane (PA449845)","isoflurane (PA450106)","methoxyflurane (PA450434)","sevoflurane (PA451341)","succinylcholine (PA451522)"', 'Pharmacogenetic disorder', 'Malignant Hyperthermia (PA444863)', '"AA:Patients with the AA genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. Please note: the A allele is considered to be inherited in an autosomal dominant manner and is almost always reported in heterozygotes. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).,"AG:Patients with the AG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).","CC:Patients with the CC genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. Please note: the C allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).","CG:Patients with the CG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).","GG:Patients with the GG genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype CC, CG, AA or AG. Other genetic or clinical factors may put a patient at risk for developing malignant hyperthermia."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (70, 'rs121918593', 'RYR1 (PA34896)', '1A', 'Toxicity/ADR', 'desflurane (PA164749136),"enflurane (PA449461)","halothane (PA449845)","isoflurane (PA450106)","methoxyflurane (PA450434)","sevoflurane (PA451341)","succinylcholine (PA451522)"', 'Pharmacogenetic disorder', 'Malignant Hyperthermia (PA444863)', '"AA:Patients with the AA genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the GG genotype. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. Please note: the A allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).,"AG:Patients with the AG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the GG genotype. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).","GG:Patients with the GG genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the AA or AG genotype. Other genetic or clinical factors may put a patient at risk for developing Malignant Hyperthermia."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (71, 'rs121918594', 'RYR1 (PA34896)', '1A', 'Toxicity/ADR', 'desflurane (PA164749136),"enflurane (PA449461)","halothane (PA449845)","isoflurane (PA450106)","methoxyflurane (PA450434)","sevoflurane (PA451341)","succinylcholine (PA451522)"', 'Pharmacogenetic disorder', 'Malignant Hyperthermia (PA444863)', '"AA:Patients with the AA genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the GG genotype. Please note: the A allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).,"AG:Patients with the AG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the GG genotype. Other genetic or clinical factors may also influence a patient''s risk of developing Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).","GG:Patients with the GG genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the AA or AG genotype. Other genetic or clinical factors may put a patient at risk for developing Malignant Hyperthermia."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (72, 'rs121918595', 'RYR1 (PA34896)', '1A', 'Toxicity/ADR', 'desflurane (PA164749136),"enflurane (PA449461)","halothane (PA449845)","isoflurane (PA450106)","methoxyflurane (PA450434)","sevoflurane (PA451341)","succinylcholine (PA451522)"', 'Pharmacogenetic disorder', 'Malignant Hyperthermia (PA444863)', '"CC:Patients with the CC genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the TT or CT genotype. Other genetic or clinical factors may put a patient at risk for developing Malignant Hyperthermia.,"CT:Patients with the CT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CC genotype. Other genetic or clinical factors may also influence whether a patient develops Malignant hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).","TT:Patients with the TT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CC genotype. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. Please note: the T allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations)."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (73, 'rs121918596', 'RYR1 (PA34896)', '1A', 'Toxicity/ADR', 'desflurane (PA164749136),"enflurane (PA449461)","halothane (PA449845)","isoflurane (PA450106)","methoxyflurane (PA450434)","sevoflurane (PA451341)","succinylcholine (PA451522)"', 'Pharmacogenetic disorder', 'Malignant Hyperthermia (PA444863)', '"GAG/GAG:Patients with the GAG/GAG genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the del/del or del/GAG genotypes. Other genetic or clinical factors may put a patient at risk for developing Malignant Hyperthermia.,"del/GAG:Patients with the del/GAG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the GAG/GAG genotype. Other clinical and genetic factors may also influence whether a patient develops Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).","del/del:Patients with the del/del genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the GAG/GAG genotype. Other clinical and genetic factors may also influence whether a patient develops Malignant Hyperthermia. Please note: the del allele is considered to confer MH in an autosomal dominant manner and is reported in heterozygotes. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations)."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (74, 'rs12248560', 'CYP2C19 (PA124)', '2A', 'Metabolism/PK', 'citalopram (PA449015),"escitalopram (PA10074)"', 'variant implication on drug metabolism', '', '"CC:Patients with the CC genotype may have decreased metabolism of citalopram or escitalopram as compared to patients with the TT or CT genotype. Other genetic factors, including other CYP2C19 alleles *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient''s citalopram or escitalopram metabolism. ,"CT:Patients with the CT genotype (CYP2C19*1/*17) may have an increased metabolism of citalopram or escitalopram as compared to patients with the CC genotype. Other genetic factors, including other CYP2C19 alleles *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient''s citalopram or escitalopram metabolism. ","TT:Patients with the TT genotype (CYP2C19*17/*17) may have an increased metabolism of citalopram or escitalopram as compared to patients with the CC genotype. Other genetic factors, including other CYP2C19 alleles *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient''s citalopram or escitalopram metabolism. "');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (75, 'rs12248560', 'CYP2C19 (PA124)', '1A', 'Dosage,"Efficacy","Toxicity/ADR"', 'clopidogrel (PA449053)', 'Cardiovascular', 'Acute coronary syndrome (PA165108401),"Coronary Artery Disease (PA443796)","Myocardial Infarction (PA445019)"', '"CC:Patients with the CC genotype (*1/*1): 1) may have decreased activation of clopidogrel 2) may have a decreased, but not absent, risk for bleeding with clopidogrel as compared to patients with the CT or TT genotype 3) may have an increased risk for adverse cardiovascular events as compared to patients with a CT or TT genotype. Other genetic, including CYP2C19 loss-of-function alleles e.g. *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient''s risk for bleeding and adverse cardiovascular events.,"CT:Patients with the CT (*1/*17) genotype: 1) may have increased activation of clopidogrel 2) may have an increased risk of bleeding with clopidogrel as compared to patients with the CC genotype 3) may have a decreased, but not absent, risk for adverse cardiovascular events as compared to patients with a CC genotype. Current CPIC guidelines recommend no change in clopidogrel dosing based on *1/*17 genotype as of yet. Other genetic, including CYP2C19 loss-of-function alleles e.g. *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient''s risk for bleeding and adverse cardiovascular events.","TT:Patients with the TT (*17/*17) genotype: 1) may have increased activation of clopidogrel 2) may have an increased risk of bleeding with clopidogrel as compared to patients with a CC genotype 3) may have a decreased, but not absent, risk for adverse cardiovascular events as compared to patients with a CC genotype. Current CPIC guidelines recommend no change in clopidogrel dosing based on *17/*17 genotype as of yet. Other genetic, including CYP2C19 loss-of-function alleles e.g. *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient''s risk for bleeding and adverse cardiovascular events."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (76, 'rs12777823', '.', '1A', 'Dosage', 'warfarin (PA451906)', 'variant implication on Dosing', '', '"AA:Patients with the AA genotype may require a lower dose of warfarin (may require a dose reduction of 9·34 mg/week) in African Americans as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient''s required dose of warfarin.,"AG:Patients with the AG genotype may require a lower dose of warfarin (may require a dose reduction of 6·92 mg/week) in African Americans as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient''s required dose of warfarin.","GG:Patients with the GG genotype may require a higher dose of warfarin in African Americans as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient''s required dose of warfarin."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (233, 'rs4693075', 'COQ2 (PA142672084)', '2B', 'Toxicity/ADR', 'atorvastatin (PA448500),"hmg coa reductase inhibitors (PA133950441)","rosuvastatin (PA134308647)"', 'Drug Response effects/ toxicity Muscular Diseases', 'Muscular Diseases (PA444997)', '"CC:Patients with the CC genotype may have decreased risk of statin-related muscle symptoms as compared to patients with genotype GG or CG. Other genetic and clinical factors may also influence a patient''s risk of toxicity.,"CG:Patients with the CG genotype may have increased risk of statin-related muscle symptoms as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient''s risk of toxicity.","GG:Patients with the GG genotype may have increased risk of statin-related muscle symptoms as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient''s risk of toxicity."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (77, 'rs12979860', 'IFNL3 (PA134952671)', '2A', 'Efficacy', 'boceprevir (PA165948902),"peginterferon alfa-2b (PA164784024)","ribavirin (PA451241)"', 'Infectious Diseases', 'Hepatitis C, Chronic (PA446863)', '"CC:Patients with the CC genotype may have better response to triple therapy (boceprevir, peginterferon alfa-2b and ribavirin) in people with Hepatitis C as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient''s response.,"CT:Patients with the CT genotype may have poorer response to triple therapy (boceprevir, peginterferon alfa-2b and ribavirin) in people with Hepatitis C as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient''s response.","TT:Patients with the TT genotype may have poorer response to triple therapy (boceprevir, peginterferon alfa-2b and ribavirin) in people with Hepatitis C as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient''s response."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (78, 'rs12979860', 'IFNL4 (PA166049147)', '2A', 'Efficacy', 'boceprevir (PA165948902),"peginterferon alfa-2b (PA164784024)","ribavirin (PA451241)"', 'Infectious Diseases', 'Hepatitis C, Chronic (PA446863)', '"CC:Patients with the CC genotype may have better response to triple therapy (boceprevir, peginterferon alfa-2b and ribavirin) in people with Hepatitis C as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient''s response.,"CT:Patients with the CT genotype may have poorer response to triple therapy (boceprevir, peginterferon alfa-2b and ribavirin) in people with Hepatitis C as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient''s response.","TT:Patients with the TT genotype may have poorer response to triple therapy (boceprevir, peginterferon alfa-2b and ribavirin) in people with Hepatitis C as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient''s response."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (79, 'rs12979860', 'IFNL3 (PA134952671)', '1A', 'Efficacy', 'peginterferon alfa-2a (PA164749390),"peginterferon alfa-2b (PA164784024)","ribavirin (PA451241)"', 'Infectious Diseases', 'Hepatitis C (PA444445)', '"CC:Patients with the CC genotype and Hepatitis C genotype 1 may have increased response (typically assayed as sustained virological response, SVR) when administered peg interferon alpha (2a, 2b) and ribavirin (with or without telaprevir, boceprevir, or simeprevir, daclatasvir) as compared to patients with the CT or TT genotype. Patients with the CC genotype may also have higher spontaneous clearance in acute HCV infections than patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient''s response to peg interferon and ribavirin.,"CT:Patients with the CT genotype and Hepatitis C genotype 1 may have decreased response (typically assayed as sustained virological response, SVR) when administered peg interferon alpha (2a, 2b) and ribavirin (with or without telaprevir, boceprevir, or simeprevir, daclatasvir) as compared to patients with the CC genotype. Patients with the CT genotype may also have lower spontaneous clearance in acute HCV infections than patients with the CC genotype. Other genetic and clinical factors may also influence a patient''s response to peg interferon and ribavirin.","TT:Patients with the TT genotype and Hepatitis C genotype 1 may have decreased response (typically assayed as sustained virological response, SVR) when administered peg interferon alpha (2a, 2b) and ribavirin (with or without telaprevir, boceprevir, or simeprevir, daclatasvir) as compared to patients with the CC genotype. Patients with the TT genotype may also have lower spontaneous clearance in acute HCV infections than patients with the CC genotype. Other genetic and clinical factors may also influence a patient''s response to peg interferon and ribavirin."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (80, 'rs12979860', 'IFNL4 (PA166049147)', '1A', 'Efficacy', 'peginterferon alfa-2a (PA164749390),"peginterferon alfa-2b (PA164784024)","ribavirin (PA451241)"', 'Infectious Diseases', 'Hepatitis C (PA444445)', '"CC:Patients with the CC genotype and Hepatitis C genotype 1 may have increased response (typically assayed as sustained virological response, SVR) when administered peg interferon alpha (2a, 2b) and ribavirin (with or without telaprevir, boceprevir, or simeprevir, daclatasvir) as compared to patients with the CT or TT genotype. Patients with the CC genotype may also have higher spontaneous clearance in acute HCV infections than patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient''s response to peg interferon and ribavirin.,"CT:Patients with the CT genotype and Hepatitis C genotype 1 may have decreased response (typically assayed as sustained virological response, SVR) when administered peg interferon alpha (2a, 2b) and ribavirin (with or without telaprevir, boceprevir, or simeprevir, daclatasvir) as compared to patients with the CC genotype. Patients with the CT genotype may also have lower spontaneous clearance in acute HCV infections than patients with the CC genotype. Other genetic and clinical factors may also influence a patient''s response to peg interferon and ribavirin.","TT:Patients with the TT genotype and Hepatitis C genotype 1 may have decreased response (typically assayed as sustained virological response, SVR) when administered peg interferon alpha (2a, 2b) and ribavirin (with or without telaprevir, boceprevir, or simeprevir, daclatasvir) as compared to patients with the CC genotype. Patients with the TT genotype may also have lower spontaneous clearance in acute HCV infections than patients with the CC genotype. Other genetic and clinical factors may also influence a patient''s response to peg interferon and ribavirin."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (81, 'rs12979860', 'IFNL3 (PA134952671)', '1A', 'Efficacy', 'peginterferon alfa-2a (PA164749390),"peginterferon alfa-2b (PA164784024)","ribavirin (PA451241)","telaprevir (PA165958354)"', 'Infectious Diseases', 'Hepatitis C, Chronic (PA446863)', '"CC:Patients with the CC genotype may have higher response rates (SVR) to triple therapy (telaprevir, peginterferon alfa-2a/b and ribavirin) in people with Hepatitis C genotype 1 as compared to patients with the CT or TT genotype. Patients with the CC genotype may also more likely to be eligible for shortened therapy (24 weeks instead of standard 48 weeks). The impact of IL28B genotype maybe dampened in patients with prior PegIFN/RBV treatment failure. Other genetic and clinical factors may also influence a patient''s response to HCV triple therapy.,"CT:Patients with the CT genotype may have lower response rates (SVR) to triple therapy (telaprevir, peginterferon alfa-2a/b and ribavirin) in people with Hepatitis C genotype 1 as compared to patients with the CC genotype. The impact of IL28B genotype maybe dampened in patients with prior PegIFN/RBV treatment failure. Other genetic and clinical factors may also influence a patient''s response to HCV triple therapy.","TT:Patients with the TT genotype may have lower response rates (SVR) to triple therapy (telaprevir, peginterferon alfa-2a/b and ribavirin) in people with Hepatitis C genotype 1 as compared to patients with the CC genotype. The impact of IL28B genotype maybe dampened in patients with prior PegIFN/RBV treatment failure. Other genetic and clinical factors may also influence a patient''s response to HCV triple therapy."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (82, 'rs12979860', 'IFNL4 (PA166049147)', '1A', 'Efficacy', 'peginterferon alfa-2a (PA164749390),"peginterferon alfa-2b (PA164784024)","ribavirin (PA451241)","telaprevir (PA165958354)"', 'Infectious Diseases', 'Hepatitis C, Chronic (PA446863)', '"CC:Patients with the CC genotype may have higher response rates (SVR) to triple therapy (telaprevir, peginterferon alfa-2a/b and ribavirin) in people with Hepatitis C genotype 1 as compared to patients with the CT or TT genotype. Patients with the CC genotype may also more likely to be eligible for shortened therapy (24 weeks instead of standard 48 weeks). The impact of IL28B genotype maybe dampened in patients with prior PegIFN/RBV treatment failure. Other genetic and clinical factors may also influence a patient''s response to HCV triple therapy.,"CT:Patients with the CT genotype may have lower response rates (SVR) to triple therapy (telaprevir, peginterferon alfa-2a/b and ribavirin) in people with Hepatitis C genotype 1 as compared to patients with the CC genotype. The impact of IL28B genotype maybe dampened in patients with prior PegIFN/RBV treatment failure. Other genetic and clinical factors may also influence a patient''s response to HCV triple therapy.","TT:Patients with the TT genotype may have lower response rates (SVR) to triple therapy (telaprevir, peginterferon alfa-2a/b and ribavirin) in people with Hepatitis C genotype 1 as compared to patients with the CC genotype. The impact of IL28B genotype maybe dampened in patients with prior PegIFN/RBV treatment failure. Other genetic and clinical factors may also influence a patient''s response to HCV triple therapy."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (83, 'rs13306278', 'COMT (PA117)', '2B', 'Efficacy', 'Selective serotonin reuptake inhibitors (PA164713257)', 'Psychiatry', 'Depressive Disorder, Major (PA447321)', '"CC:Patients with the CC genotype may have increased likelihood of remission when treated with Selective serotonin reuptake inhibitors in people with Depressive Disorder as compared to patients with the TT or CT genotype. Other genetic and clinical factors may also influence a patient''s response to Selective serotonin reuptake inhibitors.,"CT:Patients with the CT genotype may have decreased likelihood of remission when treated with Selective serotonin reuptake inhibitors in people with Depressive Disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient''s response to Selective serotonin reuptake inhibitors.","TT:Patients with the TT genotype may have decreased likelihood of remission when treated with Selective serotonin reuptake inhibitors in people with Depressive Disorder as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient''s response to Selective serotonin reuptake inhibitors."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (84, 'rs13306278', 'TXNRD2 (PA38302)', '2B', 'Efficacy', 'Selective serotonin reuptake inhibitors (PA164713257)', 'Psychiatry', 'Depressive Disorder, Major (PA447321)', '"CC:Patients with the CC genotype may have increased likelihood of remission when treated with Selective serotonin reuptake inhibitors in people with Depressive Disorder as compared to patients with the TT or CT genotype. Other genetic and clinical factors may also influence a patient''s response to Selective serotonin reuptake inhibitors.,"CT:Patients with the CT genotype may have decreased likelihood of remission when treated with Selective serotonin reuptake inhibitors in people with Depressive Disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient''s response to Selective serotonin reuptake inhibitors.","TT:Patients with the TT genotype may have decreased likelihood of remission when treated with Selective serotonin reuptake inhibitors in people with Depressive Disorder as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient''s response to Selective serotonin reuptake inhibitors."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (85, 'rs1346268', '.', '2B', 'Toxicity/ADR', 'hmg coa reductase inhibitors (PA133950441),"simvastatin (PA451363)"', 'Drug Response effects/ toxicity', '', '"CC:Patients with the CC genotype may be less likely to experience myopathy when treated with statins as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence the likelihood of myopathy when a patient is treated with statins.,"CT:Patients with the CT genotype may be less likely to experience myopathy when treated with statins as compared to patients with the TT genotype, and more likely to experience myopathy when treated with statins as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the likelihood of myopathy when a patient is treated with statins.","TT:Patients with the TT genotype may be more likely to experience myopathy when treated with statins as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence the likelihood of myopathy when a patient is treated with statins."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (86, 'rs141033578', 'CFTR (PA109)', '1A', 'Efficacy', 'ivacaftor (PA165950341)', 'Pulmonology', 'Cystic Fibrosis (PA443829)', '"CC:Patients with the CC genotype (do not have a copy of the CFTR S977F variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S945L. Other genetic and clinical factors may also influence a patient''s response to ivacaftor.,"CT:Patients with the CT genotype (one copy of the CFTR S977F variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S977F. Other genetic and clinical factors may also influence a patient''s response to ivacaftor.","TT:Patients with the TT genotype (two copies of the CFTR S977F variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S977F. Other genetic and clinical factors may also influence a patient''s response to ivacaftor."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (92, 'rs1532624', 'CETP (PA108)', '2B', 'Efficacy', 'hmg coa reductase inhibitors (PA133950441)', 'Cardiovascular', 'Hyperlipidemias (PA444528)', '"AA:Patients with the AA genotype may have decreased response to hmg coa reductase inhibitors in people with Hyperlipidemias as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient''s response to hmg coa reductase inhibitors.,"AC:Patients with the AC genotype may have decreased response to hmg coa reductase inhibitors in people with Hyperlipidemias as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient''s response to hmg coa reductase inhibitors.","CC:Patients with the CC genotype may have increased response to hmg coa reductase inhibitors in people with Hyperlipidemias as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient''s response to hmg coa reductase inhibitors."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (87, 'rs1414334', 'HTR2C (PA194)', '2B', 'Toxicity/ADR', 'antipsychotics (PA452233),"clozapine (PA449061)","olanzapine (PA450688)","risperidone (PA451257)"', 'Pharmacogenetic disorder', 'Metabolic Syndrome (PA162370415),"Schizophrenia (PA447216)"', '"C:Male patients with the C genotype who are treated with antipsychotics may have an increased risk of developing metabolic syndrome as compared to patients with the G genotype. This gene is on the X chromosome and males have only one allele. Other genetic and clinical factors may also influence a patient''s risk for developing metabolic syndrome.,"CC:Female patients with the CC genotype who are treated with antipsychotics may have an increased risk of developing metabolic syndrome as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient''s risk for developing metabolic syndrome.","CG:Female patients with the CG genotype who are treated with antipsychotics may have an increased risk of developing metabolic syndrome as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient''s risk for developing metabolic syndrome.","G:Male patients with the G genotype who are treated with antipsychotics may have a decreased risk of developing metabolic syndrome as compared to patients with the C genotype. This gene is on the X chromosome and males have only one allele. Other genetic and clinical factors may also influence a patient''s risk for developing metabolic syndrome.","GG:Female patients with the GG genotype who are treated with antipsychotics may have a decreased, but not absent, risk of developing metabolic syndrome as compared to patients with the CG and CC genotype. Other genetic and clinical factors may also influence a patient''s risk for developing metabolic syndrome."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (88, 'rs144336148', 'RYR1 (PA34896)', '1A', 'Toxicity/ADR', 'desflurane (PA164749136),"enflurane (PA449461)","halothane (PA449845)","isoflurane (PA450106)","methoxyflurane (PA450434)","sevoflurane (PA451341)","succinylcholine (PA451522)"', 'Pharmacogenetic disorder', 'Malignant Hyperthermia (PA444863)', '"AA:Patients with the AA genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the GG genotype. Other clinical and genetic factors also influence whether an individual develops malignant hyperthermia. Please note: the A allele is considered to confer MH in an autosomal dominant manner and is reported in heterozygotes. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).,"AG:Patients with the AG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the GG genotype. Other clinical and genetic factors also influence whether an individual develops malignant hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).","GG:Patients with the GG genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the AG or AA genotype. Other genetic or clinical factors may put a patient at risk for developing malignant hyperthermia."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (89, 'rs150212784', 'CFTR (PA109)', '1A', 'Efficacy', 'ivacaftor (PA165950341)', 'Pulmonology', 'Cystic Fibrosis (PA443829)', '"GG:Patients with the GG genotype (two copies of the CFTR F1052V variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including F1052V. Other genetic and clinical factors may also influence a patient''s response to ivacaftor.,"GT:Patients with the GT genotype (one copy of the CFTR F1052V variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including F1052V. Other genetic and clinical factors may also influence a patient''s response to ivacaftor.","TT:Patients with the TT genotype (do not have a copy of the CFTR F1052V variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including F1052V. Other genetic and clinical factors may also influence a patient''s response to ivacaftor."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (90, 'rs151264360', 'TYMS (PA359)', '2A', 'Efficacy', 'capecitabine (PA448771),"fluorouracil (PA128406956)"', 'Oncology', 'Neoplasms (PA445062)', '"TTAAAG/TTAAAG:Patients with the TTAAAG/TTAAAG genotype and cancer who are treated with fluoropyrimidine-based chemotherapy may have decreased survival time, and decreased risk of toxicity, as compared to patients with the TTAAAG/del or del/del genotypes. Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin) or FOLFIRI (fluorouracil, leucovorin and irinotecan) or with other drugs such as paclitaxel. Other genetic and clinical factors may also influence a patient''s response to treatment.,"TTAAAG/del:Patients with the TTAAAG/del genotype and cancer who are treated with fluoropyrimidine-based chemotherapy may have increased survival time as compared to those with the TTAAAG/TTAAAG genotyoe, and decreased risk of toxicity as compared to those with the del/del genotype. Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin) or FOLFIRI (fluorouracil, leucovorin and irinotecan) or with other drugs such as paclitaxel. Other genetic and clinical factors may also influence a patient''s response to treatment.","del/del:Patients with the del/del genotype and cancer who are treated with fluoropyrimidine-based chemotherapy may have increased survival time, and increased risk of drug toxicity, as compared to patients with the TTAAAG/TTAAAG or TTAAAG/del genotype. Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin) or FOLFIRI (fluorouracil, leucovorin and irinotecan) or with other drugs such as paclitaxel. Other genetic and clinical factors may also influence a patient''s response to treatment."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (91, 'rs1517114', 'C8orf34 (PA142672353)', '2B', 'Toxicity/ADR', 'irinotecan (PA450085)', 'Oncology', 'Carcinoma, Non-Small-Cell Lung (PA443622)', '"CC:Patients with the CC genotype may have increased severity of Diarrhea when treated with irinotecan in people with Non-Small-Cell Lung Carcinoma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient''s risk for toxicity.,"CG:Patients with the CG genotype may have increased severity of Diarrhea when treated with irinotecan in people with Non-Small-Cell Lung Carcinoma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient''s risk for toxicity.","GG:Patients with the GG genotype may have decreased severity of Diarrhea when treated with irinotecan in people with Non-Small-Cell Lung Carcinoma as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence a patient''s risk for toxicity."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (247, 'rs6065', 'GP1BA (PA178)', '2B', 'Efficacy', 'aspirin (PA448497)', 'Drug Response effects/ toxicity', '', '"CC:Patients with the CC genotype may have an increased risk for aspirin resistance as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient''s response to aspirin.,"CT:Patients with the CT genotype may have a decreased, but not absent, risk for aspirin resistance as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient''s response to aspirin.","TT:Patients with the TT genotype may have a decreased, but not absent, risk for aspirin resistance as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient''s response to aspirin."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (93, 'rs1695', 'GSTP1 (PA29028)', '2A', 'Toxicity/ADR', 'Platinum compounds (PA164713176)', 'Oncology', 'Neoplasms (PA445062)', '"AA:Patients with the AA genotype and cancer who are treated with platinum-based drugs may have the highest risk of toxicity as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient''s risk for toxicity.,"AG:Patients with the AG genotype and cancer who are treated with platinum-based drugs may have an increased risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient''s risk for toxicity.","GG:Patients with the GG genotype and cancer who are treated with platinum-based drugs may have a decreased, but not absent, risk of toxicity as compared to patients with the AG and AA genotype. Other genetic and clinical factors may also influence a patient''s risk for toxicity."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (94, 'rs1695', 'GSTP1 (PA29028)', '2A', 'Efficacy', 'fluorouracil (PA128406956),"oxaliplatin (PA131285527)"', 'Oncology', '', '"AA:Patients with the AA genotype and cancer who are treated with fluorouracil and oxaliplatin may have poorer treatment outcome (reduced responsiveness, lower overall survival time, increased risk of death) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient''s response to fluorouracil and oxaliplatin treatment.,"AG:Patients with the AG genotype and cancer who are treated with fluorouracil and oxaliplatin may have better treatment outcome as compared to patients with the AA genotype, or may have poorer treatment outcome as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient''s response to fluorouracil and oxaliplatin treatment.","GG:Patients with the GG genotype and cancer who are treated with fluorouracil and oxaliplatin may have a better treatment outcome (increased response, increased overall survival time, reduced risk of death) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient''s response to fluorouracil and oxaliplatin treatment."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (95, 'rs1695', 'GSTP1 (PA29028)', '2A', 'Efficacy,"Toxicity/ADR"', 'cyclophosphamide (PA449165),"epirubicin (PA449476)"', 'Oncology', 'Breast Neoplasms (PA443560)', '"AA:Patients with the AA genotype and Breast Neoplasms who are treated with cyclophosphamide and epirubicin may have 1) increased drug response 2) decreased severity of toxicity as compared to patients with GG genotype. Some patients were additionally treated with fluorouracil. Other genetic and clinical factors may influence a patient''s response to cyclophosphamide, epirubicin and fluorouracil.,"AG:Patients with the AG genotype and Breast Neoplasms who are treated with cyclophosphamide and epirubicin may have 1) increased drug response 2) decreased severity of toxicity as compared to patients with GG genotype. Some patients were additionally treated with fluorouracilOther genetic and clinical factors may influence a patient''s response to cyclophosphamide, epirubicin and fluorouracil.","GG:Patients with the GG genotype and Breast Neoplasms who are treated with cyclophosphamide and epirubicin may have 1) decreased drug response 2) increased severity of toxicity as compared to patients with AG and AA genotype. Some patients were additionally treated with fluorouracil. Other genetic and clinical factors may influence a patient''s response to cyclophosphamide, epirubicin and fluorouracil."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (96, 'rs1695', 'GSTP1 (PA29028)', '2B', 'Toxicity/ADR', 'cisplatin (PA449014)', 'Oncology', 'Medulloblastoma (PA444898),"Testicular Neoplasms (PA445828)"', '"AA:Pediatric patients with the AA genotype and medulloblastoma may have a decreased risk of ototoxicity when treated with cisplatin-based regimens as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence risk of ototoxicity in patients receiving cisplatin-based regimens.,"AG:Pediatric patients with the AG genotype and medulloblastoma may have an increased risk of ototoxicity when treated with cisplatin-based regimens as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of ototoxicity in patients receiving cisplatin-based regimens.","GG:Pediatric patients with the GG genotype and medulloblastoma may have an increased risk of ototoxicity when treated with cisplatin-based regimens as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of ototoxicity in patients receiving cisplatin-based regimens."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (97, 'rs16960228', 'PRKCA (PA33759)', '2B', 'Efficacy', 'hydrochlorothiazide (PA449899)', 'Cardiovascular', 'Hypertension (PA444552)', '"AA:Patients with the AA genotype and hypertension who are treated with hydrochlorothiazide may have increased reduction of diastolic blood pressure as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient''s response to hydrochlorothiazide treatment.,"AG:Patients with the AG genotype and hypertension who are treated with hydrochlorothiazide may have increased reduction of diastolic blood pressure as compared to patients with the GG genotype and decreased reduction of diastolic blood pressure as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient''s response to hydrochlorothiazide treatment.","GG:Patients with the GG genotype and hypertension who are treated with hydrochlorothiazide may have a decreased reduction of diastolic blood pressure as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence a patient''s response to hydrochlorothiazide treatment."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (98, 'rs16969968', 'CHRNA5 (PA26491)', '2B', 'Toxicity/ADR', 'nicotine (PA450626)', 'Psychiatry', 'Tobacco Use Disorder (PA445876)', '"AA:Patients with AA genotype may have an increased risk for nicotine dependence when exposed to nicotine as compared to patients with the GG genotype. Some findings are based on haplotype studies with either rs680244 or rs680244, rs569207 rs578776, and rs1051730. Other genetic and clinical factors may influence a patient''s risk for nicotine dependency.,"AG:Patients with AG genotype may have an increased risk for nicotine dependence when exposed to nicotine as compared to patients with the GG genotype. Some findings are based on haplotype studies with either rs680244 or rs680244, rs569207 rs578776, and rs1051730. Other genetic and clinical factors may influence a patient''s risk for nicotine dependency.","GG:Patients with GG genotype may have a decreased, but not absent, risk for nicotine dependence when exposed to nicotine as compared to patients with the AG and AA genotype. Some findings are based on haplotype studies with either rs680244 or rs680244, rs569207 rs578776, and rs1051730. Other genetic and clinical factors may influence a patient''s risk for nicotine dependency."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (107, 'rs1799971', 'OPRM1 (PA31945)', '2B', 'Toxicity/ADR', 'ethanol (PA448073)', 'Drug Response effects/ toxicity', '', '"AA:Patients with the AA genotype may have a decreased, but not absent, severity of intoxication and a decreased response when exposed to ethanol as compared to patients with the AG and GG genotype. Other genetic and clinical factors may also influence a patient''s ethanol response.,"AG:Patients with the AG genotype may have an increased severity of intoxication and an increased response when exposed to ethanol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient''s ethanol response.","GG:Patients with the GG genotype may have an increased severity of intoxication and an increased response when exposed to ethanol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient''s ethanol response."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (99, 'rs1719247', '.', '2B', 'Toxicity/ADR', 'hmg coa reductase inhibitors (PA133950441),"simvastatin (PA451363)"', 'Drug Response effects/ toxicity', '', '"CC:Patients with the CC genotype may be more likely to experience myopathy when treated with statins as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence the likelihood of myopathy when a patient is treated with statins.,"CT:Patients with the CT genotype may be less likely to experience myopathy when treated with statins as compared to patients with the CC genotype, and more likely to experience myopathy when treated with statins as compared to patients with the TT genotype. Other genetic and clinical factors may also influence the likelihood of myopathy when a patient is treated with statins.","TT:Patients with the TT genotype may be less likely to experience myopathy when treated with statins as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence the likelihood of myopathy when a patient is treated with statins."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (100, 'rs17244841', 'HMGCR (PA189)', '2A', 'Efficacy', 'hmg coa reductase inhibitors (PA133950441),"pravastatin (PA451089)","simvastatin (PA451363)"', 'Drug Response effects/ toxicity', '', '"AA:Patients with the AA genotype who are treated with statins may be more likely to respond as compared to patients with the AT or TT genotype. Other genetic and clinical factors may also influence a patient''s response when treated with statins.,"AT:Patients with the AT genotype who are treated with statins may be less likely to respond as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient''s response when treated with statins.","TT:Patients with the TT genotype are too infrequent to have been assessed for this response."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (101, 'rs1751034', 'ABCC4 (PA397)', '2B', 'Metabolism/PK', 'tenofovir (PA10204)', 'Infectious Diseases', 'HIV (PA447230),"HIV Infections (PA446213)"', '"CC:The CC genotype carriers had lower tenofovir renal clearance, and higher AUC than TT genotype.,"CT:The TC genotype carriers had lower tenofovir renal clearance, and higher AUC than TT genotype.","TT:The TT genotype is associated with higher tenofovir renal clearance, and lower AUC compared to TC and CC cariers."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (102, 'rs17708472', 'VKORC1 (PA133787052)', '2A', 'Dosage', 'warfarin (PA451906)', 'variant implication on Dosing', '', '"AA:Patients with the AA genotype (homozygous for VKORC1*4) may require a higher dose of warfarin as compared to patients with the GG genotype. Some studies have not found a significant association between this variant and warfarin dose, however the majority report an association. Other genetic and clinical factors may also influence a patient''s required dose of warfarin.,"AG:Patients with the AG genotype (heterozygous for VKORC1*4) may require a higher dose of warfarin as compared to patients with the GG genotype. Some studies have not found a significant association between this variant and warfarin dose, however the majority report an association. Other genetic and clinical factors may also influence a patient''s required dose of warfarin.","GG:Patients with the GG genotype may require a lower dose of warfarin as compared to patients with the AG and AA genotype. Some studies have not found a significant association between this variant and warfarin dose, however the majority report an association. Other genetic and clinical factors may also influence a patient''s required dose of warfarin."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (103, 'rs17782313', 'MC4R (PA30676)', '2B', 'Toxicity/ADR', 'antipsychotics (PA452233)', 'Psychiatry', 'Schizophrenia (PA447216)', '"CC:Patients with the CC genotype and disorders requiring antipsychotic treatment (amisulpride, clozapine, olanzapine, paliperidone, quetiapine or risperidone) may have an increased risk of weight gain when treated with antipsychotics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of weight gain.,"CT:Patients with the CT genotype and disorders requiring antipsychotic treatment (amisulpride, clozapine, olanzapine, paliperidone, quetiapine or risperidone) may have an increased risk of weight gain when treated with antipsychotics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of weight gain.","TT:Patients with the TT genotype and disorders requiring antipsychotic treatment (amisulpride, clozapine, olanzapine, paliperidone, quetiapine or risperidone) may have a decreased risk of weight gain when treated with antipsychotics as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence risk of weight gain."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (104, 'rs1799752', 'ACE (PA139)', '2A', 'Efficacy', 'captopril (PA448780)', 'Metabolic disorder; Cardiovascular; Pulmonology', 'Diabetes Mellitus, Type 2 (PA443890),"Heart Failure (PA444370)","Pulmonary Disease, Chronic Obstructive (PA447178)"', '"ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC:Patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype and conditions such as heart failure, chronic obstructive pulmonary disease and Type 2 diabetes may have an increased response when treated with captopril as compared to patients with the del/del genotype. Responses were also tested within healthy individuals in one study. Other genetic and clinical factors may also influence a patient''s response to captopril.,"ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del:Patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del genotype and conditions such as heart failure, chronic obstructive pulmonary disease and Type 2 diabetes may have an increased response when treated with captopril as compared to patients with the del/del genotype, or a decreased response compared to patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype. Responses were also tested within healthy individuals in one study. Other genetic and clinical factors may also influence a patient''s response to captopril.","del/del:Patients with the del/del genotype and conditions such as heart failure, chronic obstructive pulmonary disease and Type 2 diabetes may have a decreased response when treated with captopril as compared to patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del or ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype. Responses were also tested within healthy individuals in one study. Other genetic and clinical factors may also influence a patient''s response to captopril."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (105, 'rs1799853', 'CYP2C9 (PA126)', '1A', 'Dosage', 'warfarin (PA451906)', 'variant implication on Dosing', '', '"CC:Patients with the CC genotype who are treated with warfarin may require an increased dose as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient''s dose of warfarin.,"CT:Patients with the CT genotype who are treated with warfarin may require a decreased dose as compared to patients with the CC genotype, but an increased dose compared to patients with TT genotype. Other genetic and clinical factors may also influence a patient''s dose of warfarin.","TT:Patients with the TT genotype who are treated with warfarin may require a decreased dose as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient''s dose of warfarin."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (106, 'rs1799930', 'NAT2 (PA18)', '2A', 'Toxicity/ADR,"Metabolism/PK"', 'ethambutol (PA164784021),"isoniazid (PA450112)","pyrazinamide (PA451182)","rifampin (PA451250)"', 'Pulmonology', 'Tuberculosis (PA445941)', '"AA:Patients with the AA genotype and tuberculosis (TB) may have an increased risk of hepatotoxicity when treated with anti-TB drugs as compared to patients with the GG genotype. They also may have decreased clearance of isoniazid as compared to those with the AG or GG genotype. Other genetic and clinical factors may also influence risk for hepatotoxicity and clearance of isoniazid.,"AG:Patients with the AG genotype and tuberculosis (TB) may have an increased risk of hepatotoxicity when treated with anti-TB drugs as compared to patients with the GG genotype, or a decreased risk as compared to patients with the AA genotype. They also may have increased clearance of isoniazid as compared to those with the AA genotype, and decreased clearance as compared to those with the GG genotype. Other genetic and clinical factors may also influence risk for hepatotoxicity and clearance of isoniazid.","GG:Patients with the GG genotype and tuberculosis (TB) may have a decreased risk of hepatotoxicity when treated with anti-TB drugs as compared to patients with the AA genotype. They also may have increased clearance of isoniazid as compared to those with the AA or AG genotype. Other genetic and clinical factors may also influence risk for hepatotoxicity and clearance of isoniazid."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (108, 'rs1799971', 'OPRM1 (PA31945)', '2B', 'Dosage,"Efficacy","Metabolism/PK"', 'alfentanil (PA448084),"buprenorphine (PA448685)","fentanyl (PA449599)","heroin (PA452619)","morphine (PA450550)","opioids (PA452618)","sufentanil (PA451527)","tramadol (PA451735)"', 'Pain Medicine', 'Pain (PA445208),"Pain, Postoperative (PA445210)"', '"AA:Individuals with the AA genotype may have improved response to opioids and may require a decreased dose as compared to individuals with the AG or GG genotypes. However this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient''s response to opioid drugs. ,"AG:Individuals with the AG genotype may experience decreased response to opioids and may require an increased dose as compared to individuals with the AA genotype. However this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient''s response on opioid drugs. ","GG:Individuals with the GG genotype may experience decreased response to opioids and may require an increased dose as compared to individuals with the AA genotype. However this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient''s response on opioid drugs. "');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (109, 'rs1799971', 'OPRM1 (PA31945)', '2B', 'Efficacy', 'naloxone (PA450586)', 'Drug Response effects/ toxicity', '', '"AA:Patients with the AA genotype who are treated with naloxone may have lower cortisol response as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence the response to naloxone.,"AG:Patients with the AG genotype who are treated with naloxone may have increased peak cortisol response as compared to patients with AA genotype.","GG:Patients with the GG genotype who are treated with naloxone may have increased peak cortisol response as compared to patients with AA genotype. Other genetic and clinical factors may also influence the response to naloxone."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (110, 'rs1799978', 'DRD2 (PA27478)', '2A', 'Efficacy', 'risperidone (PA451257)', 'Psychiatry', 'Schizophrenia (PA447216)', '"CC:Patients with the CC genotype and schizophrenia who are treated with risperidone may be less likely to have improvement in symptoms as compared to patients with the TC And TT genotype.,"CT:Patients with the TC genotype and schizophrenia who are treated with risperidone may be more likely to have improvement in symptoms as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient''s response to risperidone.","TT:Patients with the TT genotype and schizophrenia who are treated with risperidone may be more likely to have improvement in symptoms as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient''s response to risperidone."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (111, 'rs1800497', 'ANKK1 (PA134872551)', '2B', 'Toxicity/ADR', 'antipsychotics (PA452233),"clozapine (PA449061)","olanzapine (PA450688)","risperidone (PA451257)"', 'Endocrinology', 'Hyperprolactinemia (PA444545),"tardive dyskinesia (PA447268)","Weight gain (PA128406954)"', '"AA:Patients with the AA genotype may have increased risk of side effects including hyperprolactinemia and weight gain, but decreased risk of tardive dyskinesia, during treatment with antipsychotic drugs as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient''s risk for side effects.,"AG:Patients with the AG genotype may have increased risk of side effects including hyperprolactinemia and weight gain, but decreased risk of tardive dyskinesia during treatment with antipsychotic drugs as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient''s risk for side effects.","GG:Patients with the GG genotype may have decreased but not non-existant risk of side effects including hyperprolactinemia and weight gain, but increased risk of tardive dyskinesia, during treatment with antipsychotic drugs as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient''s risk for side effects."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (112, 'rs1800497', 'DRD2 (PA27478)', '2B', 'Toxicity/ADR', 'antipsychotics (PA452233),"clozapine (PA449061)","olanzapine (PA450688)","risperidone (PA451257)"', 'Endocrinology', 'Hyperprolactinemia (PA444545),"tardive dyskinesia (PA447268)","Weight gain (PA128406954)"', '"AA:Patients with the AA genotype may have increased risk of side effects including hyperprolactinemia and weight gain, but decreased risk of tardive dyskinesia, during treatment with antipsychotic drugs as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient''s risk for side effects.,"AG:Patients with the AG genotype may have increased risk of side effects including hyperprolactinemia and weight gain, but decreased risk of tardive dyskinesia during treatment with antipsychotic drugs as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient''s risk for side effects.","GG:Patients with the GG genotype may have decreased but not non-existant risk of side effects including hyperprolactinemia and weight gain, but increased risk of tardive dyskinesia, during treatment with antipsychotic drugs as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient''s risk for side effects."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (113, 'rs1800497', 'ANKK1 (PA134872551)', '2B', 'Toxicity/ADR', 'ethanol (PA448073)', 'Psychiatry', 'Alcoholism (PA443309)', '"AA:Patients with AA genotype may have an increased risk for Alcoholism when exposed to ethanol as compared to patients with the GG genotype. However, other studies have found no association. Other genetic and clinical factors may influence a patient''s risk for alcohol dependency.,"AG:Patients with AG genotype may have an increased risk for Alcoholism when exposed to ethanol as compared to patients with the GG genotype. However, other studies have found no association. Other genetic and clinical factors may influence a patient''s risk for alcohol dependency.","GG:Patients with GG genotype may have a decreased, but not absent, risk for Alcoholism when exposed to ethanol as compared to patients with the AG and AA genotype. However, other studies have found no association. Other genetic and clinical factors may influence a patient''s risk for alcohol dependency."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (114, 'rs1800497', 'DRD2 (PA27478)', '2B', 'Toxicity/ADR', 'ethanol (PA448073)', 'Psychiatry', 'Alcoholism (PA443309)', '"AA:Patients with AA genotype may have an increased risk for Alcoholism when exposed to ethanol as compared to patients with the GG genotype. However, other studies have found no association. Other genetic and clinical factors may influence a patient''s risk for alcohol dependency.,"AG:Patients with AG genotype may have an increased risk for Alcoholism when exposed to ethanol as compared to patients with the GG genotype. However, other studies have found no association. Other genetic and clinical factors may influence a patient''s risk for alcohol dependency.","GG:Patients with GG genotype may have a decreased, but not absent, risk for Alcoholism when exposed to ethanol as compared to patients with the AG and AA genotype. However, other studies have found no association. Other genetic and clinical factors may influence a patient''s risk for alcohol dependency."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (115, 'rs1800559', 'CACNA1S (PA85)', '1A', 'Toxicity/ADR', 'desflurane (PA164749136),"enflurane (PA449461)","halothane (PA449845)","isoflurane (PA450106)","methoxyflurane (PA450434)","sevoflurane (PA451341)","succinylcholine (PA451522)"', 'Pharmacogenetic disorder', 'Malignant Hyperthermia (PA444863)', '"CC:Patients with the CC genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CT or TT genotype. Other genetic or clinical factors may put a patient at risk for developing malignant hyperthermia.,"CT:Patients with the CT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CC genotype. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).","TT:Patients with the TT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CC genotype. Please note: the T allele is considered to confer MH in an autosomal dominant manner. This clinical annotation is based on two case studies and there were no individuals with the TT genotype. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations)."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (116, 'rs1800566', 'NQO1 (PA31744)', '2A', 'Efficacy', 'Alkylating Agents (PA164712331),"anthracyclines and related substances (PA130620651)","fluorouracil (PA128406956)","Platinum compounds (PA164713176)"', 'Oncology', 'Breast Neoplasms (PA443560),"Carcinoma, Non-Small-Cell Lung (PA443622)","Neoplasms (PA445062)","Ovarian Neoplasms (PA445204)","Stomach Neoplasms (PA445742)"', '"AA:Patients with the AA genotype and cancer who are treated with chemotherapy regimes that include platinum compounds, anthracyclines and related substances, and nucleoside inhibitors may have worse outcome (overall survival and progression-free survival) as compared to patients with the GG genotype. However, this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient''s treatment outcome.,"AG:Patients with the AG genotype and cancer who are treated with chemotherapy regimes that include platinum compounds, anthracyclines and related substances, and nucleoside inhibitors may have a a better outcome (overall survival and progression-free survival) as compared to patients with the AA genotype and a worse outcome as compared to patients with the GG genotype. However, this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient''s treatment outcome.","GG:Patients with the GG genotype and Breast Neoplasms and cancer who are treated with chemotherapy regimes that include platinum compounds, anthracyclines and related substances, and nucleoside inhibitors may have a better outcome (overall survival and progression-free survival) as compared to patients with the AA genotype. However, this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient''s treatment outcome."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (117, 'rs1800629', 'TNF (PA435)', '2B', 'Efficacy', 'adalimumab (PA10004),"etanercept (PA449515)","infliximab (PA452639)","Tumor necrosis factor alpha (TNF-alpha) inhibitors (PA164713366)"', 'Immunology', 'Arthritis, Psoriatic (PA446198),"Arthritis, Rheumatoid (PA443434)","Crohn Disease (PA443815)","Inflammation (PA444620)","Psoriasis (PA445451)","Spondylitis, Ankylosing (PA445724)"', '"AA:Patients with the AA genotype and inflammatory diseases who are treated with anti-TNF therapies may be less likely to have improvement in symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient''s response to anti-TNF therapy.,"AG:Patients with the AG genotype and inflammatory diseases who are treated with anti-TNF therapies may be less likely to have improvement in symptoms as compared to patients with the GG genotype or may be more likely to have improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient''s response to anti-TNF therapy.","GG:Patients with the GG genotype and inflammatory diseases who are treated with anti-TNF therapies may be more likely to have improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient''s response to anti-TNF therapy."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (118, 'rs1801019', 'UMPS (PA363)', '2B', 'Toxicity/ADR', 'capecitabine (PA448771),"fluorouracil (PA128406956)","leucovorin (PA450198)","tegafur (PA452620)"', 'Pharmacogenetic disorder', 'Drug Toxicity (PA443937)', '"CC:Patients with CC genotype and cancer may have an increased risk for toxicity (Diarrhea, any grade 3 adverse event) when treated with leucovorin and tegafur or fluorouracil and leucovorin as compared to patients with the CG and GG genotype. One study found no association between the CC genotype and risk of drug toxicity in patients administered capecitabine and/or fluorouracil. Other genetic and clinical factors may also influence incidence of toxicity to leucovorin, tegafur, capecitabine and fluorouracil.,"CG:Patients with CG genotype and cancer may have a decreased, but not absent, risk for toxicity (Diarrhea, any grade 3 adverse event) when treated with leucovorin and tegafur or fluorouracil and leucovorin as compared to patients with the CC genotype. However, contradictory findings have been reported that show the CG genotype may be associated with increased risk for grade 3 to 4 diarrhea when treated with fluorouracil and leucovorin compared to the GG genotype. Another study found no association between the CG genotype and risk of drug toxicity in patients administered capecitabine and/or fluorouracil. Other genetic and clinical factors may also influence incidence of toxicity to leucovorin, tegafur, capecitabine and fluorouracil.","GG:Patients with GG genotype and cancer may have a decreased, but not absent, risk for toxicity (Diarrhea, any grade 3 adverse event) when treated with leucovorin and tegafur or fluorouracil and leucovorin as compared to patients with the CC genotype. One study found no association between the GG genotype and risk of drug toxicity in patients administered capecitabine and/or fluorouracil. Other genetic and clinical factors may also influence incidence of toxicity to leucovorin, tegafur, capecitabine and fluorouracil."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (119, 'rs1801086', 'RYR1 (PA34896)', '1A', 'Toxicity/ADR', 'desflurane (PA164749136),"enflurane (PA449461)","halothane (PA449845)","isoflurane (PA450106)","methoxyflurane (PA450434)","sevoflurane (PA451341)","succinylcholine (PA451522)"', 'Pharmacogenetic disorder', 'Malignant Hyperthermia (PA444863)', '"AA:Patients with the AA genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG. Please note: the A allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes. Other genetic or clinical factors may also influence whether a patient develops malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).,"AG:Patients with the AG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG. Other genetic or clinical factors may also influence whether a patient develops malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).","CC:Patients with the CC genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG. Please note: the C allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes. Other genetic or clinical factors may also influence whether a patient develops malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).","CG:Patients with the CG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).","GG:Patients with the GG genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype AA, AG, CC, CG. Other genetic or clinical factors may put a patient at risk for developing malignant hyperthermia."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (248, 'rs61742245', 'VKORC1 (PA133787052)', '2A', 'Dosage', 'warfarin (PA451906)', 'Drug Response effects/ toxicity', '', '"AA:Patients with the AA genotype may have increased dose of warfarin as compared to patients with genotype CC. Other genetic and clinical factors may also influence the dose of warfarin.,"AC:Patients with the AC genotype may have increased dose of warfarin as compared to patients with genotype CC. Other genetic and clinical factors may also influence the dose of warfarin.","CC:Patients with the CC genotype may have decreased dose of warfarin as compared to patients with genotype AA or AC. Other genetic and clinical factors may also influence the dose of warfarin."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (120, 'rs1801133', 'MTHFR (PA245)', '2A', 'Dosage,"Efficacy","Toxicity/ADR"', 'methotrexate (PA450428)', 'Oncology', 'Neoplasms (PA445062)', '"AA:Patients with the AA genotype and leukemia or lymphoma who are treated with methotrexate: 1) may have poorer response to treatment 2) may be at increased risk of toxicity 3) may require a lower dose of methotrexate, and 4) may be at greater risk of folate deficiency as compared to patients with the AG or GG genotype. This association has been contradicted or not found in multiple studies. Other genetic and clinical factors may also influence a patient''s risk for toxicity and response with methotrexate treatment.,"AG:Patients with the AG genotype and leukemia or lymphoma who are treated with methotrexate: 1) may have poorer response to treatment 2) may be at increased risk of toxicity 3) may require a lower dose of methotrexate, and 4) may be at greater risk of folate deficiency as compared to patients with the GG genotype, or 1) may have better response to treatment 2) may be at decreased risk of toxicity, and 3) may require a higher dose of methotrexate as compared to patients with the AA genotype. This association has been contradicted or not found in multiple studies. Other genetic and clinical factors may also influence a patient''s risk for toxicity and response with methotrexate treatment.","GG:Patients with the GG genotype and leukemia or lymphoma who are treated with methotrexate: 1) may have better response to treatment 2) may be at decreased risk of toxicity 3) may require a higher dose of methotrexate, and 4) may be at lower risk of folate deficiency as compared to patients with the AA or AG genotype. This association has been contradicted or not found in multiple studies. Other genetic and clinical factors may also influence a patient''s risk for toxicity and response with methotrexate treatment."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (121, 'rs1801133', 'MTHFR (PA245)', '2A', 'Efficacy', 'carboplatin (PA448803),"cisplatin (PA449014)"', 'Oncology', 'Neoplasms (PA445062)', '"AA:Patients with AA genotype and cancer may have increased risk of drug toxicity and an increased response to treatment with cisplatin or carboplatin as compared to patients with the AG or GG genotype. However, conflicting evidence exists for this association. Other genetic and clinical factors may also influence a patient''s response and risk for toxicity when receiving platinum-based chemotherapy.,"AG:Patients with AG genotype and cancer may have a decreased risk of drug toxicity and a decreased response to treatment with cisplatin or carboplatin as compared to patients with the AA genotype. However, conflicting evidence exists for this association. Other genetic and clinical factors may also influence a patient''s response and risk for toxicity when receiving platinum-based chemotherapy.","GG:Patients with GG genotype and cancer may have a decreased risk of drug toxicity and a decreased response to treatment with cisplatin or carboplatin as compared to patients with the AA genotype. However, conflicting evidence exists for this association. Other genetic and clinical factors may also influence a patient''s response and risk for toxicity when receiving platinum-based chemotherapy."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (122, 'rs1801274', 'FCGR2A (PA28063)', '2B', 'Efficacy', 'trastuzumab (PA451743)', 'Oncology', 'Breast Neoplasms (PA443560)', '"AA:Patients with the AA genotype may have increased response to trastuzumab and longer progression-free survival in people with Breast cancer as compared to patients with genotype AG or GG. Other genetic or clinical factors may also influence the response to trastuzumab.,"AG:Patients with the AG genotype may have decreased response to trastuzumab and shorter progression-free survival in people with Breast cancer as compared to patients with genotype AA. Other genetic or clinical factors may also influence the response to trastuzumab.","GG:Patients with the GG genotype may have decreased response to trastuzumab and shorter progression-free survival in people with Breast cancer as compared to patients with genotype AA. Other genetic or clinical factors may also influence the response to trastuzumab."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (123, 'rs1801394', 'MTRR (PA31277)', '2B', 'Toxicity/ADR', 'methotrexate (PA450428)', 'Oncology', 'Precursor Cell Lymphoblastic Leukemia-Lymphoma (PA446155)', '"AA:Pediatric ALL patients with AA genotypes may have decreased likelihood of methotrexate induced toxicity (oral mucositis), decreased response and decreased catalytic activity of TYMS in lymphoblasts when treated with methotrexate as compared to patients with the GG and AG genotype. Other genetic and clinical factors may also influence response to methotrexate.,"AG:Pediatric ALL patients with AG genotypes may have increased likelihood of methotrexate induced toxicity (oral mucositis), increased speed of platelet recovery, increased response and increased catalytic activity of TYMS in lymphoblasts when treated with methotrexate as compared to patients with the AA genotype. Allele G is not associated with decreased IQ in pediatric ALL patients treated with methotrexate. Other genetic and clinical factors may also influence response to methotrexate.","GG:Pediatric ALL patients with GG genotypes may have increased likelihood of methotrexate induced toxicity (oral mucositis), increased response, and increased catalytic activity of TYMS in lymphoblasts when treated with methotrexate as compared to patients with the AA genotype. Allele G is not associated with decreased IQ in pediatric ALL patients treated with methotrexate. Other genetic and clinical factors may also influence response to methotrexate."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (124, 'rs186045772', 'CFTR (PA109)', '1A', 'Efficacy', 'ivacaftor (PA165950341)', 'Pulmonology', 'Cystic Fibrosis (PA443829)', '"AA:Patients with the AA genotype (two copies of the CFTR F1074L variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including F1074L. Other genetic and clinical factors may also influence a patient''s response to ivacaftor.,"AT:Patients with the AT genotype (one copy of the CFTR F1074L variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including F1074L. Other genetic and clinical factors may also influence a patient''s response to ivacaftor.","TT:Patients with the TT genotype (do not have a copy of the CFTR F1074L variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including F1074L. Other genetic and clinical factors may also influence a patient''s response to ivacaftor."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (163, 'rs2231142', 'ABCG2 (PA390)', '2B', 'Dosage,"Efficacy"', 'allopurinol (PA448320)', 'Immunology', 'Gout (PA444318)', '"GG:Patients with the GG genotype and gout may have improved response when treated with allopurinol and may require a decreased dose as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also influence response to or dose of allopurinol.,"GT:Patients with the GT genotype and gout may have worse response when treated with allopurinol, and may require a higher dose as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to and dose of allopurinol.","TT:Patients with the TT genotype and gout may have worse response when treated with allopurinol and may require a higher dose as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to and dose of allopurinol."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (125, 'rs1872328', 'ACYP2 (PA24500)', '2B', 'Toxicity/ADR', 'cisplatin (PA449014)', 'Oncology', 'Brain Neoplasms (PA443557),"Deafness (PA443840)","Ototoxicity (PA162263534)"', '"AA:Patients with brain tumors, osteosarcoma, and other cancers and the AA genotype may have an increased risk of ototoxicity when treated with regimens containing cisplatin as compared to patients with the GG genotypes. Other clinical and genetic factors may also influence risk of ototoxicity in patients exposed to cisplatin. ,"AG:Patients with brain tumors, osteosarcoma, and other cancers and the AG genotype may have an increased risk of ototoxicity when treated with regimens containing cisplatin as compared to patients with the GG genotypes. Other clinical and genetic factors may also influence risk of ototoxicity in pediatric patients exposed to cisplatin. ","GG:Patients with brain tumors, osteosarcoma, and other cancers and the GG genotype may have a decreased risk of ototoxicity when treated with regimens containing cisplatin as compared to patients with the AA or AG genotypes. Other clinical and genetic factors may also influence risk of ototoxicityin patients exposed to cisplatin. "');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (126, 'rs1876828', 'CRHR1 (PA26874)', '2B', 'Efficacy', 'budesonide (PA448681),"corticosteroids (PA10832)","fluticasone propionate (PA449686)","fluticasone/salmeterol (PA165290926)","triamcinolone (PA451749)"', 'Pulmonology', 'Asthma (PA443450)', '"CC:Patients with the CC genotype may have 1) decreased short term response to inhaled corticosteroids (as measured by FEV after 6 weeks of treatment) and 2) increased endogenous cortisol compared to patients with the TT genotypes. Other genetic and clinical factors may also influence a patient''s hypothalamic pituitary adrenal axis and response to corticosteroids.,"CT:Patients with the CT genotype may have decreased short term response to inhaled corticosteroids (as measured by FEV after 6 weeks of treatment). Other genetic and clinical factors may also influence a patient''s hypothalamic pituitary adrenal axis and response to corticosteroids.","TT:Patients with the TT genotype may have 1) increased short term response to inhaled corticosteroids (as measured by FEV after 6 weeks of treatment) and 2) altered hypothalamic pituitary adrenal axis and decreased endogenous cortisol compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence a patient''s hypothalamic pituitary adrenal axis and response to corticosteroids."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (127, 'rs1902023', 'UGT2B15 (PA37188)', '2B', 'Other', 'lorazepam (PA450267),"oxazepam (PA450731)"', 'drug response clearence', '', '"AA:Subjects with the AA genotype may have decreased clearance of oxazepam or lorazepam as compared to subjects with the CC genotype. Other genetic and clinical factors may also influence the oral clearance of oxazepam or lorazepam.,"AC:Subjects with the AC genotype may have decreased clearance of oxazepam or lorazepam as compared to subjects with the CC genotype, or increased clearance as compared to subjects with the AA genotype. Other genetic and clinical factors may also influence the oral clearance of oxazepam or lorazepam.","CC:Subjects with the CC genotype may have increased clearance of oxazepam or lorazepam as compared to subjects with the AA genotype. Other genetic and clinical factors may also influence the oral clearance of oxazepam or lorazepam. "');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (128, 'rs1933437', 'FLT3 (PA28181)', '2B', 'Toxicity/ADR', 'sunitinib (PA162372840)', 'Oncology', 'Carcinoma, Renal Cell (PA443624),"Leukopenia (PA444773)"', '"AA:Patients with renal cell carcinoma and the AA genotype who are treated with sunitinib may have an increased risk of experiencing leukopenia, and possibly thrombocytopenia and neutropenia, as compared to patients with the AG and GG genotypes, however, this is contradicted in one study. Other clinical and genetic factors may also influence risk of leukopenia in patients with renal cell carcinoma who are administered sunitinib.,"AG:Patients with renal cell carcinoma and the AG genotype who are treated with sunitinib may have a decreased risk of experiencing leukopenia, and possibly thrombocytopenia and neutropenia, as compared to patients with the AA genotypes, however, this is contradicted in one study. Other clinical and genetic factors may also influence risk of leukopenia in patients with renal cell carcinoma who are administered sunitinib.","GG:Patients with renal cell carcinoma and the GG genotype who are treated with sunitinib may have a decreased risk of experiencing leukopenia, and possibly thrombocytopenia and neutropenia, as compared to patients with the AA genotypes, however, this is contradicted in one study. Other clinical and genetic factors may also influence risk of leukopenia in patients with renal cell carcinoma who are administered sunitinib."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (129, 'rs193922525', 'CFTR (PA109)', '1A', 'Efficacy', 'ivacaftor (PA165950341)', 'Pulmonology', 'Cystic Fibrosis (PA443829)', '"AA:Patients with the AA genotype (two copies of the CFTR G1349D variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including G1349D. Other genetic and clinical factors may also influence a patient''s response to ivacaftor. ,"AG:Patients with the AG genotype (one copy of the CFTR G1349D variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including G1349D. Other genetic and clinical factors may also influence a patient''s response to ivacaftor. ","GG:Patients with the GG genotype (do not have a copy of the CFTR G1349D variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including G1349D. Other genetic and clinical factors may also influence a patient''s response to ivacaftor."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (136, 'rs193922770', 'RYR1 (PA34896)', '1A', 'Toxicity/ADR', 'desflurane (PA164749136),"enflurane (PA449461)","halothane (PA449845)","isoflurane (PA450106)","methoxyflurane (PA450434)","sevoflurane (PA451341)","succinylcholine (PA451522)"', 'Pharmacogenetic disorder', 'Malignant Hyperthermia (PA444863)', '"CC:Patients with the CC genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CT or TT genotype. Other genetic or clinical factors may put a patient at risk for developing malignant hyperthermia.,"CT:Patients with the CT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CC genotype. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).","TT:Patients with the TT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CC genotype. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. Please note: the T allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations)."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (130, 'rs193922747', 'RYR1 (PA34896)', '1A', 'Toxicity/ADR', 'desflurane (PA164749136),"enflurane (PA449461)","halothane (PA449845)","isoflurane (PA450106)","methoxyflurane (PA450434)","sevoflurane (PA451341)","succinylcholine (PA451522)"', 'Pharmacogenetic disorder', 'Malignant Hyperthermia (PA444863)', '"CC:Patients with the CC genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype TT. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).,"CT:Patients with the CT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype TT. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).","TT:Patients with the TT genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype CT and CC. Other genetic or clinical factors may put a patient at risk for developing malignant hyperthermia."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (131, 'rs193922748', 'RYR1 (PA34896)', '1A', 'Toxicity/ADR', 'desflurane (PA164749136),"enflurane (PA449461)","halothane (PA449845)","isoflurane (PA450106)","methoxyflurane (PA450434)","sevoflurane (PA451341)","succinylcholine (PA451522)"', 'Pharmacogenetic disorder', 'Malignant Hyperthermia (PA444863)', '"CC:Patients with the CC genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CT or TT genotype. Other genetic or clinical factors may put a patient at risk for developing malignant hyperthermia.,"CT:Patients with the CT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CC genotype. Other clinical and genetic factors also influence whether an individual develops malignant hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).","TT:Patients with the TT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CC genotype. Other clinical and genetic factors also influence whether an individual develops malignant hyperthermia. Please note: the T allele is considered to confer MH in an autosomal dominant manner and is reported in heterozygotes. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations)."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (132, 'rs193922753', 'RYR1 (PA34896)', '1A', 'Toxicity/ADR', 'desflurane (PA164749136),"enflurane (PA449461)","halothane (PA449845)","isoflurane (PA450106)","methoxyflurane (PA450434)","sevoflurane (PA451341)","succinylcholine (PA451522)"', 'Pharmacogenetic disorder', 'Malignant Hyperthermia (PA444863)', '"GG:Patients with the GG genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GT and TT. Other genetic or clinical factors may put a patient at risk for developing malignant hyperthermia.,"GT:Patients with the GT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).","TT:Patients with the TT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG. Please note: the T allele confers MH in an autosomal dominant manner and is almost always reported in heterozygotes. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations)."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (133, 'rs193922762', 'RYR1 (PA34896)', '1A', 'Toxicity/ADR', 'desflurane (PA164749136),"enflurane (PA449461)","halothane (PA449845)","isoflurane (PA450106)","methoxyflurane (PA450434)","sevoflurane (PA451341)","succinylcholine (PA451522)"', 'Pharmacogenetic disorder', 'Malignant Hyperthermia (PA444863)', '"CC:Patients with the CC genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CT or TT genotype. Other genetic or clinical factors may put a patient at risk for developing malignant hyperthermia.,"CT:Patients with the CT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CC genotype. Other clinical and genetic factors also influence whether an individual develops malignant hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).","TT:Patients with the TT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CC genotype. Other clinical and genetic factors also influence whether an individual develops malignant hyperthermia. Please note: the T allele is considered to confer MH in an autosomal dominant manner and is reported in heterozygotes. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations)."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (134, 'rs193922764', 'RYR1 (PA34896)', '1A', 'Toxicity/ADR', 'desflurane (PA164749136),"enflurane (PA449461)","halothane (PA449845)","isoflurane (PA450106)","methoxyflurane (PA450434)","sevoflurane (PA451341)","succinylcholine (PA451522)","volatile anesthetics (PA166131630)"', 'Pharmacogenetic disorder', 'Malignant Hyperthermia (PA444863)', '"CC:Patients with the CC genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CT or TT genotype. Other genetic or clinical factors may put a patient at risk for developing malignant hyperthermia.,"CT:Patients with the CT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CC genotype. Other clinical and genetic factors also influence whether an individual develops malignant hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).","TT:Patients with the TT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CC genotype. Other clinical and genetic factors also influence whether an individual develops malignant hyperthermia. Please note: the T allele is considered to confer MH in an autosomal dominant manner and is reported in heterozygotes. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations)."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (135, 'rs193922768', 'RYR1 (PA34896)', '1A', 'Toxicity/ADR', 'desflurane (PA164749136),"enflurane (PA449461)","halothane (PA449845)","isoflurane (PA450106)","methoxyflurane (PA450434)","sevoflurane (PA451341)","succinylcholine (PA451522)"', 'Pharmacogenetic disorder', 'Malignant Hyperthermia (PA444863)', '"CC:Patients with the CC genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CT or TT genotype. Other genetic or clinical factors may put a patient at risk for developing malignant hyperthermia.,"CT:Patients with the CT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CC genotype. Other clinical and genetic factors also influence whether an individual develops malignant hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).","TT:Patients with the TT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CC genotype. Other clinical and genetic factors also influence whether an individual develops malignant hyperthermia. Please note: the T allele is considered to confer MH in an autosomal dominant manner and is reported in heterozygotes. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations)."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (249, 'rs61750900', 'UGT2B10 (PA37186)', '2B', 'Metabolism/PK', 'nicotine (PA450626)', 'variant implication on drug metabolism', '', '"GG:Patients with the GG genotype may have an increased metabolism of nicotine as compared to patients with the TT genotype. Other genetic and clinical factors may also effect patients'' response to nicotine.,"GT:Patients with the GT genotype may have a decreased metabolism of nicotine as compared to patients with the TT genotype. Other genetic and clinical factors may also effect patients'' response to nicotine.","TT:Patients with the TT genotype may have a decreased metabolism of nicotine as compared to patients with the GG genotype. Other genetic and clinical factors may also effect patients'' response to nicotine."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (137, 'rs193922772', 'RYR1 (PA34896)', '1A', 'Toxicity/ADR', 'desflurane (PA164749136),"enflurane (PA449461)","halothane (PA449845)","isoflurane (PA450106)","methoxyflurane (PA450434)","sevoflurane (PA451341)","succinylcholine (PA451522)"', 'Pharmacogenetic disorder', 'Malignant Hyperthermia (PA444863)', '"GG:Patients with the GG genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the GT or TT genotype. Other genetic or clinical factors may put a patient at risk for developing malignant hyperthermia.,"GT:Patients with the GT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the GG genotype. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).","TT:Patients with the TT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the GG genotype. Please note: the T allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations)."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (138, 'rs193922802', 'RYR1 (PA34896)', '1A', 'Toxicity/ADR', 'desflurane (PA164749136),"enflurane (PA449461)","halothane (PA449845)","isoflurane (PA450106)","methoxyflurane (PA450434)","sevoflurane (PA451341)","succinylcholine (PA451522)"', 'Pharmacogenetic disorder', 'Malignant Hyperthermia (PA444863)', '"AA:Patients with the AA genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the GG genotype. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. Please note: the A allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).,"AG:Patients with the AG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the GG genotype. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).","GG:Patients with the GG genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the AG or AA genotype. Other genetic or clinical factors may put a patient at risk for developing Malignant Hyperthermia."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (139, 'rs193922803', 'RYR1 (PA34896)', '1A', 'Toxicity/ADR', 'desflurane (PA164749136),"enflurane (PA449461)","halothane (PA449845)","isoflurane (PA450106)","methoxyflurane (PA450434)","sevoflurane (PA451341)","succinylcholine (PA451522)"', 'Pharmacogenetic disorder', 'Malignant Hyperthermia (PA444863)', '"CC:Patients with the CC genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CT or TT genotype. Other genetic or clinical factors may put a patient at risk for developing Malignant Hyperthermia.,"CT:Patients with the CT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CC genotype. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).","TT:Patients with the TT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CC genotype. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. Please note: the T allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations)."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (140, 'rs193922807', 'RYR1 (PA34896)', '1A', 'Toxicity/ADR', 'desflurane (PA164749136),"enflurane (PA449461)","halothane (PA449845)","isoflurane (PA450106)","methoxyflurane (PA450434)","sevoflurane (PA451341)","succinylcholine (PA451522)"', 'Pharmacogenetic disorder', 'Malignant Hyperthermia (PA444863)', '"CC:Patients with the CC genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the GG genotype. Please note: the C allele confers MH in an autosomal dominant manner and is almost always reported in heterozygotes. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).,"CG:Patients with the CG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the GG genotype. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).","GG:Patients with the GG genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CG or CC genotype. Other genetic or clinical factors may put a patient at risk for developing Malignant Hyperthermia."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (141, 'rs193922809', 'RYR1 (PA34896)', '1A', 'Toxicity/ADR', 'desflurane (PA164749136),"enflurane (PA449461)","halothane (PA449845)","isoflurane (PA450106)","methoxyflurane (PA450434)","sevoflurane (PA451341)","succinylcholine (PA451522)"', 'Pharmacogenetic disorder', 'Malignant Hyperthermia (PA444863)', '"AA:Patients with the AA genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the GG genotype. Please note: the A allele is considered to cause MH in an autosomal dominant manner and is almost always reported in heterozygotes. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).,"AG:Patients with the AG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the GG genotype. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).","GG:Patients with the GG genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the AG or AA genotype. Other genetic or clinical factors may put a patient at risk for developing Malignant Hyperthermia."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (142, 'rs193922816', 'RYR1 (PA34896)', '1A', 'Toxicity/ADR', 'desflurane (PA164749136),"enflurane (PA449461)","halothane (PA449845)","isoflurane (PA450106)","methoxyflurane (PA450434)","sevoflurane (PA451341)","succinylcholine (PA451522)"', 'Pharmacogenetic disorder', 'Malignant Hyperthermia (PA444863),"Myopathy, Central Core (PA447048)"', '"CC:Patients with the CC genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CT or TT genotype. Other genetic or clinical factors may put a patient at risk for developing Malignant Hyperthermia.,"CT:Patients with the CT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CC genotype. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia.The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).","TT:Patients with the TT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CC genotype. Please note: the T allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations)."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (143, 'rs193922818', 'RYR1 (PA34896)', '1A', 'Toxicity/ADR', 'desflurane (PA164749136),"enflurane (PA449461)","halothane (PA449845)","isoflurane (PA450106)","methoxyflurane (PA450434)","sevoflurane (PA451341)","succinylcholine (PA451522)"', 'Pharmacogenetic disorder', 'Malignant Hyperthermia (PA444863)', '"AA:Patients with the AA genotype may develop Malignant Hyperthermia (MH) when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the GG genotype. Please note: the A allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).,"AG:Patients with the AG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the GG genotype. The A allele is considered to confer MH in an autosomal dominant manner. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).","GG:Patients with the GG genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with AG or AA genotype. Other genetic or clinical factors may put a patient at risk for developing Malignant Hyperthermia."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (257, 'rs6988229', 'COL22A1 (PA134914705)', '2B', 'Efficacy', 'salbutamol (PA448068)', 'Pulmonology', 'Asthma (PA443450)', '"CC:Patients with CC genotypes may have decreased bronchodilator response (FEV1) when treated with salbutamol in asthma when compared to patients with TT genotypes. Other genetic and clinical factors may also influence a patient''s response to therapy.,"TC:Patients with TC genotypes may have increased bronchodilator response (FEV1) when treated with salbutamol in asthma when compared to patients with CC genotypes. Other genetic and clinical factors may also influence a patient''s response to therapy.","TT:Patients with TT genotypes may have increased bronchodilator response (FEV1) when treated with salbutamol in asthma when compared to patients with CC genotypes. Other genetic and clinical factors may also influence a patient''s response to therapy."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (144, 'rs193922832', 'RYR1 (PA34896)', '1A', 'Toxicity/ADR', 'desflurane (PA164749136),"enflurane (PA449461)","halothane (PA449845)","isoflurane (PA450106)","methoxyflurane (PA450434)","sevoflurane (PA451341)","succinylcholine (PA451522)","volatile anesthetics (PA166131630)"', 'Pharmacogenetic disorder', 'Malignant Hyperthermia (PA444863)', '"AA:Patients with the AA genotype may develop Malignant Hyperthermia (MH) when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the GG genotype. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. Please note: the A allele is considered to confer MH in an autosomal dominant manner and is reported in heterozygotes. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).,"AG:Patients with the AG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the GG genotype. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).","GG:Patients with the GG genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with AA or AG genotype. Other genetic or clinical factors may put a patient at risk for developing Malignant Hyperthermia."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (145, 'rs193922843', 'RYR1 (PA34896)', '1A', 'Toxicity/ADR', 'desflurane (PA164749136),"enflurane (PA449461)","halothane (PA449845)","isoflurane (PA450106)","methoxyflurane (PA450434)","sevoflurane (PA451341)","succinylcholine (PA451522)","volatile anesthetics (PA166131630)"', 'Pharmacogenetic disorder', 'Malignant Hyperthermia (PA444863)', '"GG:Patients with the GG genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the AG or AA genotype. Other genetic or clinical factors may put a patient at risk for developing Malignant Hyperthermia.,"GT:Patients with the GT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the GG genotype. Other clinical and genetic factors also influence whether an individual develops Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).","TT:Patients with the TT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the GG genotype. Other clinical and genetic factors also influence whether an individual develops Malignant Hyperthermia. Please note: the T allele is considered to confer MH in an autosomal dominant manner and is reported in heterozygotes. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations)."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (146, 'rs193922876', 'RYR1 (PA34896)', '1A', 'Toxicity/ADR', 'desflurane (PA164749136),"enflurane (PA449461)","halothane (PA449845)","isoflurane (PA450106)","methoxyflurane (PA450434)","sevoflurane (PA451341)","succinylcholine (PA451522)"', 'Pharmacogenetic disorder', 'Malignant Hyperthermia (PA444863)', '"CC:Patients with the CC genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CT or TT genotype. Other genetic or clinical factors may put a patient at risk for developing Malignant Hyperthermia.,"CT:Patients with the CT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CC genotype. Other clinical and genetic factors also influence whether an individual develops malignant hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).","TT:Patients with the TT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CC genotype. Other clinical and genetic factors also influence whether an individual develops malignant hyperthermia. Please note: the T allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations)."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (147, 'rs193922878', 'RYR1 (PA34896)', '1A', 'Toxicity/ADR', 'desflurane (PA164749136),"enflurane (PA449461)","halothane (PA449845)","isoflurane (PA450106)","methoxyflurane (PA450434)","sevoflurane (PA451341)","succinylcholine (PA451522)"', 'Pharmacogenetic disorder', 'Malignant Hyperthermia (PA444863)', '"CC:Patients with the CC genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CG or GG genotype. Other genetic or clinical factors may put a patient at risk for developing Malignant Hyperthermia.,"CG:Patients with the CG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CC genotype. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).","GG:Patients with the GG genotype may develop Malignant Hyperthermia (MH) when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CC genotype. Please note: the G allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations)."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (148, 'rs1954787', 'GRIK4 (PA28976)', '2B', 'Efficacy', 'antidepressants (PA452229)', 'Psychiatry', 'Depression (PA447278),"Depressive Disorder (PA447207)","Depressive Disorder, Major (PA447321)"', '"CC:Patients with the CC genotype and Depressive Disorder or Depression may be more likely to respond to antidepressant treatment as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient''s response to anti-depressants. ,"CT:Patients with the CT genotype and Depressive Disorder or Depression may be less likely to respond to antidepressant treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient''s response to anti-depressants. ","TT:Patients with the TT genotype and Depressive Disorder or Depression may be less likely to respond to antidepressant treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient''s response to anti-depressants. "');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (149, 'rs2011425', 'UGT1A4 (PA37179)', '2B', 'Other', 'lamotrigine (PA450164)', 'Neurology', 'Epilepsy (PA444065)', '"GG:Patients with the GG genotype and epilepsy who are administered lamotrigine may have decreased serum concentrations of lamotrigine, as well as a worse response to lamotrigine as compared to patients with the TT genotype, although this is contradicted in some studies. Other clinical and genetic factors may also influence metabolism of and response to lamotrigine. ,"GT:Patients with the GT genotype and epilepsy who are administered lamotrigine may have decreased serum concentrations of lamotrigine, as well as worse response to lamotrigine as compared to patients with the TT genotype, although this is contradicted in some studies. Other clinical and genetic factors may also influence metabolism of and response to lamotrigine. ","TT:Patients with the TT genotype and epilepsy who are administered lamotrigine may have increased serum concentrations of lamotrigine, as well as improved response to lamotrigine as compared to patients with the GG genotype, although this is contradicted in some studies. Other clinical and genetic factors may also influence metabolism of response to lamotrigine. "');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (150, 'rs202179988', 'CFTR (PA109)', '1A', 'Efficacy', 'ivacaftor (PA165950341)', 'Pulmonology', 'Cystic Fibrosis (PA443829)', '"CC:Patients with the CC genotype (do not have a copy of the CFTR R1070W variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R1070W. Other genetic and clinical factors may also influence a patient''s response to ivacaftor.,"CT:Patients with the CT genotype (one copy of the CFTR R1070W variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R1070W. Other genetic and clinical factors may also influence a patient''s response to ivacaftor.","TT:Patients with the TT genotype (two copies of the CFTR R1070W variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R1070W. Other genetic and clinical factors may also influence a patient''s response to ivacaftor."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (151, 'rs2032582', 'ABCB1 (PA267)', '2A', 'Efficacy', 'simvastatin (PA451363)', 'Cardiovascular', 'Hypercholesterolemia (PA444516)', '"AA:Patients with the AA genotype who are treated with simvastatin may have a better response (as measured by higher reductions in total cholesterol) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient''s response to simvastatin treatment. ,"AC:Patients with the AC genotype who are treated with simvastatin may have a better response (as measured by higher reductions in total cholesterol) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient''s response to simvastatin treatment. ","AT:Patients with the AT genotype who are treated with simvastatin may have a better response (as measured by higher reductions in total cholesterol) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient''s response to simvastatin treatment. ","CC:Patients with the CC genotype who are treated with simvastatin may have a reduced response (as measured by lower reductions in total cholesterol) as compared to patients with the AC, AA, TT or AT genotype. Other genetic and clinical factors may also influence a patient''s response to simvastatin treatment. ","TT:Patients with the TT genotype who are treated with simvastatin may have a better response (as measured by higher reductions in total cholesterol) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient''s response to simvastatin treatment. "');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (152, 'rs2032582', 'ABCB1 (PA267)', '2A', 'Efficacy', 'ondansetron (PA450705)', 'Drug Response effects/ toxicity', '', '"AA:Patients with genotype AA may have decreased likelihood of nausea and vomiting shortly after being treated with ondansetron as compared to patients with other genotypes. Other genetic and clinical factors may also influence a patient''s response to ondansetron.,"AC:Patients with genotype AC may have increased likelihood of nausea and vomiting shortly after being treated with ondansetron as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient''s response to ondansetron.","AT:Patients with genotype AT may have increased likelihood of nausea and vomiting shortly after being treated with ondansetron as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient''s response to ondansetron.","CC:Patients with genotype CC may have increased likelihood of nausea and vomiting shortly after being treated with ondansetron as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient''s response to ondansetron.","TT:Patients with genotype TT may have increased likelihood of nausea and vomiting shortly after being treated with ondansetron as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient''s response to ondansetron."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (153, 'rs20455', 'KIF6 (PA134920075)', '2B', 'Efficacy', 'pravastatin (PA451089)', 'Cardiovascular', 'Coronary Disease (PA443797),"Myocardial Infarction (PA445019)"', '"AA:Patients with the AA genotype may have a lower risk of coronary disease and may be less likely to benefit from pravastatin treatment as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient''s response to pravastatin treatment. ,"AG:Patients with the AG genotype may have a higher risk of coronary disease and may be more likely to benefit from pravastatin treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient''s response to pravastatin treatment. ","GG:Patients with the GG genotype may have a higher risk of coronary disease and may be more likely to benefit from pravastatin treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient''s response to pravastatin treatment. "');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (154, 'rs20455', 'KIF6 (PA134920075)', '2B', 'Efficacy', 'atorvastatin (PA448500)', 'Cardiovascular', 'Coronary Disease (PA443797),"Hypercholesterolemia (PA444516)","Myocardial Infarction (PA445019)"', '"AA:Patients with the AA genotype may have a lower risk of coronary disease and may be less likely to benefit from atorvastatin treatment as compared to patients with the AG or GG genotype. However, one study has contradicted this observation. Other genetic and clinical factors may also influence a patient''s response to atorvastatin treatment.,"AG:Patients with the AG genotype may have a higher risk of coronary disease and may be more likely to benefit from atorvastatin treatment as compared to patients with the AA genotype. However, one study has contradicted this observation. Other genetic and clinical factors may also influence a patient''s response to atorvastatin treatment.","GG:Patients with the GG genotype may have a higher risk of coronary disease and may be more likely to benefit from atorvastatin treatment as compared to patients with the AA genotype. However, one study has contradicted this observation. Other genetic and clinical factors may also influence a patient''s response to atorvastatin treatment."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (155, 'rs2072661', 'CHRNB2 (PA115)', '2B', 'Efficacy,"Toxicity/ADR"', 'nicotine (PA450626)', 'Psychiatry', 'Tobacco Use Disorder (PA445876)', '"AA:Patients with the AA genotype may have a increased risk for smoking addiction, and a decreased likelihood of smoking cessation, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence smoking addiction and cessation.,"AG:Patients with the AG genotype may have a increased risk for smoking addiction, and a decreased likelihood of smoking cessation, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence smoking addiction and cessation.","GG:Patients with the GG genotype may have a decreased risk for smoking addiction, and have an increased likelihood of smoking cessation, as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence smoking addiction and cessation."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (156, 'rs2108622', 'CYP4F2 (PA27121)', '1A', 'Dosage', 'warfarin (PA451906)', 'Cardiovascular', 'Hemorrhage (PA444417),"Intracranial Hemorrhages (PA446997)","Myocardial Infarction (PA445019)","Peripheral Vascular Diseases (PA153619833)","Thromboembolism (PA445848)","venous thromboembolism (PA447298)"', '"CC:Patients with the CC genotype who are treated with warfarin may require a lower dose as compared to patients with the TT genotype. However, this is contradicted in some studies. Other genetic and clinical factors may also influence a patient''s required warfarin dose.,"CT:Patients with the CT genotype who are treated with warfarin may require a lower dose as compared to patients with the TT genotype. However, this is contradicted in some studies. Other genetic and clinical factors may also influence a patient''s required warfarin dose.","TT:Patients with the TT genotype who are treated with warfarin may require a higher dose as compared to patients with the CC and CT genotypes. However, this is contradicted in some studies. Other genetic and clinical factors may also influence a patient''s required warfarin dose."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (157, 'rs2108622', 'CYP4F2 (PA27121)', '2A', 'Other', 'warfarin (PA451906)', 'Hematology', 'over-anticoagulation (PA166123298)', '"CC:Patients with the CC genotype who are treated with warfarin may have an increased risk of over-coagulation as compared to patients with the TT genotype, although this is contradicted in one study, which found that the CC genotype may have an increased risk versus the CT genotype as well as the TT genotype. Other clinical and genetic factors may also influence risk of over-coagulation in patients administered warfarin.,"CT:Patients with the CT genotype who are treated with warfarin may have a decreased risk of over-coagulation as compared to patients with the TT genotype, although this is contradicted in one study which found that the CT genotype may have an increased risk of over-coagulation versus the TT genotype. Other clinical and genetic factors may also influence risk of over-coagulation in patients administered warfarin.","TT:Patients with the TT genotype who are treated with warfarin may have a decreased risk of over-coagulation as compared to patients with the CT or CC genotype, although this is contradicted in one study which found that it had a decreased risk of over-coagulation as compared only to patients with the CC genotype. Other clinical and genetic factors may also influence risk of over-coagulation in patients administered warfarin."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (158, 'rs2108622', 'CYP4F2 (PA27121)', '2A', 'Dosage', 'phenprocoumon (PA450921)', 'variant implication on Dosing', '', '"CC:Patients with the CC genotype who are treated with phenprocoumon may require a lower dose as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient''s required phenprocoumon dose.,"CT:Patients with the CT genotype who are treated with phenprocoumon may require a higher dose as compared to patients with the CC genotype or a lower dose as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient''s required phenprocoumon dose.","TT:Patients with the TT genotype who are treated with phenprocoumon may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient''s required phenprocoumon dose."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (159, 'rs2108622', 'CYP4F2 (PA27121)', '2A', 'Dosage', 'acenocoumarol (PA452632)', 'Cardiovascular', 'Atrial Fibrillation (PA443459)', '"CC:Patients with the CC genotype who are treated with acenocoumarol may require a lower dose as compared to patients with the CT or TT genotype, although this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient''s required acenocoumarol dose.,"CT:Patients with the CT genotype who are treated with acenocoumarol may require a lower dose as compared to patients with the TT genotype or may require a higher dose as compared to patients with the CC genotype, although this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient''s required acenocoumarol dose.","TT:Patients with the TT genotype who are treated with acenocoumarol may require a higher dose as compared to patients with the CC genotype, although this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient''s required acenocoumarol dose."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (160, 'rs2228001', 'XPC (PA37413)', '1B', 'Toxicity/ADR', 'cisplatin (PA449014)', 'Oncology', 'Neoplasms (PA445062),"Osteosarcoma (PA445601)","Testicular Neoplasms (PA445828)","Urinary Bladder Neoplasms (PA443512)"', '"GG:Patients with the GG genotype may have an increased risk for toxicity with cisplatin treatment, including hearing loss and neutropenia, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient''s risk for toxicity.,"GT:Patients with the GT genotype may have an increased risk for toxicity with cisplatin treatment, including hearing loss and neutropenia, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient''s risk for toxicity.","TT:Patients with the TT genotype may have a decreased but not non-existent risk for toxicity with cisplatin treatment as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence a patient''s risk for toxicity."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (161, 'rs2228570', 'VDR (PA37301)', '2A', 'Efficacy', 'peginterferon alfa-2b (PA164784024),"ribavirin (PA451241)"', 'Infectious Diseases', 'Hepatitis C, Chronic (PA446863)', '"AA:Patients with the AA genotype and chronic hepatitis C may have an increased likelihood of sustained virological response when treated with peginterferon alfa-2b and ribavirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to peginterferon alfa-2b and ribavirin treatment.,"AG:Patients with the AG genotype and chronic hepatitis C may have an increased likelihood of sustained virological response when treated with peginterferon alfa-2b and ribavirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to peginterferon alfa-2b and ribavirin treatment.","GG:Patients with the GG genotype and chronic hepatitis C may have a decreased likelihood of sustained virological response when treated with peginterferon alfa-2b and ribavirin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to peginterferon alfa-2b and ribavirin treatment."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (162, 'rs2231142', 'ABCG2 (PA390)', '2B', 'Efficacy', 'rosuvastatin (PA134308647)', 'Cardiovascular', 'Hypercholesterolemia (PA444516),"Myocardial Infarction (PA445019)"', '"GG:Patients with the GG genotype and who are treated with rosuvastatin 1) may have lower plasma concentrations of rosuvastatin 2) may have a reduced response to treatment as determined by a lower reduction in LDL-C as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient''s response to rosuvastatin treatment and rosuvastatin pharmacokinetics.,"GT:Patients with the GT genotype and who are treated with rosuvastatin 1) may have lower plasma concentrations of rosuvastatin 2) may have a reduced response to treatment as determined by a lower reduction in LDL-C as compared to patients with the TT genotype, or 1) may have higher plasma concentrations of rosuvastatin 2) may have a better response to treatment as determined by a higher reduction in LDL-C as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient''s response to rosuvastatin treatment and rosuvastatin pharmacokinetics.","TT:Patients with the TT genotype and who are treated with rosuvastatin 1) may have higher plasma concentrations of rosuvastatin 2) may have a better response to treatment as determined by a higher reduction in LDL-C as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient''s response to rosuvastatin treatment and rosuvastatin pharmacokinetics."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (258, 'rs7089580', 'CYP2C9 (PA126)', '2A', 'Dosage', 'warfarin (PA451906)', 'variant implication on Dosing', '', '"AA:Patients with the AA genotype may require lower dose of warfarin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient''s warfarin dose.,"TA:Patients with the TA genotype may require higher dose of warfarin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient''s warfarin dose.","TT:Patients with the TT genotype may require higher dose of warfarin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient''s warfarin dose."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (164, 'rs2232228', 'HAS3 (PA29196)', '2B', 'Toxicity/ADR', 'anthracyclines and related substances (PA130620651)', 'Cardiovascular', 'Cardiomyopathies (PA445018)', '"AA:Patients with genotype AA may have increased cardiomyopathy risk when exposed to high-dose (> 250 mg/m2) anthracyclines in children with Neoplasms as compared to patients with genotype GG. Other genetic or clinical factors may also influence a patient''s risk of toxicity to anthracyclines.,"AG:Patients with genotype AG may have increased cardiomyopathy risk when exposed to high-dose (> 250 mg/m2) anthracyclines in children with Neoplasms as compared to patients with genotype GG. Other genetic or clinical factors may also influence a patient''s risk of toxicity to anthracyclines.","GG:Patients with genotype GG may have decreased cardiomyopathy risk when exposed to high-dose (> 250 mg/m2) anthracyclines in children with Neoplasms as compared to patients with genotype AA or AG. Other genetic or clinical factors may also influence a patient''s risk of toxicity to anthracyclines."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (165, 'rs2234922', 'EPHX1 (PA27829)', '2B', 'Dosage', 'carbamazepine (PA448785)', 'Neurology', 'Epilepsy (PA444065)', '"AA:Patients with the AA genotype may require a decreased dose of carbamazepine as compared to patients with the AG or GG genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence dose of carbamazepine.,"AG:Patients with the AG genotype may require an increased dose of carbamazepine as compared to patients with the AA genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence dose of carbamazepine.","GG:Patients with the GG genotype may require an increased dose of carbamazepine as compared to patients with the AA genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence dose of carbamazepine."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (166, 'rs2279343', 'CYP2B6 (PA123)', '2A', 'Metabolism/PK', 'efavirenz (PA449441)', 'Infectious Diseases', 'HIV (PA447230)', '"AA:Patients with the AA genotype and HIV may have increased clearance and decreased plasma concentration of efavirenz as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient''s exposure to efavirenz.,"AG:Patients with the AG genotype and HIV may have increased clearance and decreased plasma concentration of efavirenz as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient''s exposure to efavirenz.","GG:Patients with the GG genotype and HIV may have decreased clearance and increased plasma concentration of efavirenz as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient''s exposure to efavirenz."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (167, 'rs2279345', 'CYP2B6 (PA123)', '2A', 'Metabolism/PK', 'efavirenz (PA449441)', 'Pulmonology; Infectious Diseases', 'HIV (PA447230),"Tuberculosis (PA445941)"', '"CC:Patients with the CC genotype and HIV may have increased metabolism of efavirenz resulting in lower efavirenz plasma levels as compared to patients with the TT genotype. Other genetic and clinical factors may also influence metabolism and plasma concentrations of efavirenz.,"CT:Patients with the CT genotype and HIV may have increased metabolism of efavirenz resulting in lower efavirenz plasma levels as compared to patients with the TT genotype. Other genetic and clinical factors may also influence metabolism and plasma concentrations of efavirenz.","TT:Patients with the TT genotype and HIV may have decreased metabolism of efavirenz resulting in higher efavirenz plasma levels as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence metabolism and plasma concentrations of efavirenz."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (168, 'rs2297480', 'FDPS (PA28075)', '2B', 'Efficacy', 'Bisphosphonates (PA164712563)', 'Bone disorders', 'Osteoporosis (PA445190),"Osteoporosis, Postmenopausal (PA446214)"', '"GG:Patients with the GG genotype may have a decreased chance of response to bisphosphonate treatment as compared to patients with the GT and TT genotype. Other genetic and clinical factors may also influence a patient''s chance of response.,"GT:Patients with the GT genotype may have an increased chance of response to bisphosphonate treatment as compared to patients with the GG genotype. Patients with the GT genotype may still be at risk for non-response to bisphosphonate treatment based on their genotype. Other genetic and clinical factors may also influence a patient''s chance of response.","TT:Patients with the TT genotype may have an increased chance of response to bisphosphonate treatment, or may have an increase in bone density when treated with atorvastatin, as compared to patients with the GG or GT genotype. Patients with the TT genotype may still be at risk for non-response to bisphosphonate treatment based on their genotype. Other genetic and clinical factors may also influence a patient''s chance of response."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (169, 'rs2298383', 'ADORA2A (PA24584)', '2B', 'Toxicity/ADR', 'caffeine (PA448710)', 'Drug Response effects/ toxicity', '', '"CC:Patients with the CC genotype may have increased anxiety when exposed to caffeine as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence a patients response to caffeine.,"CT:Patients with the CT genotype may have decreased anxiety when exposed to caffeine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to caffeine.","TT:Patients with the TT genotype may have decreased anxiety when exposed to caffeine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to caffeine."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (170, 'rs2359612', 'VKORC1 (PA133787052)', '2A', 'Dosage', 'warfarin (PA451906)', 'variant implication on Dosing', '', '"AA:Patients with the AA genotype who are treated with warfarin may require a decreased dose as compared to patients with the GG genotype. Other genetic and clinical factors may also influence dose of warfarin.,"AG:Patients with the AG genotype who are treated with warfarin may require a decreased dose as compared to patients with the GG genotype. Other genetic and clinical factors may also influence dose of warfarin.","GG:Patients with the GG genotype who are treated with warfarin may require an increased dose as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence dose of warfarin."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (171, 'rs25487', 'XRCC1 (PA369)', '2B', 'Efficacy', 'Platinum compounds (PA164713176)', 'Oncology', 'Neoplasms (PA445062)', '"CC:Patients with cancer and the CC genotype may have increased response when treated with platinum-based therapies as compared to patients with the CT or TT genotype. However, a few studies report no association or decreased survival and response for patients with the CC as compared to the TT genotype only. Other genetic and clinical factors may also influence response to platinum-based regimens.,"CT:Patients with cancer and the CT genotype may have decreased response when treated with platinum-based therapies as compared to patients with the CC genotype. However, a few studies report no association or increased response for patients with the CT genotype as compared to the TT genotype. Other genetic and clinical factors may also influence response to platinum-based regimens.","TT:Patients with cancer and the TT genotype may have decreased response when treated with platinum-based therapies as compared to patients with the CC genotype. However, a few studies report no association or decreased response for patients with the TT genotype as compared to the CT genotype also. Other genetic and clinical factors may also influence response to platinum-based regimens."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (172, 'rs264588', 'TANC1 (PA142670838)', '2B', 'Toxicity/ADR', 'radiotherapy (PA166122986)', 'Oncology', 'Prostatic Neoplasms (PA445425)', '"AA:Patients with the AA genotype and prostate cancer who are treated with radiotherapy may have an increased risk of late stage toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient''s risk of radiotherapy-induced toxicity. ,"AC:Patients with the AC genotype and prostate cancer who are treated with radiotherapy may have an increased risk of late stage toxicity as compared to patients with the CC genotype, or may have a reduced risk of late stage toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient''s risk of radiotherapy-induced toxicity. ","CC:Patients with the CC genotype and prostate cancer who are treated with radiotherapy may have a reduced risk of late stage toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient''s risk of radiotherapy-induced toxicity. "');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (173, 'rs264631', 'TANC1 (PA142670838)', '2B', 'Toxicity/ADR', 'radiotherapy (PA166122986)', 'Oncology', 'Prostatic Neoplasms (PA445425)', '"CC:Patients with the CC genotype and prostate cancer who are treated with radiotherapy may have a reduced risk of late stage toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient''s risk of radiotherapy-induced toxicity. ,"CG:Patients with the CG genotype and prostate cancer who are treated with radiotherapy may have an increased risk of late stage toxicity as compared to patients with the CC genotype, or may have a reduced risk of late stage toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient''s risk of radiotherapy-induced toxicity. ","GG:Patients with the GG genotype and prostate cancer who are treated with radiotherapy may have an increased risk of late stage toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient''s risk of radiotherapy-induced toxicity. "');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (174, 'rs264651', 'TANC1 (PA142670838)', '2B', 'Toxicity/ADR', 'radiotherapy (PA166122986)', 'Oncology', 'Prostatic Neoplasms (PA445425)', '"AA:Patients with the AA genotype and prostate cancer who are treated with radiotherapy may have a reduced risk of late stage toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient''s risk of radiotherapy-induced toxicity. ,"AG:Patients with the AG genotype and prostate cancer who are treated with radiotherapy may have an increased risk of late stage toxicity as compared to patients with the AA genotype, or may have a reduced risk of late stage toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient''s risk of radiotherapy-induced toxicity.","GG:Patients with the GG genotype and prostate cancer who are treated with radiotherapy may have an increased risk of late stage toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient''s risk of radiotherapy-induced toxicity. "');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (175, 'rs267606617', 'MT-RNR1 (PA31274)', '1B', 'Toxicity/ADR', 'amikacin (PA164744372),"aminoglycoside antibacterials (PA452167)","gentamicin (PA449753)","kanamycin (PA450137)","neomycin (PA450608)","streptomycin (PA451512)","tobramycin (PA451704)"', 'Pharmacogenetic disorder', 'Ototoxicity (PA162263534)', '"A:Patients with the 1555A allele may have a lower, but not absent, risk of experiencing aminoglycoside-induced hearing loss as compared to patients with the 1555G allele. Other genetic and clinical factors may also influence risk of aminoglycoside-induced hearing loss.,"G:Patients with the 1555G allele may have a greater risk of experiencing aminoglycoside-induced hearing loss as compared to patients with the 1555A allele. In the majority of studies, every individual who carried the 1555G allele developed hearing loss after receiving aminoglycoside antibiotics. Most individuals studied were homoplasmic for the G allele; it is unclear how heteroplasmy affects the severity or occurrence of aminoglycoside-induced hearing loss. Other genetic and clinical factors may also influence risk of aminoglycoside-induced hearing loss."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (176, 'rs267606618', 'MT-RNR1 (PA31274)', '2B', 'Toxicity/ADR', 'amikacin (PA164744372),"aminoglycoside antibacterials (PA452167)","gentamicin (PA449753)","kanamycin (PA450137)","neomycin (PA450608)","streptomycin (PA451512)","tobramycin (PA451704)"', 'Pharmacogenetic disorder', 'Ototoxicity (PA162263534)', '"C:Patients with the 1095C allele may have a greater risk of experiencing aminoglycoside-induced hearing loss as compared to patients with the 1095T allele. Other genetic and clinical factors may also influence risk of aminoglycoside-induced hearing loss,"T:Patients with the 1095T allele may have a lower, but not absent, risk of experiencing aminoglycoside-induced hearing loss as compared to patients with the 1095C allele. Other genetic and clinical factors may also influence risk of aminoglycoside-induced hearing loss."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (177, 'rs267606619', 'MT-RNR1 (PA31274)', '2B', 'Toxicity/ADR', 'amikacin (PA164744372),"aminoglycoside antibacterials (PA452167)","gentamicin (PA449753)","kanamycin (PA450137)","neomycin (PA450608)","streptomycin (PA451512)","tobramycin (PA451704)"', 'Pharmacogenetic disorder', 'Ototoxicity (PA162263534)', '"C:Patients with the 1494C allele may have a lower, but not absent, risk of experiencing aminoglycoside-induced hearing loss as compared to patients with the 1494T allele. Other genetic and clinical factors may also influence risk of aminoglycoside-induced hearing loss.,"T:Patients with the 1494T allele may have a greater risk of experiencing aminoglycoside-induced hearing loss as compared to patients with the 1494C allele. In the majority of studies, every individual who carried the 1494T allele developed hearing loss after receiving aminoglycoside antibiotics. Almost all individuals studied were homoplasmic for the T allele. Other genetic and clinical factors may also influence risk of aminoglycoside-induced hearing loss."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (178, 'rs267606723', 'CFTR (PA109)', '1A', 'Efficacy', 'ivacaftor (PA165950341)', 'Pulmonology', 'Cystic Fibrosis (PA443829)', '"AA:Patients with the AA genotype (two copies of the CFTR G1244E variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including G1244E. Other genetic and clinical factors may also influence a patient''s response to ivacaftor. ,"AG:Patients with the AG genotype (one copy of the CFTR G1244E variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including G1244E. Other genetic and clinical factors may also influence a patient''s response to ivacaftor. ","GG:Patients with the GG genotype (do not have a copy of the CFTR G1244E variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including G1244E. Other genetic and clinical factors may also influence a patient''s response to ivacaftor."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (179, 'rs2740574', 'CYP3A4 (PA130)', '2A', 'Dosage', 'tacrolimus (PA451578)', 'Transplantation Medicine', 'Organ Transplantation (PA133888799)', '"CC:Transplant recipients with the CC (CYP3A4 *1B/*1B) genotype may require an increased dose of tacrolimus as compared to patients with the TT (*1/*1) genotype. Other genetic and clinical factors, such as CYP3A5 *3 (rs776746), may also influence a patient''s dose requirements.,"CT:Transplant recipients with the CT (CYP3A4 *1B/*1) genotype may require an increased dose of tacrolimus as compared to patients with the TT (*1/*1) genotype. Other genetic and clinical factors, such as CYP3A5 *3 (rs776746), may also influence a patient''s dose requirements.","TT:Transplant recipients with the TT (CYP3A4 (*1/*1) genotype may require a decreased dose of tacrolimus as compared to patients with the CT (*1B/*1) or CC (*1/*1) genotype. Other genetic and clinical factors, such as CYP3A5 *3 (rs776746), may also influence a patient''s dose requirements."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (180, 'rs28371686', 'CYP2C9 (PA126)', '2A', 'Dosage', 'warfarin (PA451906)', 'Cardiovascular', 'Atrial Fibrillation (PA443459),"Pulmonary Embolism (PA445465)","Stroke (PA447054)","Venous Thrombosis (PA446969)"', '"CC:Patients with the CC genotype who are treated with warfarin may require an increased dose as compared to patients with the CG and GG genotype. Other genetic and clinical factors may also influence a patient''s required dose of warfarin.,"CG:Patients with the CG genotype who are treated with warfarin may require a decreased dose as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patient''s required dose of warfarin.","GG:Patients with the GG genotype who are treated with warfarin may require the lowest dose as compared to patients with the CG or CC genotype. Other genetic and clinical factors may also influence a patient''s required dose of warfarin."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (181, 'rs28399499', 'CYP2B6 (PA123)', '2A', 'Metabolism/PK', 'efavirenz (PA449441)', 'Infectious Diseases', 'HIV (PA447230)', '"CC:Patients with the CC genotype may have increased plasma drug exposure when treated with efavirenz as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient''s drug metabolism.,"CT:Patients with the CT genotype may have increased plasma drug exposure when treated with efavirenz as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient''s drug metabolism.","TT:Patients with the TT genotype may have decreased plasma drug exposure when treated with efavirenz as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient''s drug metabolism."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (182, 'rs28399499', 'CYP2B6 (PA123)', '2A', 'Other', 'nevirapine (PA450616)', 'Infectious Diseases', 'HIV (PA447230)', '"CC:Patients with the CC genotype may have increased plasma drug exposure when treated with nevirapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient''s drug metabolism.,"CT:Patients with the CT genotype may have increased plasma drug exposure when treated with nevirapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient''s drug metabolism.","TT:Patients with the TT genotype may have decreased plasma drug exposure when treated with nevirapine as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient''s drug metabolism."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (183, 'rs28399499', 'CYP2B6 (PA123)', '2B', 'Toxicity/ADR', 'nevirapine (PA450616)', 'Pharmacogenetic disorder', 'Epidermal Necrolysis, Toxic (PA444059),"Stevens-Johnson Syndrome (PA445738)"', '"CC:Patients with the CC genotype and HIV may have an increased risk for Stevens-Johnson Syndrome/toxic epidermal necrolysis (SJS/TEN) when treated with nevirapine as compared to patients with the TT genotype, but may not be associated with hepatotoxicity. Other genetic and clinical factors may also influence risk for developing SJS/TEN when receiving nevirapine.,"CT:Patients with the CT genotype and HIV may have an increased risk for Stevens-Johnson Syndrome/toxic epidermal necrolysis (SJS/TEN) when treated with nevirapine as compared to patients with the TT genotype, but may not be associated with hepatotoxicity. Other genetic and clinical factors may also influence risk for developing SJS/TEN when receiving nevirapine.","TT:Patients with the TT genotype and HIV may have a decreased risk for Stevens-Johnson Syndrome/toxic epidermal necrolysis (SJS/TEN) when treated with nevirapine as compared to patients with the CC or CT genotype, but may not be associated with hepatotoxicity. Other genetic and clinical factors may also influence risk for developing SJS/TEN when receiving nevirapine."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (184, 'rs28399504', 'CYP2C19 (PA124)', '1A', 'Efficacy', 'clopidogrel (PA449053)', 'Cardiovascular', 'Acute coronary syndrome (PA165108401),"Cardiovascular Diseases (PA443635)"', '"AA:Patients with the AA genotype 1) may have increased metabolism of clopidogrel and 2) may have a decreased, but not absent, risk for secondary cardiovascular events when treated with clopidogrel as compared to patients with the GG and AG genotype. Other genetic and clinical factors may influence a patient''s risk for secondary cardiovascular events and response to clopidogrel.,"AG:Patients with the AG genotype 1) may have poor metabolism of clopidogrel and 2) may have an increased risk for secondary cardiovascular events when treated with clopidogrel as compared to patients with the AA genotype. Other genetic and clinical factors may influence a patient''s risk for secondary cardiovascular events and response to clopidogrel.","GG:Patients with the GG genotype 1) may have poor metabolism of clopidogrel and 2) may have an increased risk for secondary cardiovascular events when treated with clopidogrel as compared to patients with the AA genotype. Other genetic and clinical factors may influence a patient''s risk for secondary cardiovascular events and response to clopidogrel."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (185, 'rs2884737', 'VKORC1 (PA133787052)', '2A', 'Dosage', 'warfarin (PA451906)', 'variant implication on Dosing', '', '"AA:Patients with the AA genotype may require higher dose of warfarin as compared to patients with the CC genotype. Other clinical and genetic factors may also influence a patient''s warfarin dose. ,"AC:Patients with the AC genotype may require higher dose of warfarin as compared to patients with the CC genotype. Other clinical and genetic factors may also influence a patient''s warfarin dose. ","CC:Patients with the CC genotype may require lower dose of warfarin as compared to patients with the AA genotype. Other clinical and genetic factors may also influence a patient''s warfarin dose. "');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (186, 'rs28933396', 'RYR1 (PA34896)', '1A', 'Toxicity/ADR', 'desflurane (PA164749136),"enflurane (PA449461)","halothane (PA449845)","isoflurane (PA450106)","methoxyflurane (PA450434)","sevoflurane (PA451341)","succinylcholine (PA451522)"', 'Pharmacogenetic disorder', 'Malignant Hyperthermia (PA444863)', '"AA:Patients with the AA genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the GG genotype. Please note: the A allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).,"AG:Patients with the AG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the GG genotype. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia.The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).","GG:Patients with the GG genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the AG and AA genotype. Other genetic or clinical factors may put a patient at risk for developing Malignant Hyperthermia."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (187, 'rs28933397', 'RYR1 (PA34896)', '1A', 'Toxicity/ADR', 'desflurane (PA164749136),"enflurane (PA449461)","halothane (PA449845)","isoflurane (PA450106)","methoxyflurane (PA450434)","sevoflurane (PA451341)","succinylcholine (PA451522)"', 'Pharmacogenetic disorder', 'Malignant Hyperthermia (PA444863)', '"CC:Patients with the CC genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the TT or CT genotype. Other genetic or clinical factors may put a patient at risk for developing Malignant Hyperthermia.,"CT:Patients with the CT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CC genotype. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).","TT:Patients with the TT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CC genotype. Please note: the T allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations)."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (188, 'rs2952768', '.', '2B', 'Dosage', 'buprenorphine (PA448685),"fentanyl (PA449599)","meperidine (PA450369)","morphine (PA450550)","opioids (PA452618)","pentazocine (PA164744326)"', 'variant implication on Dosing', '', '"CC:Patients with the CC genotype may have increased opioid analgesic requirements after surgery as compared to patients with the CT or TT genotype. Other genetic and clinical factors may influence a patient''s opioid dose requirement.,"CT:Patients with the CT genotype may have decreased opioid analgesic requirements after surgery as compared to patients with the CC genotype. Other genetic and clinical factors may influence a patient''s opioid dose requirement.","TT:Patients with the TT genotype may have decreased opioid analgesic requirements after surgery as compared to patients with the CC genotype. Other genetic and clinical factors may influence a patient''s opioid dose requirement."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (189, 'rs3212986', 'ERCC1 (PA155)', '2B', 'Toxicity/ADR', 'cisplatin (PA449014),"platinum (PA150595617)","Platinum compounds (PA164713176)"', 'Oncology', 'Neoplasms (PA445062),"Ovarian Neoplasms (PA445204)"', '"AA:Patients with the AA genotype may have decreased risk for nephrotoxicity with platinum-based regimens as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence response to platinum-based regimens.,"AC:Patients with the AC genotype may have increased risk for nephrotoxicity with platinum-based regimens as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence response to platinum-based regimens.","CC:Patients with the CC genotype may have increased risk for nephrotoxicity with platinum-based regimens as compared to patients with the AA genotypes. Other genetic and clinical factors may also influence response to platinum-based regimens."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (190, 'rs339097', 'CALU (PA26047)', '2B', 'Dosage', 'warfarin (PA451906)', 'variant implication on Dosing', '', '"AA:Patients with the AA genotype who are treated with warfarin may require a lower maintenance dose as compared to patients with the AG or GG genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence a patient''s warfarin dose.,"AG:Patients with the AG genotype who are treated with warfarin may require a higher maintenance dose as compared to patients with the AA genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence a patient''s warfarin dose.","GG:Patients with the GG genotype who are treated with warfarin may require a higher maintenance dose as compared to patients with the AA genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence a patient''s warfarin dose."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (191, 'rs368234815', '.', '2B', 'Efficacy', 'boceprevir (PA165948902),"peginterferon alfa-2a (PA164749390)","peginterferon alfa-2b (PA164784024)","ribavirin (PA451241)","simeprevir (PA166122590)","telaprevir (PA165958354)"', 'Infectious Diseases', 'Hepatitis C, Chronic (PA446863)', '"G/TT:Patients with the G/TT genotype and Hepatitis C, genotype 1 may have decreased response (including sustained virological response (svr)) to pegIFN-alpha/ribavirin as compared to people with with TT/TT genotype. Please note: this SNP has been found to be in high LD with rs12979860, and in one case rs8099917, both of which are also associated with response to pegIFN-alpha/ribavirin. Other genetic and clinical factors may also influence the response to pegIFN-alpha/ribavirin-based therapy.,"GG:Patients with the G/G genotype and Hepatitis C, genotype 1 may have decreased response (including sustained virological response (svr)) to pegIFN-alpha/ribavirin as compared to people with with TT/TT genotype. Please note: this SNP has been found to be in high LD with rs12979860, and in one case rs8099917, both of which are also associated with response to pegIFN-alpha/ribavirin. Other genetic and clinical factors may also influence the response to pegIFN-alpha/ribavirin-based therapy.","TT/TT:Patients with the TT/TT genotype and Hepatitis C, genotype 1 may have improved response (including sustained virological response (svr)) to pegIFN-alpha/ribavirin as compared to people with with G/TT or G/G genotypes. Please note: this SNP has been found to be in high LD with rs12979860, and in one case rs8099917, both of which are also associated with response to pegIFN-alpha/ribavirin. Other genetic and clinical factors may also influence the response to pegIFN-alpha/ribavirin-based therapy."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (192, 'rs368505753', 'CFTR (PA109)', '1A', 'Efficacy', 'ivacaftor (PA165950341)', 'Pulmonology', 'Cystic Fibrosis (PA443829)', '"CC:Patients with the CC genotype (do not have a copy of the CFTR P67L variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including P67L. Other genetic and clinical factors may also influence a patient''s response to ivacaftor.,"CT:Patients with the CT genotype (one copy of the CFTR P67L variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including P67L. Other genetic and clinical factors may also influence a patient''s response to ivacaftor.","TT:Patients with the TT genotype (two copies of the CFTR P67L variant) and cystic fibrosis may respond to ivacaftor treatment.FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including P67L. Other genetic and clinical factors may also influence a patient''s response to ivacaftor."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (193, 'rs3745274', 'CYP2B6 (PA123)', '1B', 'Dosage', 'efavirenz (PA449441)', 'Infectious Diseases', 'HIV (PA447230)', '"GG:Patients with the GG genotype and HIV infection may have decreased plasma concentrations and increased clearance of efavirenz as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence a patient''s exposure to efavirenz.,"GT:Patients with the GT genotype and HIV infection may have increased plasma concentrations and decreased clearance of efavirenz as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient''s exposure to efavirenz.","TT:Patients with the TT genotype and HIV infection may have increased plasma concentrations and decreased clearance of efavirenz as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence a patient''s exposure to efavirenz."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (194, 'rs3745274', 'CYP2B6 (PA123)', '2A', 'Toxicity/ADR', 'efavirenz (PA449441)', 'Infectious Diseases', 'HIV (PA447230)', '"GG:Patients with the GG genotype may have a decreased, but not absent risk of efavirenz-induced side effects, including sleep- and central nervous system-related side effects, as compared to patients with the GT or TT genotype. However, patients with the GG genotype may also have an increased risk for immunological failure, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient''s risk for toxicity.,"GT:Patients with the GT genotype may have a decreased risk of efavirenz-induced side effects, including sleep- and central nervous system-related side effects, as compared to patients with the TT genotype. One study shows an increased risk for sleep disorders as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient''s risk for toxicity.","TT:Patients with the TT genotype may have an increased risk for efavirenz-induced side effects, including sleep- and central nervous system-related side effects, as compared to patients with the GG or GT genotype. However, patients with the TT genotype may also have a decreased risk for immunological failure, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient''s risk for toxicity."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (195, 'rs3745274', 'CYP2B6 (PA123)', '2A', 'Other', 'nevirapine (PA450616)', 'Infectious Diseases', 'HIV Infections (PA446213)', '"GG:Patients with the GG genotype and HIV infection may have increased clearance of and decreased exposure to nevirapine as compared to patients with the TT or GT genotype. Other genetic and clinical factors may also influence clearance of nevirapine and exposure to drug.,"GT:Patients with the GT genotype and HIV infection may have decreased clearance of and increased exposure to nevirapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence clearance of nevirapine and exposure to drug.","TT:Patients with the TT genotype and HIV infection may have decreased clearance of and increased exposure to nevirapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence clearance of nevirapine and exposure to drug."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (196, 'rs3745274', 'CYP2B6 (PA123)', '2A', 'Dosage', 'methadone (PA450401)', 'Psychiatry', 'Heroin Dependence (PA444460)', '"GG:Patients with the GG genotype who are being treated with methadone for heroin addiction may require an increased dose of the drug as compared to patients with the TT genotype. Other genetic and clinical factors may also influence dose of methadone.,"GT:Patients with the GT genotype who are being treated with methadone for heroin addiction may require an increased dose of the drug as compared to patients with the TT genotype. Other genetic and clinical factors may also influence dose of methadone.","TT:Patients with the TT genotype who are being treated with methadone for heroin addiction may require a decreased dose of the drug as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence dose of methadone."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (197, 'rs3753380', 'PTGFR (PA290)', '2B', 'Efficacy', 'latanoprost (PA164774763)', 'Oncology', 'Glaucoma, Open-Angle (PA444282)', '"CC:Patients with the CC genotype and open angle glaucoma, may have an increased response to latanoprost (as determined by a reduction in intraocular pressure) compared to patients with genotypes CT or TT. Other genetic and clinical factors may affect response to latanoprost. *Please note: One study that reported this SNP''s association with response to latanoprost compared the haplotype of rs3753380 C and rs3766355 C versus rs3753380 T and rs3766355 A.,"CT:Patients with the CT genotype and open angle glaucoma, may have a decreased response to latanoprost (as determined by a reduction in intraocular pressure) compared to patients with genotype CC. Other genetic and clinical factors may affect response to latanoprost. *Please note: One study that reported this SNP''s association with response to latanoprost compared the haplotype of rs3753380 C and rs3766355 C versus rs3753380 T and rs3766355 A.","TT:Patients with the TT genotype and open angle glaucoma, may have a decreased response to latanoprost (as determined by a reduction in intraocular pressure) compared to patients with genotype CC. Other genetic and clinical factors may affect response to latanoprost. *Please note: One study that reported this SNP''s association with response to latanoprost compared the haplotype of rs3753380 C and rs3766355 C versus rs3753380 T and rs3766355 A."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (198, 'rs3812718', 'SCN1A (PA301)', '2B', 'Dosage', 'carbamazepine (PA448785)', 'Neurology', 'Epilepsy (PA444065)', '"CC:Patients with the CC genotype who are treated with carbamazepine may require a lower dose as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence dose of carbamazepine.,"CT:Patients with the CT genotype who are treated with carbamazepine may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence dose of carbamazepine.","TT:Patients with the TT genotype who are treated with carbamazepine may require the highest dose as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence dose of carbamazepine."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (199, 'rs3812718', 'SCN1A (PA301)', '2B', 'Dosage', 'phenytoin (PA450947)', 'Neurology', 'Epilepsy (PA444065)', '"CC:Patients with the CC genotype who are treated with phenytoin may require a lower dose as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence dose of phenytoin.,"CT:Patients with the CT genotype who are treated with phenytoin may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence dose of phenytoin.","TT:Patients with the TT genotype who are treated with phenytoin may require the highest dose as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence dose of phenytoin."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (200, 'rs3812718', 'SCN1A (PA301)', '2B', 'Efficacy', 'antiepileptics (PA143485705),"carbamazepine (PA448785)"', 'Neurology', 'Epilepsy (PA444065)', '"CC:Patients with the CC genotype and epilepsy may be less likely to be resistant to antiepileptic treatment, particularly carbamazepine, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence resistance to antiepileptic drugs.,"CT:Patients with the CT genotype and epilepsy may be less likely to be resistant to antiepileptic treatment, particularly carbamazepine, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence resistance to antiepileptic drugs.","TT:Patients with the TT genotype and epilepsy may be more likely to be resistant to antiepileptic treatment, particularly carbamazepine, as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence resistance to antiepileptic drugs."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (201, 'rs3813929', 'HTR2C (PA194)', '2B', 'Toxicity/ADR', 'antipsychotics (PA452233)', 'Psychiatry', '', '"C:Male patients with the C genotype and psychiatric disorders who are treated with antipsychotics may have an increased risk of weight gain as compared to patients with the T genotype. This gene is on the X chromosome and males have only one allele. However, some studies find no association with weight gain.,"CC:Female patients with the CC genotype and psychiatric disorders who are treated with antipsychotics may have an increased risk of weight gain as compared to patients with the TT genotype. However, some studies find no association with weight gain. Other genetic and clinical factors may also influence a patient''s risk for weight gain with antipsychotic treatment.","CT:Female patients with the CT genotype and psychiatric disorders or schizophrenia who are treated with antipsychotics may have a decreased, but not absent, risk of weight gain as compared to patients with the CC genotype. However, some studies find no association with weight gain, or an association in the opposite direction. Other genetic and clinical factors may also influence a patient''s risk for weight gain with antipsychotic treatment.","T:Male patients with the T genotype and psychiatric disorders who are treated with antipsychotics may have a decreased risk of weight gain as compared to patients with the C genotype. This gene is on the X chromosome and males have only one allele. However, some studies find no association with weight gain.","TT:Female patients with the TT genotype and psychiatric disorders or schizophrenia who are treated with antipsychotics may have a decreased, but not absent, risk of weight gain as compared to patients with the CC genotype. However, some studies find no association with weight gain. Other genetic and clinical factors may also influence a patient''s risk for weight gain with antipsychotic treatment."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (202, 'rs3832043', 'UGT1A9 (PA419)', '2B', 'Other', 'SN-38 (PA165110775)', 'Oncology', 'Carcinoma, Non-Small-Cell Lung (PA443622)', '"T/del:Patients with the T/del genotype and non-small cell lung cancer may have decreased glucuronidation of SN-38 as compared to patients with the TT genotype, or increased glucuronidation of SN-38 as compared to patients with the del/del genotype. SN-38 is the active metabolite of irinotecan, and is glucuronidated by UGT1A9 into an inactive form (SN-38G). Other genetic and clinical factors may also influence glucuronidation of SN-38.,"TT:Patients with the TT genotype and non-small cell lung cancer may have increased glucuronidation of SN-38 as compared to patients with the T/del or del/del genotype. SN-38 is the active metabolite of irinotecan, and is glucuronidated by UGT1A9 into an inactive form (SN-38G). Other genetic and clinical factors may also influence glucuronidation of SN-38.","del/del:Patients with the del/del genotype and non-small cell lung cancer may have decreased glucuronidation of SN-38 as compared to patients with the TT or T/del genotype. SN-38 is the active metabolite of irinotecan, and is glucuronidated by UGT1A9 into an inactive form (SN-38G). Other genetic and clinical factors may also influence glucuronidation of SN-38."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (203, 'rs3892097', 'CYP2D6 (PA128)', '1A', 'Dosage,"Toxicity/ADR"', 'amitriptyline (PA448385),"antidepressants (PA452229)","clomipramine (PA449048)","desipramine (PA449233)","doxepin (PA449409)","imipramine (PA449969)","nortriptyline (PA450657)","trimipramine (PA451791)"', 'Psychiatry', 'Depression (PA447278)', '"CC:Patients with the CC genotype (CYP2D6*1/*1) and depression who are treated with tricyclic antidepressants 1) may have a decreased likelihood of switching treatment indicating a reduced risk of side effects 2) may require an increased dose of drug as compared to patients with the TT genotype (CYP2D6*4/*4). Other genetic and clinical factors may also influence a patient''s metabolism of tricyclic antidepressants and risk of adverse effects. ,"CT:Patients with the CT genotype (CYP2D6*1/*4) and depression who are treated with tricyclic antidepressants 1) may have an increased likelihood of switching treatment indicating an increased risk of side effects as compared to patients with the CC genotype (CYP2D6*1/*1) 2) may require an increased dose of drug as compared to patients with the TT genotype (CYP2D6*4/*4) or may require a decreased dose of drug as compared to patients with the CC genotype (CYP2D6*1/*1). Other genetic and clinical factors may also influence a patient''s metabolism of tricyclic antidepressants and risk of adverse effects. ","TT:Patients with the TT genotype (CYP2D6*4/*4) and depression who are treated with tricyclic antidepressants 1) may have an increased likelihood of switching treatment indicating an increased risk of side effects 2) may require a decreased dose of drug as compared to patients with the CC genotype (CYP2D6*1/*1). Other genetic and clinical factors may also influence a patient''s metabolism of tricyclic antidepressants and risk of adverse effects. "');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (204, 'rs3892097', 'CYP2D6 (PA128)', '2A', 'Efficacy,"Toxicity/ADR"', 'tamoxifen (PA451581)', 'Oncology', 'Breast Neoplasms (PA443560)', '"CC:Patients with the CC genotype who are treated with tamoxifen: 1) may have a decreased, but not absent, risk of relapse as compared to patients with the TT genotype 2) may have an increased severity in hot flashes as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient''s risk of relapse.,"CT:Patients with the CT genotype who are treated with tamoxifen: 1) may have a decreased, but not absent, risk of relapse as compared to patients with the TT genotype 2) may have an increased severity in hot flashes as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient''s risk of relapse.","TT:Patients with the TT genotype who are treated with tamoxifen: 1) may have an increased risk of relapse as compared to patients with the CT or CC genotype 2) may have a decreased severity in hot flashes as compared to patients with the CT or CC genotype."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (205, 'rs3918290', 'DPYD (PA145)', '1A', 'Toxicity/ADR,"Metabolism/PK"', 'capecitabine (PA448771),"fluorouracil (PA128406956)","Pyrimidine analogues (PA164713220)","tegafur (PA452620)"', 'Oncology', 'Neoplasms (PA445062)', '"CC:Patients with the CC genotype (DPYD *1/*1) and cancer who are treated with fluoropyrimidine-based chemotherapy may have 1) increased clearance of fluoropyrimidine drugs and 2) decreased, but not non-existent, risk for drug toxicity as compared to patients with the CT or TT genotype (DPYD *1/*2A or *2A/*2A). Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin), FOLFIRI (fluorouracil, leucovorin and irinotecan) or FEC (fluorouracil, epirubicin and cyclophosphamide) or with other drugs such as bevacizumab, cetuximab, raltitrexed. The combination and delivery of the drug may influence risk for toxicity. Other genetic and clinical factors may also influence response to fluoropyrimidine based chemotherapy.,"CT:Patients with the CT genotype (DPYD *1/*2A) and cancer who are treated with fluoropyrimidine-based chemotherapy may 1) have DPYD deficiency and decreased clearance of fluoropyrimidine drugs and 2) be at risk for severe or even fatal drug toxicity as compared to patients with the CC genotype (DPYD *1/*1). Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin), FOLFIRI (fluorouracil, leucovorin and irinotecan) or FEC (fluorouracil, epirubicin and cyclophosphamide) or with other drugs such as bevacizumab, cetuximab, raltitrexed. The combination and delivery of the drug may influence risk for toxicity. Other genetic and clinical factors may also influence response to fluoropyrimidine based chemotherapy.","TT:Patients with the TT genotype (DPYD *2A/*2A) and cancer who are treated with fluoropyrimidine-based chemotherapy may 1) have complete DPYD deficiency and decreased clearance of fluoropyrimidine drugs and 2) be at risk for severe or even fatal drug toxicity as compared to patients with the CC genotype (DPYD *1/*1). Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin), FOLFIRI (fluorouracil, leucovorin and irinotecan) or FEC (fluorouracil, epirubicin and cyclophosphamide) or with other drugs such as bevacizumab, cetuximab, raltitrexed. The combination and delivery of the drug may influence risk for toxicity. Other genetic and clinical factors may also influence response to fluoropyrimidine based chemotherapy."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (206, 'rs396991', 'FCGR3A (PA28065)', '2B', 'Efficacy', 'rituximab (PA451261)', 'Oncology', 'Lymphoma, B-Cell (PA446304),"Lymphoma, Follicular (PA444841)","Lymphoma, Large-Cell, Diffuse (PA446313)","Lymphoma, Non-Hodgkin (PA444845)"', '"AA:Lymphoma patients with the AA genotype who are treated with rituximab may be less likely to have tumor shrinkage as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient''s response to rituximab.,"AC:Lymphoma patients with the AC genotype who are treated with rituximab may be more likely to have tumor shrinkage as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient''s response to rituximab.","CC:Lymphoma patients with the CC genotype who are treated with rituximab may be more likely to have tumor shrinkage as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient''s response to rituximab."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (207, 'rs396991', 'FCGR3A (PA28065)', '2B', 'Efficacy', 'trastuzumab (PA451743)', 'Oncology', 'Breast Neoplasms (PA443560)', '"AA:Patients with the AA genotype may have decreased response to trastuzumab and shorter progression-free survival in people with Breast cancer as compared to patients with genotype CC. Other genetic or clinical factors may also influence the response to trastuzumab.,"AC:Patients with the AC genotype may have decreased response to trastuzumab and shorter progression-free survival in people with Breast cancer as compared to patients with genotype CC. Other genetic or clinical factors may also influence the response to trastuzumab.","CC:Patients with the CC genotype may have increased response to trastuzumab and longer progression-free survival in people with Breast cancer as compared to patients with genotype AA or AC. Other genetic or clinical factors may also influence the response to trastuzumab."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (208, 'rs397508256', 'CFTR (PA109)', '1A', 'Efficacy', 'ivacaftor (PA165950341)', 'Pulmonology', 'Cystic Fibrosis (PA443829)', '"AA:Patients with the AA genotype (two copies of the CFTR E56K variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including E56K. Other genetic and clinical factors may also influence a patient''s response to ivacaftor.,"AG:Patients with the AG genotype (one copy of the CFTR E56K variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including E56K. Other genetic and clinical factors may also influence a patient''s response to ivacaftor.","GG:Patients with the GG genotype (do not have a copy of the CFTR E56K variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including E56K. Other genetic and clinical factors may also influence a patient''s response to ivacaftor."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (209, 'rs397508288', 'CFTR (PA109)', '1A', 'Efficacy', 'ivacaftor (PA165950341)', 'Pulmonology', 'Cystic Fibrosis (PA443829)', '"AA:Patients with the AA genotype (do not have a copy of the CFTR D579G variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including D579G. Other genetic and clinical factors may also influence a patient''s response to ivacaftor.,"AG:Patients with the AG genotype (one copy of the CFTR D579G variant) and cystic fibrosis may respond to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including D579G. Other genetic and clinical factors may also influence a patient''s response to ivacaftor.","GG:Patients with the GG genotype (two copies of the CFTR D579G variant) and cystic fibrosis may respond to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including D579G. Other genetic and clinical factors may also influence a patient''s response to ivacaftor."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (210, 'rs397508442', 'CFTR (PA109)', '1A', 'Efficacy', 'ivacaftor (PA165950341)', 'Pulmonology', 'Cystic Fibrosis (PA443829)', '"CC:Patients with the CC genotype (do not have a copy of the CFTR S945L variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S945L. Other genetic and clinical factors may also influence a patient''s response to ivacaftor.,"CT:Patients with the CT genotype (one copy of the CFTR S945L variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S945L. Other genetic and clinical factors may also influence a patient''s response to ivacaftor.","TT:Patients with the TT genotype (two copies of the CFTR S945L variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S945L. Other genetic and clinical factors may also influence a patient''s response to ivacaftor."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (211, 'rs397508513', 'CFTR (PA109)', '1A', 'Efficacy', 'ivacaftor (PA165950341)', 'Pulmonology', 'Cystic Fibrosis (PA443829)', '"AA:Patients with the AA genotype (do not have a copy of the CFTR K1060T variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including K1060T. Other genetic and clinical factors may also influence a patient''s response to ivacaftor.,"AC:Patients with the AC genotype (one copy of the CFTR K1060T variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including K1060T. Other genetic and clinical factors may also influence a patient''s response to ivacaftor.","CC:Patients with the CC genotype (two copies of the CFTR K1060T variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including K1060T. Other genetic and clinical factors may also influence a patient''s response to ivacaftor."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (218, 'rs4149056', 'SLCO1B1 (PA134865839)', '2A', 'Toxicity/ADR', 'cerivastatin (PA448897)', 'Drug Response effects/ toxicity Muscular Diseases', 'Rhabdomyolysis (PA445549)', '"CC:Patients with the CC genotype may have a higher risk of cerivastatin-related rhabdomyolysis as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient''s risk for toxicity. Cerivastatin was withdrawn from the market because of 52 deaths attributed to drug-related rhabdomyolysis that lead to kidney failure.,"CT:Patients with the CT genotype may have a higher risk of cerivastatin-related rhabdomyolysis as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient''s risk for toxicity. Cerivastatin was withdrawn from the market because of 52 deaths attributed to drug-related rhabdomyolysis that lead to kidney failure.","TT:Patients with the TT genotype may have a lower risk of cerivastatin-related rhabdomyolysis as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient''s risk for toxicity. Cerivastatin was withdrawn from the market because of 52 deaths attributed to drug-related rhabdomyolysis that lead to kidney failure."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (212, 'rs397508537', 'CFTR (PA109)', '1A', 'Efficacy', 'ivacaftor (PA165950341)', 'Pulmonology', 'Cystic Fibrosis (PA443829)', '"AA:Patients with the AA genotype (two copies of the CFTR D110E variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including D110E. Other genetic and clinical factors may also influence a patient''s response to ivacaftor.,"AC:Patients with the AC genotype (one copy of the CFTR D110E variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including D110E. Other genetic and clinical factors may also influence a patient''s response to ivacaftor.","CC:Patients with the CC genotype (do not have a copy of the CFTR D110E variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including D110E. Other genetic and clinical factors may also influence a patient''s response to ivacaftor."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (213, 'rs397508759', 'CFTR (PA109)', '1A', 'Efficacy', 'ivacaftor (PA165950341)', 'Pulmonology', 'Cystic Fibrosis (PA443829)', '"AA:Patients with the AA genotype (two copies of the CFTR E193K variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including E193K. Other genetic and clinical factors may also influence a patient''s response to ivacaftor.,"AG:Patients with the AG genotype (one copy of the CFTR E193K variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including E193K. Other genetic and clinical factors may also influence a patient''s response to ivacaftor.","GG:Patients with the GG genotype (do not have a copy of the CFTR E193K variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including E193K. Other genetic and clinical factors may also influence a patient''s response to ivacaftor."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (214, 'rs4148323', 'UGT1A1 (PA420)', '2A', 'Other', 'SN-38 (PA165110775)', 'Oncology', 'Neoplasms (PA445062)', '"AA:Patients with the AA genotype and cancer may have decreased metabolism of SN-38 when treated with irinotecan as compared to patients with the AG or GG genotype. SN-38 is the active metabolite of irinotecan, and is glucuronidated by UGT1A1. One in vitro study found decreased enzyme activity for the A allele compared to the G allele. Other genetic and clinical factors may also influence metabolism of SN-38.,"AG:Patients with the AG genotype and cancer may have increased metabolism of SN-38 when treated with irinotecan as compared to patients with the AA genotype. SN-38 is the active metabolite of irinotecan, and is glucuronidated by UGT1A1. One in vitro study found decreased enzyme activity for the A allele compared to the G allele. Other genetic and clinical factors may also influence metabolism of SN-38.","GG:Patients with the GG genotype and cancer may have increased metabolism of SN-38 when treated with irinotecan as compared to patients with the AA genotype. SN-38 is the active metabolite of irinotecan, and is glucuronidated by UGT1A1. One in vitro study found increased enzyme activity for the G allele compared to the A allele. Other genetic and clinical factors may also influence metabolism of SN-38."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (215, 'rs4148323', 'UGT1A1 (PA420)', '2A', 'Other', 'irinotecan (PA450085)', 'Oncology', 'Neoplasms (PA445062)', '"AA:Patients with the AA genotype with cancer who are treated with irinotecan-based regimens may have an increased risk of neutropenia as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient''s risk of neutropenia.,"AG:Patients with the AG genotype with cancer who are treated with irinotecan-based regimens may have an increased risk of neutropenia as compared to patients with the GG genotype, or a decreased risk of neutropenia compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient''s risk of neutropenia.","GG:Patients with the GG genotype with cancer who are treated with irinotecan-based regimens may have a decreased risk of neutropenia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient''s risk of neutropenia."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (216, 'rs4149015', 'SLCO1B1 (PA134865839)', '2A', 'Efficacy', 'pravastatin (PA451089)', 'Drug Response effects/ toxicity', '', '"AA:Patients carrying the AA genotype may have increased pravastatin plasma AUC and decreased response to pravastatin compared with patients carrying the GG genotype. This variant is part of the SLCO1B1*17 haplotype. Other genetic and clinical factors may also influence a patient''s response.,"AG:Patients carrying the AG genotype may have increased pravastatin plasma AUC and decreased response to pravastatin compared with patients carrying the GG genotype. Other genetic and clinical factors may also influence a patient''s response.","GG:Patients carrying the GG genotype may have increased chance of response to pravastatin compared to patients carrying the AA or AG genotype. Other genetic and clinical factors may also influence a patient''s response."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (217, 'rs4149056', 'SLCO1B1 (PA134865839)', '1A', 'Toxicity/ADR', 'simvastatin (PA451363)', 'Drug Response effects/ toxicity Muscular Diseases', 'Muscular Diseases (PA444997),"Myopathy, Central Core (PA447048)"', '"CC:Patients with the CC genotype may have a higher risk of simvastatin-related myopathy as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient''s risk for toxicity.,"CT:Patients with the CT genotype may have a higher risk of simvastatin-related myopathy as compared to patients with the TT genotype, but a lower risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient''s risk for toxicity.","TT:Patients with the TT genotype may have a lower risk of simvastatin-related myopathy as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient''s risk for toxicity."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (219, 'rs4149056', 'SLCO1B1 (PA134865839)', '2A', 'Metabolism/PK', 'pravastatin (PA451089)', 'variant implication on drug metabolism', '', '"CC:Patients with the CC genotype may have increased plasma concentrations of pravastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient''s metabolism of pravastatin.,"CT:Patients with the CT genotype may have increased plasma concentrations of pravastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient''s metabolism of pravastatin.","TT:Patients with the TT genotype may have decreased plasma concentrations of pravastatin as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient''s metabolism of pravastatin."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (220, 'rs4149056', 'SLCO1B1 (PA134865839)', '2A', 'Toxicity/ADR,"Metabolism/PK"', 'hmg coa reductase inhibitors (PA133950441)', 'Drug Response effects/ toxicity Muscular Diseases', 'Muscular Diseases (PA444997),"Rhabdomyolysis (PA445549)"', '"CC:Patients with the CC genotype may have increased plasma drug concentrations of particular statins as compared to patients with the TT genotype. For some statins this is associated with increased risk of adverse events - see individual drug annotations particularly for simvastatin. Other genetic and clinical factors may also influence a patient''s metabolism and response to statins.,"CT:Patients with the CT genotype may have increased plasma drug concentrations of particular statins as compared to patients with the TT genotype. For some statins this is associated with increased risk of adverse events - see individual drug annotations particularly for simvastatin. Other genetic and clinical factors may also influence a patient''s metabolism and response to statins.","TT:Patients with the TT genotype may have decreased plasma drug concentrations of particular statins as compared to patients with the CC or CT genotype. For some statins this is associated with decreased risk of adverse events - see individual drug annotations particularly for simvastatin. Other genetic and clinical factors may also influence a patient''s metabolism and response to statins."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (221, 'rs4149056', 'SLCO1B1 (PA134865839)', '2A', 'Other', 'rosuvastatin (PA134308647)', 'Cardiovascular', 'Hypercholesterolemia (PA444516)', '"CC:Patients with the CC genotype may have higher plasma concentrations of rosuvastatin as compared to patients with the TT genotype. No association is seen between genotypes of this variant and change in LDL-cholesterol levels in response to rosuvastatin treatment. Other genetic and clinical factors may also influence a patient''s metabolism and response to rosuvastatin.,"CT:Patients with the CT genotype may have higher plasma concentrations of rosuvastatin as compared to patients with the TT genotype. No association is seen between genotypes of this variant and change in LDL-cholesterol levels in response to rosuvastatin treatment. Other genetic and clinical factors may also influence a patient''s metabolism and response to rosuvastatin.","TT:Patients with the TT genotype may have lower plasma concentrations of rosuvastatin as compared to patients with the CC genotype. No association is seen between genotypes of this variant and change in LDL-cholesterol levels in response to rosuvastatin treatment. Other genetic and clinical factors may also influence a patient''s metabolism and response to rosuvastatin."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (222, 'rs4149056', 'SLCO1B1 (PA134865839)', '2B', 'Metabolism/PK', 'simvastatin acid (PA166129446)', 'variant implication on drug metabolism', '', '"CC:Patients with the CC genotype may have increased serum concentrations of simvastatin acid as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect serum concentrations of simvastatin acid in patients.,"CT:Patients with the CT genotype may have increased serum concentrations of simvastatin acid as compared to patients with the TT genotype, but decreased concentrations as compared to patients with the CC genotype. Other genetic and clinical factors may also affect serum concentrations of simvastatin acid in patients.","TT:Patients with the TT genotype may have decreased serum concentrations of simvastatin acid as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect serum concentrations of simvastatin acid in patients."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (223, 'rs4149601', 'NEDD4L (PA31534)', '2B', 'Efficacy', 'diuretics (PA151249535),"hydrochlorothiazide (PA449899)"', 'Cardiovascular', 'Hypertension (PA444552)', '"AA:White patients with the AA genotype and hypertension who are treated with hydrochlorothiazide may have poorer response as compared with patients with genotype GG. The opposite result has been seen in Asians (at a lower level of evidence). Other genetic and clinical factors may also influence a patient''s response to hydrochlorothiazide or other diuretic treatment.,"AG:White patients with the AG genotype and hypertension who are treated with hydrochlorothiazide may have better response as compared with patients with genotype AA. The opposite result has been seen in Asians (at a lower level of evidence). Other genetic and clinical factors may also influence a patient''s response to hydrochlorothiazide or other diuretic treatment.","GG:White patients with the GG genotype and hypertension who are treated with hydrochlorothiazide may have better response as compared with patients with genotype AA. The opposite result has been seen in Asians (at a lower level of evidence). Other genetic and clinical factors may also influence a patient''s response to hydrochlorothiazide or other diuretic treatment."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (224, 'rs4244285', 'CYP2C19 (PA124)', '2A', 'Efficacy', 'clomipramine (PA449048)', 'variant implication on drug metabolism', '', '"AA:Patients with the AA genotype may have a decreased metabolism of clomipramine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient''s clomipramine metabolism. ,"AG:Patients with the AG genotype may have a decreased metabolism of clomipramine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient''s clomipramine metabolism. ","GG:Patients with the GG genotype may have an increased metabolism of clomipramine as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient''s clomipramine metabolism. "');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (225, 'rs4244285', 'CYP2C19 (PA124)', '2A', 'Efficacy', 'citalopram (PA449015)', 'variant implication on drug metabolism', '', '"AA:Patients with AA genotype may have a decreased metabolism of citalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient''s citalopram metabolism. ,"AG:Patients with AG genotype may have a decreased metabolism of citalopram as compared to patients with the GG genotype or an increased metabolism of citalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient''s citalopram metabolism. ","GG:Patients with GG genotype may have an increased metabolism of citalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient''s citalopram metabolism. "');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (232, 'rs4680', 'COMT (PA117)', '2A', 'Efficacy', 'nicotine (PA450626)', 'Psychiatry', 'Tobacco Use Disorder (PA445876)', '"AA:Patients with the AA genotype who are treated with nicotine replacement therapy may have an increased likelihood of smoking cessation and decreased risk of relapse as compared to patients with the GG genotype. However, some contradictory evidence exists. Other genetic and clinical factors may also influence a patient''s response to nicotine replacement therapy.,"AG:Patients with the AG genotype who are treated with nicotine replacement therapy may have a decreased likelihood of smoking cessation and increased risk of relapse as compared to patients with the AA genotype. However, some contradictory evidence exists. Other genetic and clinical factors may also influence a patient''s response to nicotine replacement therapy.","GG:Patients with the GG genotype who are treated with nicotine replacement therapy may have a decreased likelihood of smoking cessation and increased risk of relapse as compared to patients with the AA genotype. However, some contradictory evidence exists. Other genetic and clinical factors may also influence a patient''s response to nicotine replacement therapy."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (226, 'rs4244285', 'CYP2C19 (PA124)', '1A', 'Efficacy', 'amitriptyline (PA448385)', 'variant implication on drug metabolism', '', '"AA:Patients with the AA genotype who are treated with amitriptyline may have decreased metabolism of amitriptyline (increased amitriptyline plasma concentrations and decreased nortriptyline plasma concentrations) as compared to patients with the GG genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560 and *3 rs4986893, along with clinical factors, may also influence a patient''s required dose and should be taken into consideration.,"GA:Patients with the AG genotype who are treated with amitriptyline may have decreased metabolism of amitriptyline (increased amitriptyline plasma concentrations and decreased nortriptyline plasma concentrations) as compared to patients with the GG genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560 and *3 rs4986893, along with clinical factors, may also influence a patient''s required dose and should be taken into consideration.","GG:Patients with the GG genotype who are treated with amitriptyline may have increased metabolism of amitriptyline (decreased amitriptyline plasma concentrations and increased nortriptyline plasma concentrations) as compared to patients with the AA or AG genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560 and *3 rs4986893, along with clinical factors, may also influence a patient''s required dose and should be taken into consideration."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (227, 'rs4244285', 'CYP2C19 (PA124)', '1A', 'Efficacy,"Toxicity/ADR"', 'clopidogrel (PA449053)', 'Cardiovascular', 'Acute coronary syndrome (PA165108401),"Cardiovascular Diseases (PA443635)","Thrombosis (PA445850)"', '"AA:Patients with the AA genotype: 1) may have poor metabolism of clopidogrel and decreased formation of active drug metabolite, resulting in decreased response 2) may have an increased risk for secondary cardiovascular events when treated with clopidogrel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient''s risk for secondary cardiovascular events and response to clopidogrel.,"AG:Patients with the AG genotype: 1) may have poor metabolism of clopidogrel and decreased formation of active drug metabolite, resulting in decreased response 2) may have an increased risk for secondary cardiovascular events when treated with clopidogrel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient''s risk for secondary cardiovascular events and response to clopidogrel.","GG:Patients with the GG genotype: 1) may have sufficient metabolism of clopidogrel and increased formation of active drug metabolite 2) may have a decreased risk for secondary cardiovascular events with clopidogrel as compared to patients with the AA or AG genotype. Patients with the GG genotype may still be at risk for secondary cardiovascular events when taking clopidogrel based on their genotype. Other genetic and clinical factors may also influence a patient''s risk for secondary cardiovascular events and response to clopidogrel."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (228, 'rs4444903', 'EGF (PA27664)', '2B', 'Efficacy', 'cetuximab (PA10040)', 'Oncology', 'Colorectal Neoplasms (PA446108),"Rectal Neoplasms (PA445503)"', '"AA:Patients with the AA genotype who are treated with cetuximab may have a poorer response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient''s response to cetuximab treatment.,"AG:Patients with the AG genotype who are treated with cetuximab may have a poorer response as compared to patients with the GG genotype or may have a better response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient''s response to cetuximab treatment.","GG:Patients with the GG genotype who are treated with cetuximab may have a better response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient''s response to cetuximab treatment."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (229, 'rs4646', 'CYP19A1 (PA27091)', '2B', 'Efficacy', 'anastrozole (PA448432),"cyclophosphamide (PA449165)","docetaxel (PA449383)","doxorubicin (PA449412)","epirubicin (PA449476)","exemestane (PA449563)","fluorouracil (PA128406956)","paclitaxel (PA450761)","radiotherapy (PA166122986)","tamoxifen (PA451581)"', 'Oncology', 'Breast Neoplasms (PA443560),"Menopause (PA166048848)"', '"AA:The AA genotype in women with breast cancer who are treated with tamoxifen (with or without anastrozole, cyclophosphamide, docetaxel, doxorubicin, epirubicin, exemestane, fluorouracil, letrozole, paclitaxel, radiotherapy) may have INCREASED treatment EFFICACY in PRE-MENOPAUSAL women AND DECREASED treatment EFFICACY in POST-MENOPAUSAL women as compared to patients with the AC and CC genotypes. Other genetic and clinical factors may also influence response to tamoxifen and other treatment regimens in pre- and post-menopausal women with breast cancer. ,"AC:The AC genotype in women with breast cancer who are treated with tamoxifen (with or without anastrozole, cyclophosphamide, docetaxel, doxorubicin, epirubicin, exemestane, fluorouracil, letrozole, paclitaxel, radiotherapy) may have DECREASED treatment EFFICACY in PRE-MENOPAUSAL women and INCREASED treatment EFFICACY in POST-MENOPAUSAL women as compared to patients with the AA genotypes. Other genetic and clinical factors may also influence response to tamoxifen and other treatment regimens in pre- and post-menopausal women with breast cancer. ","CC:The CC genotype in women with breast cancer who are treated with tamoxifen (with or without anastrozole, cyclophosphamide, docetaxel, doxorubicin, epirubicin, exemestane, fluorouracil, letrozole, paclitaxel, radiotherapy) may have DECREASED treatment EFFICACY in PRE-MENOPAUSAL women and INCREASED treatment EFFICACY in POST-MENOPAUSAL women as compared to patients with the AA genotypes. Other genetic and clinical factors may also influence response to tamoxifen and other treatment regimens in pre- and post-menopausal women with breast cancer."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (230, 'rs4673993', 'ATIC (PA25094)', '2B', 'Efficacy', 'methotrexate (PA450428)', 'Immunology', 'Arthritis, Rheumatoid (PA443434)', '"CC:Patients with the CC genotype and Rheumatoid Arthritis who are treated with methotrexate may have a better response to treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient''s response to methotrexate treatment.,"CT:Patients with the CT genotype and Rheumatoid Arthritis who are treated with methotrexate may have a better response to treatment as compared to patients with the TT genotype or may have a poorer response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient''s response to methotrexate treatment.","TT:Patients with the TT genotype and Rheumatoid Arthritis who are treated with methotrexate may have a poorer response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient''s response to methotrexate treatment."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (231, 'rs4680', 'COMT (PA117)', '2B', 'Dosage,"Efficacy"', 'methadone (PA450401),"morphine (PA450550)","opioids (PA452618)","oxycodone (PA450741)","sufentanil (PA451527)","tramadol (PA451735)"', 'Pain Medicine', 'Low Back Pain (PA446444),"Pain (PA445208)"', '"AA:Patients with the AA genotype who are treated with opioids for pain may have an increased response and therefore require a lower dose as compared to patients with the AG or GG genotypes. Contradictory studies exist for this association. Other genetic and clinical factors may also influence a patient''s opioids dosage and response.,"AG:Patients with the AG genotype who are treated with opioids for pain may have an increased response and therefore require a lower dose as compared to patients with the GG genotype but a decreased response and higher dose requirement as compared to patients with the AA genotype. Contradictory studies exist for this association. Other genetic and clinical factors may also influence a patient''s opioids dosage and response. ","GG:Patients with the GG genotype who are treated with opioids for pain may have an decreased response and therefore require a higher dose as compared to patients with the AA or AG genotypes. Contradictory studies exist for this association. Other genetic and clinical factors may also influence a patient''s opioids dosage and response."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (234, 'rs4713916', 'FKBP5 (PA28162)', '2B', 'Efficacy', 'antidepressants (PA452229),"citalopram (PA449015)","fluoxetine (PA449673)","mirtazapine (PA450522)","paroxetine (PA450801)","Selective serotonin reuptake inhibitors (PA164713257)","venlafaxine (PA451866)"', 'Psychiatry', 'Depressive Disorder (PA447207),"Depressive Disorder, Major (PA447321)","Mood Disorders (PA447209)"', '"AA:Patients with the AA genotype may have a better response to antidepressants as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient''s response to antidepressant treatment. ,"AG:Patients with the AG genotype may have a better response to antidepressants as compared to patients with the GG genotype or may have a reduced response to antidepressants as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient''s response to antidepressant treatment. ","GG:Patients with the GG genotype may have a reduced response to antidepressants as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient''s response to antidepressant treatment. "');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (235, 'rs4803419', 'CYP2B6 (PA123)', '2B', 'Metabolism/PK', 'efavirenz (PA449441)', 'Infectious Diseases', 'HIV (PA447230)', '"CC:Patients with HIV and the CC genotype may have lower plasma concentrations of efavirenz as compared to patients with the TT genotype. Other clinical and genetic factors may also influence plasma concentrations of efavirenz in patients with HIV.,"CT:Patients with HIV and the CT genotype may have higher plasma concentrations of efavirenz as compared to patients with the CC genotype and lower plasma concentrations as compared to patients with the TT genotype. Other clinical and genetic factors may also influence plasma concentrations of efavirenz in patients with HIV. ","TT:Patients with HIV and the TT genotype may have higher plasma concentrations of efavirenz as compared to patients with the CT or CC genotype. Other clinical and genetic factors may also influence plasma concentrations of efavirenz in patients with HIV."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (236, 'rs4880', 'SOD2 (PA36017)', '2B', 'Efficacy', 'cyclophosphamide (PA449165)', 'Oncology', 'Breast Neoplasms (PA443560)', '"AA:Patients with the AA genotype and breast cancer who are treated with cyclophosphamide may have increased survival as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient''s survival when treated with cyclophosphamide.,"AG:Patients with the AG genotype and breast cancer who are treated with cyclophosphamide may have a decreased survival as compared to patients with the AA genotype or may have increased survival as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient''s survival when treated with cyclophosphamide.","GG:Patients with the GG genotype and breast cancer who are treated with cyclophosphamide may have a decreased survival as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient''s survival when treated with cyclophosphamide."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (237, 'rs489693', 'MC4R (PA30676)', '2B', 'Toxicity/ADR', 'amisulpride (PA162565877),"aripiprazole (PA10026)","clozapine (PA449061)","haloperidol (PA449841)","olanzapine (PA450688)","paliperidone (PA163518919)","quetiapine (PA451201)","risperidone (PA451257)","ziprasidone (PA451974)"', 'Psychiatry', 'Autism Spectrum Disorder (PA153906318),"schizoaffective disorder (PA166123368)","Schizophrenia (PA447216)"', '"AA:Patients with schizophrenia, schizoaffective disorder, or autism spectrum disorder and genotype AA may have an increased likelihood of weight gain and hypertriglyceridemia when taking amisulpride, aripiprazole, clozapine, olanzapine, haloperidol, paliperidone, quetiapine, ziprasidone, or risperidone as compared to patients with the AC and CC genotypes, although this is contradicted in one study. Other clinical and genetic factors may also influence likelihood of weight gain in patients taking amisulpride, aripiprazole, clozapine, olanzapine, haloperidol, paliperidone, quetiapine, ziprasidone, or risperidone. ,"AC:Patients with schizophrenia, schizoaffective disorder, or autism spectrum disorder and genotype AC may have a decreased likelihood of weight gain and hypertriglyceridemia when taking amisulpride, aripiprazole, clozapine, olanzapine, haloperidol, paliperidone, quetiapine, ziprasidone, or risperidone as compared to patients with the AA genotypes, although this is contradicted in one study. Other clinical and genetic factors may also influence likelihood of weight gain in patients taking amisulpride, aripiprazole, clozapine, olanzapine, haloperidol, paliperidone, quetiapine, ziprasidone, or risperidone. ","CC:Patients with schizophrenia, schizoaffective disorder, or autism spectrum disorder and genotype CC may have a decreased likelihood of weight gain and hypertriglyceridemia when taking amisulpride, aripiprazole, clozapine, olanzapine, haloperidol, paliperidone, quetiapine, ziprasidone, or risperidone as compared to patients with the AA genotypes, although this is contradicted in one study. Other clinical and genetic factors may also influence likelihood of weight gain in patients taking amisulpride, aripiprazole, clozapine, olanzapine, haloperidol, paliperidone, quetiapine, ziprasidone, or risperidone. "');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (238, 'rs4917639', 'CYP2C9 (PA126)', '2A', 'Dosage', 'warfarin (PA451906)', 'variant implication on Dosing', '', '"AA:Patients with the AA genotype may require increased dose of warfarin as compared to patients with the CC or CA genotype. Other clinical or genetic factors may also influence warfarin dose.,"CA:Patients with the CA genotype may require decreased dose of warfarin as compared to patients with the AA genotype. Other clinical or genetic factors may also influence warfarin dose.","CC:Patients with the CC genotype may require decreased dose of warfarin as compared to patients with the AA genotype. Other clinical or genetic factors may also influence warfarin dose."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (239, 'rs4961', 'ADD1 (PA31)', '2B', 'Efficacy', 'furosemide (PA449719),"spironolactone (PA451483)"', 'Drug Response effects/ toxicity Liver Cirrhosis', 'Liver Cirrhosis (PA444797)', '"GG:Patients with the GG genotype and Liver Cirrhosis who are treated with furosemide and spironolactone may be more likely to respond to diuretic treatment as compared to patients with the GT and TT genotype. Other genetic and clinical factors may also influence a patient''s response to diuretics.,"GT:Patients with the GT genotype and Liver Cirrhosis who are treated with furosemide and spironolactone may be less likely to respond to diuretic treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient''s response to diuretics.","TT:Patients with the TT genotype and Liver Cirrhosis who are treated with furosemide and spironolactone may be less likely to respond to diuretic treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient''s response to diuretics."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (240, 'rs4986893', 'CYP2C19 (PA124)', '1A', 'Efficacy,"Toxicity/ADR"', 'clopidogrel (PA449053)', 'Cardiovascular', 'Acute coronary syndrome (PA165108401),"Coronary Artery Disease (PA443796)"', '"AA:Patients with the AA genotype 1) may have poor metabolism of clopidogrel and decreased formation of active drug metabolite, resulting in decreased response 2) may have an increased risk for secondary cardiovascular events when treated with clopidogrel as compared to patients with the GG genotype. Other genetic and clinical factors may influence a patient''s risk for secondary cardiovascular events and response to clopidogrel.,"AG:Patients with the AG genotype 1) may have poor metabolism of clopidogrel and decreased formation of active drug metabolite, resulting in decreased response 2) may have an increased risk for secondary cardiovascular events when treated with clopidogrel as compared to patients with the GG genotype. Other genetic and clinical factors may influence a patient''s risk for secondary cardiovascular events and response to clopidogrel.","GG:Patients with the GG genotype 1) may have increased metabolism of clopidogrel and formation of active drug metabolite, resulting in increased response 2) may have a decreased, but not absent, risk for secondary cardiovascular events when treated with clopidogrel as compared to patients with the AA or AG genotype. Other genetic and clinical factors may influence a patient''s risk for secondary cardiovascular events and response to clopidogrel."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (241, 'rs5219', 'KCNJ11 (PA217)', '2A', 'Efficacy', 'glibenclamide (PA449782),"gliclazide (PA10892)","glimepiride (PA449761)","glipizide (PA449762)","gliquidone (PA164744895)","sulfonamides, urea derivatives (PA10390)"', 'Metabolic disorder', 'Diabetes Mellitus (PA443886)', '"CC:Patients with diabetes melitus and the CC genotype who are taking sulfonylureas (gliclazides, glibenclamide, glimepiride, glipizide, or gliquidone) may have worse response as compared to patients with the CT or TT genotypes, although this is contradicted in some studies, and one found that the CT genotype had an improved response as compared to the CC or TT genotypes. Other clinical and genetic factors may also influence response to sulfonylureas in patients with diabetes melitus. ,"CT:Patients with diabetes melitus and the CT genotype who are taking sulfonylureas (gliclazides, glibenclamide, glimepiride, glipizide, or gliquidone) may have improved response as compared to patients with the CC genotypes, although this is contradicted in some studies, and one found that the CT genotype had an improved response as compared to the CC or TT genotypes. Other clinical and genetic factors may also influence response to sulfonylureas in patients with diabetes melitus. ","TT:Patients with diabetes melitus and the TT genotype who are taking sulfonylureas (gliclazide, glibenclamide, glimepiride, glipizide, or gliquidone) may have improved response as compared to patients with the CC genotypes, although this is contradicted in some studies, and one found that the CT genotype had an improved response as compared to the CC or TT genotypes. Other clinical and genetic factors may also influence response to sulfonylureas in patients with diabetes melitus. "');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (242, 'rs5443', 'GNB3 (PA176)', '2B', 'Efficacy', 'sildenafil (PA451346)', 'Endocrinology', 'Erectile Dysfunction (PA444606)', '"CC:Patients with the CC genotype and erectile dysfunction who are treated with sildenafil may be less likely to have positive erectile response as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient''s response to sildenafil.,"CT:Patients with the CT genotype and erectile dysfunction who are treated with sildenafil may be less likely to have positive erectile response as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient''s response to sildenafil.","TT:Patients with the TT genotype and erectile dysfunction who are treated with sildenafil may be more likely to have positive erectile response as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient''s response to sildenafil."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (243, 'rs55886062', 'DPYD (PA145)', '1A', 'Toxicity/ADR', 'capecitabine (PA448771),"fluorouracil (PA128406956)","Pyrimidine analogues (PA164713220)","tegafur (PA452620)"', 'Oncology', 'Neoplasms (PA445062)', '"AA:Patients with the AA genotype (DPYD *1/*1) and cancer who are treated with fluoropyrimidine-based chemotherapy may have a decreased, but not absent, risk for drug toxicity as compared to patients with the AC or CC genotype (DPYD *1/*13 or *13/*13). Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin), FOLFIRI (fluorouracil, leucovorin and irinotecan) or FEC (fluorouracil, epirubicin and cyclophosphamide) or with other drugs such as bevacizumab, cetuximab or raltitrexed. The combination and delivery of the drug may influence risk for toxicity. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.,"AC:Patients with the AC genotype (DPYD *1/*13) and cancer who are treated with fluoropyrimidine-based chemotherapy may have 1) partial DYPD deficiency and 2) an increased risk and increased severity of drug toxicity as compared to patients with the AA genotype (DPYD *1/*1). Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin), FOLFIRI (fluorouracil, leucovorin and irinotecan) or FEC (fluorouracil, epirubicin and cyclophosphamide) or with other drugs such as bevacizumab, cetuximab or raltitrexed. The combination and delivery of the drug may influence risk for toxicity. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.","CC:Patients with the CC genotype (DPYD *13/*13) and cancer who are treated with fluoropyrimidine-based chemotherapy may have 1) complete DYPD deficiency and 2) an increased risk and increased severity of drug toxicity as compared to patients with the AA genotype (DPYD *1/*1). Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin), FOLFIRI (fluorouracil, leucovorin and irinotecan) or FEC (fluorouracil, epirubicin and cyclophosphamide) or with other drugs such as bevacizumab, cetuximab or raltitrexed. The combination and delivery of the drug may influence risk for toxicity. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (244, 'rs56165452', 'CYP2C9 (PA126)', '2A', 'Dosage', 'warfarin (PA451906)', 'variant implication on Dosing', '', '"CC:Patients with the CC genotype may required reduced dose of warfarin as compared to patients with the TT genotype. Other clinical or genetic factors may also influence warfarin dose. This variant rs56165452 defines CYP2C9*4.,"CT:Patients with the CT genotype may required reduced dose of warfarin as compared to patients with the TT genotype. Other clinical or genetic factors may also influence warfarin dose. This variant rs56165452 defines CYP2C9*4.","TT:Patients with the TT genotype may required higher dose of warfarin as compared to patients with the CT or CC genotype. Other clinical or genetic factors may also influence warfarin dose. This variant rs56165452 defines CYP2C9*4."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (245, 'rs578776', 'CHRNA3 (PA113)', '2B', 'Toxicity/ADR,"Metabolism/PK"', 'nicotine (PA450626)', 'Psychiatry', 'Tobacco Use Disorder (PA445876)', '"AA:Patients with the AA genotype may have a decreased risk for tobacco addiction as compared to patients with the GG genotype. Patients with the AA genotype may also show decreased levels of cotinine as compared to those with the GG genotype. Other genetic and clinical factors may also influence risk for tobacco addiction and cotinine levels. ,"AG:Patients with the AG genotype may have a decreased risk for tobacco addiction as compared to patients with the GG genotype, or an increased risk as compared to patients with the AA genotype. Patients with the AG genotype may also show decreased levels of cotinine as compared to those with the GG genotype, or increased levels as compared to those with the AA genotype. Other genetic and clinical factors may also influence risk for tobacco addiction and cotinine levels. ","GG:Patients with the GG genotype may have an increased risk for tobacco addiction as compared to patients with the AA genotype. Patients with the GG genotype may also show increased levels of cotinine as compared to those with the AA genotype. Other genetic and clinical factors may also influence risk for tobacco addiction and cotinine levels. "');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (246, 'rs6025', 'F5 (PA159)', '2A', 'Toxicity/ADR', 'hormonal contraceptives for systemic use (PA452637)', 'Hematology', 'Thrombosis (PA445850)', '"CC:Patients with the CC genotype (normal Factor V) may have a decreased risk of experiencing thrombosis when receiving oral contraceptives as compared to patients with the CT or TT genotype (carriers of Factor V Leiden). Both Factor V Leiden and oral contraceptives have been found to independently increase the risk for thrombosis, but together they may have a cumulative effect on thrombosis risk. Other genetic and clinical factors may also influence risk of thrombosis. ,"CT:Patients with the CT genotype (heterozygote for Factor V Leiden) may have an increased risk of experiencing thrombosis when receiving oral contraceptives as compared to patients with the CC genotype (normal Factor V). Both Factor V Leiden and oral contraceptives have been found to independently increase the risk for thrombosis, but together they may have a cumulative effect on thrombosis risk. Other genetic and clinical factors may also influence risk of thrombosis. ","TT:Patients with the TT genotype (homozygote for Factor V Leiden) may have an increased risk of experiencing thrombosis when receiving oral contraceptives as compared to patients with the CC genotype (normal Factor V). Both Factor V Leiden and oral contraceptives have been found to independently increase the risk for thrombosis, but together they may have a cumulative effect on thrombosis risk. Other genetic and clinical factors may also influence risk of thrombosis. "');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (250, 'rs6295', 'HTR1A (PA192)', '2B', 'Efficacy', 'paroxetine (PA450801)', 'Psychiatry', 'Panic Disorder (PA447212)', '"CC:Patients with the CC genotype with panic disorder who are treated with paroxetine may have an reduced response at 4 weeks of treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient''s response to paroxetine. ,"CG:Patients with the CG genotype with panic disorder who are treated with paroxetine may have an reduced response at 4 weeks of treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient''s response to paroxetine. ","GG:Patients with the GG genotype with panic disorder who are treated with paroxetine may have a better response at 4 weeks of treatment as compared to patients with the CG or CC genotype. Other genetic and clinical factors may also influence a patient''s response to paroxetine. "');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (251, 'rs63749869', 'RYR1 (PA34896)', '1A', 'Toxicity/ADR', 'desflurane (PA164749136),"enflurane (PA449461)","halothane (PA449845)","isoflurane (PA450106)","methoxyflurane (PA450434)","sevoflurane (PA451341)","succinylcholine (PA451522)"', 'Pharmacogenetic disorder', 'Malignant Hyperthermia (PA444863)', '"AA:Patients with the AA genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the GG genotype. Please note: the A allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).,"AG:Patients with the AG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the GG genotype. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).","GG:Patients with the GG genotype may not develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the AG or GG genotype. Other genetic or clinical factors may put a patient at risk for developing Malignant Hyperthermia."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (252, 'rs6432512', 'TANC1 (PA142670838)', '2B', 'Toxicity/ADR', 'radiotherapy (PA166122986)', 'Oncology', 'Prostatic Neoplasms (PA445425)', '"CC:Patients with the CC genotype and prostate cancer who are treated with radiotherapy may have a reduced risk of late stage toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient''s risk of radiotherapy-induced toxicity. ,"CT:Patients with the CT genotype and prostate cancer who are treated with radiotherapy may have an increased risk of late stage toxicity as compared to patients with the CC genotype, or may have a reduced risk of late stage toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient''s risk of radiotherapy-induced toxicity. ","TT:Patients with the TT genotype and prostate cancer who are treated with radiotherapy may have an increased risk of late stage toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient''s risk of radiotherapy-induced toxicity. "');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (253, 'rs662799', 'APOA5 (PA24888)', '2B', 'Efficacy', 'atorvastatin (PA448500),"lovastatin (PA450272)","simvastatin (PA451363)"', 'Cardiovascular', 'Hyperlipidemias (PA444528)', '"AA:Patients with the AA genotype and Hyperlipidemia who are treated with atorvastatin, lovastatin or simvastatin may have a higher reduction in LDL-cholesterol as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient''s response to statin treatment. ,"AG:Patients with the AG genotype and Hyperlipidemia who are treated with atorvastatin, lovastatin or simvastatin may have less reduction in LDL-cholesterol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient''s response to statin treatment. ","GG:Patients with the GG genotype and Hyperlipidemia who are treated with atorvastatin, lovastatin or simvastatin may have less reduction in LDL-cholesterol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient''s response to statin treatment. "');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (254, 'rs67376798', 'DPYD (PA145)', '1A', 'Toxicity/ADR,"Metabolism/PK"', 'capecitabine (PA448771),"fluorouracil (PA128406956)","Pyrimidine analogues (PA164713220)","tegafur (PA452620)"', 'Oncology', 'Neoplasms (PA445062)', '"AA:Patients with the AA genotype and cancer who are treated with fluoropyrimidine-based chemotherapy may have 1) complete DPYD deficiency and decreased clearance of fluoropyrimidine drugs and 2) increased risk and increased severity of drug toxicity, in particular diarrhea, as compared to patients with the TT genotype. Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin), FOLFIRI (fluorouracil, leucovorin and irinotecan) or FEC (fluorouracil, epirubicin and cyclophosphamide) or with other drugs such as bevacizumab, cetuximab or raltitrexed. The combination and delivery of the drug may influence risk for toxicity. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.,"AT:Patients with the AT genotype and cancer who are treated with fluoropyrimidine-based chemotherapy may have 1) DPYD deficiency and decreased clearance of fluoropyrimidine drugs and 2) increased risk and increased severity of drug toxicity, in particular diarrhea, as compared to patients with the TT genotype. Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin), FOLFIRI (fluorouracil, leucovorin and irinotecan) or FEC (fluorouracil, epirubicin and cyclophosphamide) or with other drugs such as bevacizumab, cetuximab or raltitrexed. The combination and delivery of the drug may influence risk for toxicity. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.","TT:Patients with the TT genotype and cancer who are treated with fluoropyrimidine-based chemotherapy may have 1) increased clearance of the drug and 2) decreased, but not absent, risk and reduced severity of drug toxicity as compared to patients with the AA or AT genotypes. Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin), FOLFIRI (fluorouracil, leucovorin and irinotecan) or FEC (fluorouracil, epirubicin and cyclophosphamide) or with other drugs such as bevacizumab, cetuximab or raltitrexed. The combination and delivery of the drug may influence risk for toxicity. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (255, 'rs678849', 'OPRD1 (PA31942)', '2B', 'Efficacy', 'buprenorphine (PA448685)', 'Pharmacogenetic disorder', 'Opioid-Related Disorders (PA445043)', '"CC:African-American patients with the CC genotype may have a decreased response to buprenorphine when being treated for opioid dependence, as compared to patients with the CT or TT genotypes. This association was not seen in European-American patients. Response to buprenorphine treatment was measured by the number of opioid-positive drug screens during treatment. Other genetic and clinical factors may also affect a patient''s response to buprenorphine.,"CT:African-American patients with the CT genotype may have an increased response to buprenorphine when being treated for opioid dependence, as compared to patients with the CC genotype. This association was not seen in European-American patients. Response to buprenorphine treatment was measured by the number of opioid-positive drug screens during treatment. Other genetic and clinical factors may also affect a patient''s response to buprenorphine.","TT:African-American patients with the TT genotype may have an increased response to buprenorphine when being treated for opioid dependence, as compared to patients with the CC genotype. This association was not seen in European-American patients. Response to buprenorphine treatment was measured by the number of opioid-positive drug screens during treatment. Other genetic and clinical factors may also affect a patient''s response to buprenorphine."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (256, 'rs6977820', '.', '2B', 'Toxicity/ADR', 'antipsychotics (PA452233)', 'Psychiatry', 'Schizophrenia (PA447216),"tardive dyskinesia (PA447268)"', '"CC:Patients with the CC genotype may have decreased likelihood of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence the risk of toxicity to antipsychotics.,"CT:Patients with the CT genotype may have increased likelihood of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to patients with genotype CC. Other genetic and clinical factors may also influence the risk of toxicity to antipsychotics.","TT:Patients with the TT genotype may have increased likelihood of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to patients with genotype CC. Other genetic and clinical factors may also influence the risk of toxicity to antipsychotics."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (259, 'rs716274', 'DYNC2H1 (PA27433)', '2B', 'Toxicity/ADR', 'etoposide (PA449552),"Platinum compounds (PA164713176)"', 'Oncology', '', '"AA:Patients with the AA genotype may have decreased risk of Death when treated with etoposide and Platinum compounds in people with Carcinoma, Small Cell as compared to patients with genotype GG or AG. Other genetic and clinical factors may also influence the response to etoposide and Platinum compounds.,"AG:Patients with the AG genotype may have increased risk of Death when treated with etoposide and Platinum compounds in people with Carcinoma, Small Cell as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to etoposide and Platinum compounds.","GG:Patients with the GG genotype may have increased risk of Death when treated with etoposide and Platinum compounds in people with Carcinoma, Small Cell as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to etoposide and Platinum compounds."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (260, 'rs71647871', 'CES1 (PA107)', '2B', 'Efficacy', 'clopidogrel (PA449053)', 'Drug Response effects/ toxicity', '', '"CC:Patients with the CC genotype who are treated with clopidogrel may have higher on-treatment ADP-induced platelet aggregation and lower levels of clopidogrel active metabolite as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient''s response to clopidogrel.,"CT:Patients with the CT genotype who are treated with clopidogrel may have lower on-treatment ADP-induced platelet aggregation and higher levels of clopidogrel active metabolite as compared to patients with the CC genotype. The T allele is associated with impaired catalytic activity towards hydrolysis of clopidogrel and 2-oxo-clopidogrel. Other genetic and clinical factors may also influence a patient''s response to clopidogrel.","TT:Patients with the TT genotype who are treated with clopidogrel may have lower on-treatment ADP-induced platelet aggregation and higher levels of clopidogrel active metabolite as compared to patients with the CC genotype. The T allele is associated with impaired catalytic activity towards hydrolysis of clopidogrel and 2-oxo-clopidogrel. Other genetic and clinical factors may also influence a patient''s response to clopidogrel."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (261, 'rs7196161', 'VKORC1 (PA133787052)', '2B', 'Dosage', 'warfarin (PA451906)', 'variant implication on Dosing', '', '"AA:Patients with the AA genotype may require an increased dose of warfarin as compared to patients with the AG and GG genotypes. Other clinical and genetic factors may also influence the dose of warfarin. ,"AG:Patients with the AG genotype may require an increased dose of warfarin as compared to patients with the GG genotype and a decreased dose of warfarin as compared to patients with the AA genotype. Other clinical and genetic factors may also influence the dose of warfarin. ","GG:Patients with the GG genotype may require a decreased dose of warfarin as compared to patients with the AG and AA genotypes. Other clinical and genetic factors may also influence the dose of warfarin. "');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (262, 'rs7270101', 'ITPA (PA29973)', '2B', 'Toxicity/ADR', 'azathioprine (PA448515)', 'Oncology', 'Inflammatory Bowel Diseases (PA446116),"Precursor Cell Lymphoblastic Leukemia-Lymphoma (PA446155)"', '"AA:Patients with inflammatory bowel diseases, or precursor cell lymphoblastic leukemia-lymphoma and the AA genotype who are treated with azathioprine may metabolize it more slowly and have decreased likelihood of adverse events as compared to patients with the CC genotype, however this is contradicted in most studies. Other clinical and genetic factors may also influence likelihood of adverse events in patients with inflammatory bowel disease. ,"AC:Patients with inflammatory bowel diseases, or precursor cell lymphoblastic leukemia-lymphoma and the AC genotype who are treated with azathioprine may metabolize it more rapidly and may have an increased likelihood of adverse events as compared to patients with the CC genotype, however this is contradicted in most studies. Other clinical and genetic factors may also influence likelihood of adverse events in patients with inflammatory bowel disease. ","CC:Patients with inflammatory bowel diseases, or precursor cell lymphoblastic leukemia-lymphoma and the CC genotype who are treated with azathioprine may metabolize it more rapidly and may have an increased likelihood of adverse events as compared to patients with the AA genotype, however this is contradicted in most studies. Other clinical and genetic factors may also influence likelihood of adverse events in patients with inflammatory bowel disease. "');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (263, 'rs7270101', 'ITPA (PA29973)', '2B', 'Toxicity/ADR', 'peginterferon alfa-2b (PA164784024),"ribavirin (PA451241)"', 'Infectious Diseases', 'Hepatitis C, Chronic (PA446863)', '"AA:Patients with chronic hepatitis C and the AA genotype may have an increased risk of anemia but a decreased risk of thrombocytopenia when compared to patients with the AC and CC genotype who are taking peg interferon alfa-2b and ribavirin. Studies have looked at the composite genotypes of rs1127354 CC and rs7270101 AA to identify normal ITPas activity" vs. "deficient". Normal ITPase activity is associated with increased risk of anemia and possibly decreased risk of thrombocytopenia as compared to deficient activity. Other clinical and genetic factors may influence risk of anemia in patients with hepatitis C who are taking peg interferon alfa-2b and ribavirin.","AC:Patients with chronic hepatitis C and the AC genotype may have an decreased risk of anemia but an increased risk of thrombocytopenia when compared to patients with the AA genotype who are taking peg interferon alfa-2b and ribavirin. Studies have looked at the composite genotypes of rs1127354 CC and rs7270101 AA to identify "normal ITPas activity" vs. "deficient". Normal ITPase activity is associated with increased risk of anemia and possibly decreased risk of thrombocytopenia as compared to deficient activity. Other clinical and genetic factors may influence risk of anemia in patients with hepatitis C who are taking peg interferon alfa-2b and ribavirin.","CC:Patients with chronic hepatitis C and the CC genotype may have an decreased risk of anemia but an increased risk of thrombocytopenia when compared to patients with the AA genotype who are taking peg interferon alfa-2b and ribavirin. Studies have looked at the composite genotypes of rs1127354 CC and rs7270101 AA to identify "normal ITPas activity" vs. "deficient". Normal ITPase activity is associated with increased risk of anemia and possibly decreased risk of thrombocytopenia as compared to deficient activity. Other clinical and genetic factors may influence risk of anemia in patients with hepatitis C who are taking peg interferon alfa-2b and ribavirin."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (264, 'rs7294', 'VKORC1 (PA133787052)', '1B', 'Dosage', 'warfarin (PA451906)', 'variant implication on Dosing', '', '"CC:Patients with the CC genotype who are treated with warfarin may require a lower dose as compared to patients with the TC or TT genotype. Other genetic and clinical factors may also influence a patient''s required dose of warfarin.,"CT:Patients with the CT genotype who are treated with warfarin may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient''s required dose of warfarin.","TT:Patients with the TT genotype who are treated with warfarin may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient''s required dose of warfarin."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (265, 'rs7297610', 'YEATS4 (PA134992686)', '2B', 'Efficacy', 'hydrochlorothiazide (PA449899)', 'Cardiovascular', 'Essential hypertension (PA447288),"Hypertension (PA444552)"', '"CC:Patients with the CC genotype and hypertension who are treated with hydrochlorothiazide may have an increased response as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient''s response to hydrochlorothiazide.,"CT:Patients with the CT genotype and hypertension who are treated with hydrochlorothiazide may have a decreased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient''s response to hydrochlorothiazide.","TT:Patients with the TT genotype and hypertension who are treated with hydrochlorothiazide may have a decreased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient''s response to hydrochlorothiazide."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (266, 'rs730012', 'LTC4S (PA235)', '2B', 'Toxicity/ADR', 'aspirin (PA448497)', 'Organ Health Drug Response effects/ toxicity', 'Urticaria (PA445999)', '"AA:Patients with the AA genotype who are treated with aspirin may have a decreased, but not absent, risk of urticaria as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient''s risk for urticaria.,"AC:Patients with the AC genotype who are treated with aspirin may have an increased risk of urticaria as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient''s risk for urticaria.","CC:Patients with the CC genotype who are treated with aspirin may have an increased risk of urticaria as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient''s risk for urticaria."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (267, 'rs738409', 'PNPLA3 (PA38592)', '2B', 'Toxicity/ADR', 'asparaginase (PA448492),"cyclophosphamide (PA449165)","daunorubicin (PA449212)","prednisolone (PA451096)","vincristine (PA451879)"', 'Oncology', 'Precursor Cell Lymphoblastic Leukemia-Lymphoma (PA446155)', '"CC:Patients with the CC genotype may have decreased risk of hepatotoxicity when treated with remission induction therapy (including asparaginase) in children with acute lymphoblastic leukemia (ALL) as compared to patients with genotype GG or CG. Other genetic and clinical factors may also influence the risk of toxicity to remission induction therapy.,"CG:Patients with the CG genotype may have increased risk of hepatotoxicity when treated with remission induction therapy (including asparaginase) in children with acute lymphoblastic leukemia (ALL) as compared to patients with genotype CC. Other genetic and clinical factors may also influence the risk of toxicity to remission induction therapy.","GG:Patients with the GG genotype may have increased risk of hepatotoxicity when treated with remission induction therapy (including asparaginase) in children with acute lymphoblastic leukemia (ALL) as compared to patients with genotype CC. Other genetic and clinical factors may also influence the risk of toxicity to remission induction therapy."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (268, 'rs7412', 'APOE (PA55)', '2A', 'Efficacy', 'atorvastatin (PA448500)', 'Cardiovascular', 'Coronary Disease (PA443797),"Hyperlipidemias (PA444528)"', '"CC:Patients with the CC genotype who are treated with atorvastatin may have a reduced response (less reduction in LDL-cholesterol) as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient''s response to atorvastatin treatment. ,"CT:Patients with the CT genotype who are treated with atorvastatin may have a better response (higher reduction in LDL-cholesterol) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient''s response to atorvastatin treatment. ","TT:Patients with the TT genotype who are treated with atorvastatin may have a better response (higher reduction in LDL-cholesterol) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient''s response to atorvastatin treatment. "');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (269, 'rs74503330', 'CFTR (PA109)', '1A', 'Efficacy', 'ivacaftor (PA165950341)', 'Pulmonology', 'Cystic Fibrosis (PA443829)', '"AA:Patients with the AA genotype (two copies of the CFTR S1251N variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S1251N. Other genetic and clinical factors may also influence a patient''s response to ivacaftor. ,"AG:Patients with the AG genotype (one copy of the CFTR S1251N variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S1251N. Other genetic and clinical factors may also influence a patient''s response to ivacaftor. ","GG:Patients with the GG genotype (do not have a copy of the CFTR S1251N variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S1251N. Other genetic and clinical factors may also influence a patient''s response to ivacaftor."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (270, 'rs74551128', 'CFTR (PA109)', '1A', 'Efficacy', 'ivacaftor (PA165950341)', 'Pulmonology', 'Cystic Fibrosis (PA443829)', '"AA:Patients with the AA genotype (two copies of the CFTR A455E variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including A455E. Other genetic and clinical factors may also influence a patient''s response to ivacaftor.,"AC:Patients with the AC genotype (one copy of the CFTR A455E variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including A455E. Other genetic and clinical factors may also influence a patient''s response to ivacaftor.","CC:Patients with the CC genotype (do not have a copy of the CFTR A455E variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including A455E. Other genetic and clinical factors may also influence a patient''s response to ivacaftor."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (271, 'rs746647', 'CCHCR1 (PA134942738)', '2B', 'Toxicity/ADR', 'nevirapine (PA450616)', 'Infectious Diseases', 'HIV (PA447230)', '"AA:Patients with the AA genotype may have decreased risk of Nevirapine-induced rash when treated with nevirapine in people with HIV as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient''s response to nevirapine.,"AG:Patients with the AG genotype may have increased risk of Nevirapine-induced rash when treated with nevirapine in people with HIV as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient''s response to nevirapine.","GG:Patients with the GG genotype may have increased risk of Nevirapine-induced rash when treated with nevirapine in people with HIV as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient''s response to nevirapine."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (297, 'rs8175347', 'UGT1A1 (PA420)', '2A', 'Toxicity/ADR', 'irinotecan (PA450085)', 'Oncology', 'Neoplasms (PA445062)', '"(TA)6/(TA)6:Patients with the (TA)6/(TA)6 genotype (i.e. UGT1A1*1/*1) and cancer who are treated with irinotecan-based regimens may have a decreased risk of neutropenia, diarrhea, or asthenia, as compared to patients with the (TA)7/(TA)7 (*28/*28) genotype. Evidence for an association between this genotype and neutropenia is stronger than that for diarrhea or asthenia, and some studies only show significant associations with neutropenia and diarrhea at medium and high doses of the drug (>125 mg/m2). No significant associations have been seen for nausea, mucositis, infection, overall gastrointestinal toxicities (diarrhea, nausea, vomiting, and mucositis combined) or tumor response. One study found a decreased risk of vomiting for this genotype, and another found a decreased risk of treatment-related death, both compared to the (TA)7/(TA)7 genotype. Other genetic and clinical factors may also influence a patient''s risk of neutropenia, diarrhea, asthenia, vomiting, or treatment-related death. ,"(TA)6/(TA)7:Patients with the (TA)6/(TA)7 genotype (i.e. UGT1A1*1/*28) with cancer who are treated with irinotecan-based regimens may have an increased risk of neutropenia, diarrhea, or asthenia, as compared to patients with the (TA)6/(TA)6 (*1/*1) genotype, and a decreased risk compared to those with the (TA)7/(TA)7 (*28/*28) genotype. Evidence for an association between this genotype and neutropenia is stronger than that for diarrhea or asthenia, and some studies only show significant associations with neutropenia at medium and high doses of the drug (>125 mg/m2). No significant associations have been seen for nausea, mucositis, infection, or tumor response. One study found a decreased overall survival time for carriers of the (TA)7 allele. One study found an increased risk of vomiting for this genotype, and another found an increased risk of treatment-related death, both compared to the (TA)6/(TA)6 genotype. Other genetic and clinical factors may also influence a patient''s survival time and risk of neutropenia, diarrhea, asthenia, vomiting, or treatment-related death. ","(TA)7/(TA)7:Patients with the (TA)7/(TA)7 genotype (i.e. UGT1A1*28/*28) with cancer who are treated with irinotecan-based regimens may have an increased risk of neutropenia, diarrhea, or asthenia, as compared to patients with the (TA)6/(TA)6 (*1/*1) or (TA)6/(TA)7 (*1/*28) genotype. Evidence for an association between this genotype and neutropenia is stronger than that for diarrhea or asthenia, and some studies only show significant associations with neutropenia and diarrhea at medium and high doses of the drug (>125 mg/m2). No significant associations have been seen for nausea, mucositis, infection, overall gastrointestinal toxicities (diarrhea, nausea, vomiting, and mucositis combined), or tumor response. One study found a decreased overall survival time for carriers of the (TA)7 allele. One study found an increased risk of vomiting for this genotype, and another found an increased risk of treatment-related death, both compared to the (TA)6/(TA)6 genotype. Other genetic and clinical factors may also influence a patient''s survival time and risk of neutropenia, diarrhea, asthenia, vomiting, or treatment-related death. "');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (272, 'rs75039782', 'CFTR (PA109)', '2A', 'Efficacy', 'ataluren (PA166151864)', 'Pulmonology', 'Cystic Fibrosis (PA443829)', '"CC:Patients with the CC genotype and cystic fibrosis may not respond to treatment with ataluren. Randomized clinical trials did not find improvement in chloride transport or improved pulmonary function after 2 rounds of 2 weeks of treatment. Other genetic and clinical factors may also influence changes in chloride transport and improvement of pulmonary symptoms in patients with cystic fibrosis.,"CT:Patients with the CT genotype and cystic fibrosis may have increased response when treated with ataluren as compared to patients with the CC genotype. Randomized clinical trials found improvement in chloride transport, but did not find evidence for improved pulmonary function after 2 rounds of 2 weeks of treatment. Other genetic and clinical factors may also influence changes in chloride transport and improvement of pulmonary symptoms in patients with cystic fibrosis.","TT:Patients with the TT genotype and cystic fibrosis may have increased response when treated with ataluren as compared to patients with the CC genotype. Randomized clinical trials found improvement in chloride transport, but did not find evidence for improved pulmonary function after 2 weeks of treatment. Other genetic and clinical factors may also influence changes in chloride transport and improvement of pulmonary symptoms in patients with cystic fibrosis."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (273, 'rs75527207', 'CFTR (PA109)', '1A', 'Efficacy', 'ivacaftor (PA165950341)', 'Pulmonology', 'Cystic Fibrosis (PA443829)', '"AA:Ivacaftor is indicated in cystic fibrosis patients with the AA genotype (two copies of the CFTR G551D variant). FDA-approved drug labeling information indicates use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including G551D. Other genetic and clinical factors may also influence a patient''s response to ivacaftor.,"AG:Ivacaftor is indicated in cystic fibrosis patients with the AG genotype (one copy of the CFTR G551D variant). FDA-approved drug labeling information indicates use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including G551D. Other genetic and clinical factors may also influence a patient''s response to ivacaftor.","GG:Indication of ivacaftor in cystic fibrosis patients with the GG genotype (no copies of the CFTR G551D variant) is dependent on the presence of other variants within the CFTR gene. FDA-approved drug labeling information indicates use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including G551D. Other genetic and clinical factors may also influence a patient''s response to ivacaftor. "');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (274, 'rs75541969', 'CFTR (PA109)', '1A', 'Efficacy', 'ivacaftor (PA165950341)', 'Pulmonology', 'Cystic Fibrosis (PA443829)', '"CC:Patients with the CC genotype (two copies of the CFTR D1152H variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including D1152H. Other genetic and clinical factors may also influence a patient''s response to ivacaftor.,"CG:Patients with the CG genotype (one copy of the CFTR D1152H variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including D1152H. Other genetic and clinical factors may also influence a patient''s response to ivacaftor.","GG:Patients with the GG genotype (do not have a copy of the CFTR D1152H variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including D1152H. Other genetic and clinical factors may also influence a patient''s response to ivacaftor."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (275, 'rs7582141', 'TANC1 (PA142670838)', '2B', 'Toxicity/ADR', 'radiotherapy (PA166122986)', 'Oncology', 'Prostatic Neoplasms (PA445425)', '"GG:Patients with the GG genotype and prostate cancer who are treated with radiotherapy may have a reduced risk of late stage toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient''s risk of radiotherapy-induced toxicity. ,"GT:Patients with the GT genotype and prostate cancer who are treated with radiotherapy may have an increased risk of late stage toxicity as compared to patients with the GG genotype, or may have a reduced risk of late stage toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient''s risk of radiotherapy-induced toxicity. ","TT:Patients with the TT genotype and prostate cancer who are treated with radiotherapy may have an increased risk of late stage toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient''s risk of radiotherapy-induced toxicity. "');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (276, 'rs77010898', 'CFTR (PA109)', '2A', 'Efficacy', 'ataluren (PA166151864)', 'Pulmonology', '', '"AA:Patients with the AA genotype and cystic fibrosis may have increased response when treated with ataluren as compared to patients with the GG genotype. Randomized clinical trials found improvement in chloride transport, but did not find evidence for improved pulmonary function after 2 weeks of treatment. Other genetic and clinical factors may also influence changes in chloride transport and improvement of pulmonary symptoms in patients with cystic fibrosis.,"AG:Patients with the AG genotype and cystic fibrosis may have increased response when treated with ataluren as compared to patients with the GG genotype. Randomized clinical trials found improvement in chloride transport, but did not find evidence for improved pulmonary function after 2 weeks of treatment. Other genetic and clinical factors may also influence changes in chloride transport and improvement of pulmonary symptoms in patients with cystic fibrosis.","GG:Patients with the GG genotype and cystic fibrosis may not respond to treatment with ataluren. Randomized clinical trials did not find improvement in chloride transport or improved pulmonary function after 2 rounds of 2 weeks of treatment. Other genetic and clinical factors may also influence changes in chloride transport and improvement of pulmonary symptoms in patients with cystic fibrosis."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (277, 'rs772226819', 'CACNA1S (PA85)', '1A', 'Toxicity/ADR', 'desflurane (PA164749136),"enflurane (PA449461)","halothane (PA449845)","isoflurane (PA450106)","methoxyflurane (PA450434)","sevoflurane (PA451341)","succinylcholine (PA451522)"', 'variant implication on Dosing', '', '"AA:Patients with the AA genotype may have a decreased, but not absent, risk for Malignant Hyperthermia based on this variant when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the AG genotype. Other genetic or clinical factors may put a patient at risk for developing Malignant Hyperthermia.,"AG:Patients with the AG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the AA genotype. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations).","GG:Patients with the GG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the AA genotype. Please note: the G allele is considered to confer MH in an autosomal dominant manner. This clinical annotation is based on one study and there were no individuals with the GG genotype. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. The variant is on the diagnostic Malignant Hyperthermia mutation list from the European Malignant Hyperthermia Group (https://www.emhg.org/diagnostic-mutations)."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (278, 'rs776746', 'CYP3A5 (PA131)', '2A', 'Dosage,"Metabolism/PK"', 'tacrolimus (PA451578)', 'Transplantation Medicine', 'liver transplantation (PA447247)', '"CC:Patients who are recipients of a liver transplantation from a donor with the CC (CYP3A5 *3/*3) genotype may have decreased metabolism of tacrolimus resulting in increased exposure, and may require a lower dose as compared to patients who receive a liver transplantation from a donor with the CT or TT (*1/*3 or *1/*1) genotype. Other genetic and clinical factors, such as recipient genotype, may also influence a patient''s tacrolimus dose requirement.,"CT:Patients who are recipients of a liver transplantation from a donor with the CT (CYP3A5 *1/*3) genotype may have increased metabolism of tacrolimus resulting in decreased exposure, and may require a higher dose as compared to patients who receive a liver transplantation from a donor with the CC (*3/*3) genotype. Other genetic and clinical factors, such as recipient genotype, may also influence a patient''s tacrolimus dose requirement.","TT:Patients who are recipients of a liver transplantation from a donor with the TT (CYP3A5 *1/*1) genotype may have increased metabolism of tacrolimus resulting in decreased exposure, and may require a higher dose as compared to patients who receive a liver transplantation from a donor with the CC (*3/*3) genotype. Other genetic and clinical factors, such as recipient genotype, may also influence a patient''s tacrolimus dose requirement."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (279, 'rs776746', 'CYP3A5 (PA131)', '2B', 'Dosage,"Metabolism/PK"', 'cyclosporine (PA449167)', 'Transplantation Medicine', 'Organ Transplantation (PA133888799),"Transplantation (PA134850491)"', '"CC:Patients with the CC genotype (CYP3A5 *3/*3) may require a lower dose of cyclosporine to reach target blood concentration as compared to patients with the CT (CYP3A5 *1/*3) or TT (CYP3A5 *1/*1) genotype, although this is contradicted in some studies. Other genetic and clinical factors may also influence dose of cyclosporine.,"CT:Patients with the CT (CYP3A5 *1/*3) genotype may require a higher dose of cyclosporine to reach target blood concentration as compared to patients with the CC (CYP3A5 *3/*3) genotype, although this is contradicted in some studies. Other genetic and clinical factors may also influence dose of cyclosporine.","TT:Patients with the TT genotype (CYP3A5 *1/*1) may require a higher dose of cyclosporine to reach target blood concentration as compared to patients with the CC (CYP3A5 *3/*3) genotype, although this is contradicted in some studies. Other genetic and clinical factors may also influence dose of cyclosporine."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (280, 'rs776746', 'CYP3A5 (PA131)', '2A', 'Dosage', 'sirolimus (PA451365)', 'Transplantation Medicine', 'Transplantation (PA134850491)', '"CC:Patients with the CC genotype (*3/*3) and who are recipients of transplants may have decreased metabolism of sirolimus and require a lower dose as compared to patients with the CT and TT genotype (*1/*3 and *3*/3). Other genetic and clinical factors may also influence a patient''s sirolimus dose requirements.,"CT:Patients with the CT genotype (*1/*3) and who are recipients of transplants may have increased metabolism of sirolimus and require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient''s sirolimus dose requirements.","TT:Patients with the TT genotype (*1/*1) and who are recipients of transplants may have increased metabolism of sirolimus and require a higher dose as compared to patients with the CC genotype (*3/*3). Other genetic and clinical factors may also influence a patient''s sirolimus dose requirements."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (281, 'rs776746', 'CYP3A5 (PA131)', '1A', 'Dosage,"Metabolism/PK"', '', 'Transplantation Medicine', '', '"CC:Patients with the CC genotype (CYP3A5*3/*3) who are recipients of a kidney, heart, lung or hematopoietic stem cell transplant, or have other diseases, who are treated with tacrolimus may have decreased metabolism of tacrolimus resulting in increased exposure, and may require a lower dose as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient''s tacrolimus dose requirement.,"CT:Patients with the CT genotype (CYP3A5*1/*3) who are recipients of a kidney, heart, lung or hematopoietic stem cell transplant, or have other diseases, who are treated with tacrolimus may have increased metabolism of tacrolimus resulting in decreased exposure, and may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient''s tacrolimus dose requirement.","TT:Patients with the TT genotype (CYP3A5*1/*1) who are recipients of a kidney, heart, lung or hematopoietic stem cell transplant, or have other diseases, who are treated with tacrolimus may have increased metabolism of tacrolimus resulting in decreased exposure, and may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient''s tacrolimus dose requirement."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (282, 'rs776746', 'CYP3A5 (PA131)', '2A', 'Efficacy', 'tacrolimus (PA451578)', 'Transplantation Medicine', 'transplant rejection (PA166114454)', '"CC:Patients with the CC (*3/*3) genotype and recipients of kidney or hematopoietic stem cell transplant who are treated with tacrolimus may have a decreased, but not absent, risk of transplant rejection as compared to patients with the CT or TT genotype (*1/*3 or *1/*1). Other genetic and clinical factors may also influence a patient''s response to tacrolimus treatment and risk of transplant rejection.,"CT:Patients with the CT genotype (*1/*3) and recipients of kidney or hematopoietic stem cell transplant who are treated with tacrolimus may have an increased risk of transplant rejection as compared to patients with the CC genotype (*3/*3) or a decreased risk of transplant rejection as compared to patients with the TT genotype (*1/*1). Other genetic and clinical factors may also influence a patient''s response to tacrolimus treatment and risk of transplant rejection.","TT:Patients with the TT (*1/*1) genotype and recipients of kidney or hematopoietic stem cell transplant who are treated with tacrolimus may have an increased risk of transplant rejection as compared to patients with the CC genotype (*3/*3). Other genetic and clinical factors may also influence a patient''s response to tacrolimus treatment and risk of transplant rejection."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (283, 'rs7779029', 'SEMA3C (PA35647)', '2B', 'Toxicity/ADR', 'irinotecan (PA450085)', 'Oncology', 'Carcinoma, Non-Small-Cell Lung (PA443622)', '"CC:Patients with the CC genotype may have increased severity of Neutropenia when treated with irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to patients with genotype TT. Other genetic or clinical factors may also influence the toxicity to irinotecan.,"CT:Patients with the CT genotype may have increased severity of Neutropenia when treated with irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to patients with genotype TT. Other genetic or clinical factors may also influence the toxicity to irinotecan.","TT:Patients with the TT genotype may have decreased severity of Neutropenia when treated with irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to patients with genotype CC or CT. Other genetic or clinical factors may also influence the toxicity to irinotecan."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (284, 'rs77834169', 'CFTR (PA109)', '1A', 'Efficacy', 'ivacaftor (PA165950341)', 'Pulmonology', 'Cystic Fibrosis (PA443829)', '"CC:Patients with the CC genotype (do not have a copy of the CFTR R117C variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R117C. Other genetic and clinical factors may also influence a patient''s response to ivacaftor.,"CT:Patients with the CT genotype (one copy of the CFTR R117C variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R117C. Other genetic and clinical factors may also influence a patient''s response to ivacaftor.","TT:Patients with the TT genotype (two copies of the CFTR R117C variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R117C. Other genetic and clinical factors may also influence a patient''s response to ivacaftor."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (285, 'rs77932196', 'CFTR (PA109)', '1A', 'Efficacy', 'ivacaftor (PA165950341)', 'Pulmonology', 'Cystic Fibrosis (PA443829)', '"AA:Patients with the AA genotype (two copies of the CFTR R347H variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R347H. Other genetic and clinical factors may also influence a patient''s response to ivacaftor.,"AC:Patients with the AC genotype (one copy of the CFTR R347H variant and one copy of the CFTR R347P variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R347H. R347P is not on this list of approved variants. Other genetic and clinical factors may also influence a patient''s response to ivacaftor.","AG:Patients with the AG genotype (one copy of the CFTR R347H variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R347H. Other genetic and clinical factors may also influence a patient''s response to ivacaftor.","CC:Patients with the CC genotype (two copies of the CFTR R347P variant) and cystic fibrosis may not respond to ivacaftor treatment. Other genetic and clinical factors may also influence a patient''s response to ivacaftor.","CG:Patients with the CG genotype (one copy of the CFTR R347P variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence a patient''s response to ivacaftor.","GG:Patients with the GG genotype (do not have a copy of the CFTR R347H or R347P variants) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence a patient''s response to ivacaftor."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (286, 'rs7793837', 'CRHR2 (PA26875)', '2B', 'Efficacy', 'salbutamol (PA448068),"selective beta-2-adrenoreceptor agonists (PA134687887)"', 'Pulmonology', 'Asthma (PA443450)', '"AA:Patients with the AA genotype and asthma who are treated with short-acting beta2-antagonists may have a better response (increased acute bronchodilation) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient''s response to short-acting beta2-antagonists.,"AT:Patients with the AT genotype and asthma who are treated with short-acting beta2-antagonists may have a poorer response (decreased acute bronchodilation) as compared to patients with the AA genotype, or may have a better response (increased acute bronchodilation) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient''s response to short-acting beta2-antagonists.","TT:Patients with the TT genotype and asthma who are treated with short-acting beta2-antagonists may have a poorer response (decreased acute bronchodilation) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient''s response to short-acting beta2-antagonists."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (287, 'rs7853758', 'SLC28A3 (PA426)', '2B', 'Toxicity/ADR', 'anthracyclines and related substances (PA130620651)', 'Oncology', 'Neoplasms (PA445062)', '"AA:Patients with the AA genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype GG. Other genetic or clinical factors may also influence the toxicity to anthracyclines.,"AG:Patients with the AG genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype GG. Other genetic or clinical factors may also influence the toxicity to anthracyclines.","GG:Patients with the GG genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype AA or AG. Other genetic or clinical factors may also influence the toxicity to anthracyclines."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (288, 'rs78655421', 'CFTR (PA109)', '1A', 'Efficacy', 'ivacaftor (PA165950341)', 'Pulmonology', 'Cystic Fibrosis (PA443829)', '"AA:Patients with the AA genotype (two copies of the CFTR R117H variant) and cystic fibrosis may have an improved response when treated with ivacaftor as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the efficacy of ivacaftor.,"AG:Patients with the AG genotype (one copy of the CFTR R117H variant) and cystic fibrosis may have an improved response when treated with ivacaftor as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the efficacy of ivacaftor.","GG:Patients with the GG genotype (do not carry a copy of the CFTR R117H variant) and cystic fibrosis may not respond when treated with ivacaftor as compared to patients with the AA and AG genotypes. Other genetic and clinical factors may also influence the efficacy of ivacaftor."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (289, 'rs78769542', 'CFTR (PA109)', '1A', 'Efficacy', 'ivacaftor (PA165950341)', 'Pulmonology', 'Cystic Fibrosis (PA443829)', '"AA:Patients with the AA genotype (two copies of the CFTR R1070Q variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R1070Q. Other genetic and clinical factors may also influence a patient''s response to ivacaftor.,"AG:Patients with the AG genotype (one copy of the CFTR R1070Q variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R1070Q. Other genetic and clinical factors may also influence a patient''s response to ivacaftor.","GG:Patients with the GG genotype (do not have a copy of the CFTR R1070Q variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R1070Q. Other genetic and clinical factors may also influence a patient''s response to ivacaftor."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (290, 'rs7900194', 'CYP2C9 (PA126)', '2A', 'Dosage,"Toxicity/ADR"', 'warfarin (PA451906)', 'Cardiovascular', 'Atrial Fibrillation (PA443459),"Pulmonary Embolism (PA445465)","Stroke (PA447054)","Venous Thrombosis (PA446969)"', '"AA:Patients with the AA genotype who are treated with warfarin may require the lowest maintenance dose as compared to patients with the AG or GG genotype. Other clinical or genetic factors may also influence warfarin dose.,"AG:Patients with the AG genotype who are treated with warfarin may require a lower maintenance dose as compared to patients with the GG genotype. Other clinical or genetic factors may also influence warfarin dose.","GG:Patients with the GG genotype who are treated with warfarin may require a higher maintenance dose as compared to patients with the AG or GG genotype. Other clinical or genetic factors may also influence warfarin dose."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (291, 'rs7903146', 'TCF7L2 (PA36394)', '2B', 'Efficacy', 'sulfonamides, urea derivatives (PA10390)', 'Metabolic disorder', '', '"CC:Patients with the CC genotype may have increased response (reductions in haemoglobin A1c (HbA1c) and fasting plasma glucose (FPG) levels) when treated with sulfonamides, urea derivatives in people with Diabetes Mellitus, Type 2 as compared to patients with CT or TT genotype. Other clinical and genetic factors may also influence a patient''s response to sulfonamides, urea derivatives.,"CT:Patients with the CT genotype may have decreased response (reductions in haemoglobin A1c (HbA1c) and fasting plasma glucose (FPG) levels) when treated with sulfonamides, urea derivatives in people with Diabetes Mellitus, Type 2 as compared to patients with CC genotype. Other clinical and genetic factors may also influence a patient''s response to sulfonamides, urea derivatives.","TT:Patients with the TT genotype may have decreased response (reductions in haemoglobin A1c (HbA1c) and fasting plasma glucose (FPG) levels) when treated with sulfonamides, urea derivatives in people with Diabetes Mellitus, Type 2 as compared to patients with CC genotype. Other clinical and genetic factors may also influence a patient''s response to sulfonamides, urea derivatives."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (292, 'rs7997012', 'HTR2A (PA193)', '2B', 'Efficacy', 'antidepressants (PA452229),"citalopram (PA449015)","Selective serotonin reuptake inhibitors (PA164713257)"', 'Psychiatry', 'Depression (PA447278),"Depressive Disorder (PA447207)"', '"AA:Patients with the AA genotype and depression who are treated with citalopram or antidepressants may be more likely to have improvement in symptoms as compared to patients with the GG genotype. However, no association has been reported in studies that determined response to different Selective serotonin reuptake inhibitors (SSRIs) or antidepressants as a drug class. Other genetic and clinical factors may also influence a patient''s response to antidepressants.,"AG:Patients with the AG genotype and depression who are treated with citalopram may be more likely to have improvement in symptoms as compared to patients with the GG genotype. However, no association has been reported in studies that determined response to different Selective serotonin reuptake inhibitors (SSRIs) or antidepressants as a drug class. Other genetic and clinical factors may also influence a patient''s response to antidepressants.","GG:Patients with the GG genotype and depression who are treated with citalopram may be less likely to have improvement in symptoms as compared to patients with the AA genotype. However, no association has been reported in studies that determined response to different Selective serotonin reuptake inhibitors (SSRIs) or antidepressants as a drug class. Other genetic and clinical factors may also influence a patient''s response to antidepressants."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (293, 'rs80282562', 'CFTR (PA109)', '1A', 'Efficacy', 'ivacaftor (PA165950341)', 'Pulmonology', 'Cystic Fibrosis (PA443829)', '"AA:Patients with the AA genotype (two copies of the CFTR G178R variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including G178R. Other genetic and clinical factors may also influence a patient''s response to ivacaftor. ,"AG:Patients with the AG genotype (one copy of the CFTR G178R variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including G178R. Other genetic and clinical factors may also influence a patient''s response to ivacaftor. ","GG:Patients with the GG genotype (do not have a copy of the CFTR G178R variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including G178R. Other genetic and clinical factors may also influence a patient''s response to ivacaftor."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (294, 'rs8050894', 'VKORC1 (PA133787052)', '2A', 'Dosage', 'warfarin (PA451906)', 'variant implication on Dosing', '', '"CC:Patients with the CC genotype who are treated with warfarin may require a higher dose as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patient''s required dose of warfarin.,"CG:Patients with the CG genotype who are treated with warfarin may require a lower dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient''s required dose of warfarin.","GG:Patients with the GG genotype who are treated with warfarin may require the lowest dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient''s required dose of warfarin."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (295, 'rs8099917', 'IFNL3 (PA134952671)', '1B', 'Efficacy', 'interferons (PA451999),"peginterferon alfa-2a (PA164749390)","peginterferon alfa-2b (PA164784024)","ribavirin (PA451241)"', 'Infectious Diseases', 'Hepatitis C, Chronic (PA446863)', '"GG:Patients with the GG genotype may have decreased response (lower SVR) to peginterferon alfa and ribavirin therapy in people with HCV genotype 1 as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient''s response to peginterferon alfa and ribavirin therapy. This association is significant in HCV genotype 1 patients, but may not be significant in HCV genotype 2, genotype 3 or genotype 5 patients. ,"GT:Patients with the GT genotype may have decreased response (lower SVR) to peginterferon alfa and ribavirin therapy in people with HCV genotype 1 as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient''s response to peginterferon alfa and ribavirin therapy. This association is significant in HCV genotype 1 patients, but may not be significant in HCV genotype 2, genotype 3 or genotype 5 patients. ","TT:Patients with the TT genotype may have increased response (higher SVR) to peginterferon alfa and ribavirin therapy in people with HCV genotype 1 as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence a patient''s response to peginterferon alfa and ribavirin therapy. This association is significant in HCV genotype 1 patients, but may not be significant in HCV genotype 2, genotype 3 or genotype 5 patients. "');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (296, 'rs8099917', 'IFNL3 (PA134952671)', '1B', 'Efficacy', 'peginterferon alfa-2a (PA164749390),"peginterferon alfa-2b (PA164784024)","ribavirin (PA451241)","telaprevir (PA165958354)"', 'Infectious Diseases', 'Hepatitis C, Chronic (PA446863)', '"GG:Patients with the GG genotype may have lower response rates (SVR) to triple therapy (telaprevir, peginterferon alfa-2a/b and ribavirin) in people with Hepatitis C genotype 1 as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient''s response to HCV triple therapy.,"GT:Patients with the GT genotype may have lower response rates (SVR) to triple therapy (telaprevir, peginterferon alfa-2a/b and ribavirin) in people with Hepatitis C genotype 1 as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient''s response to HCV triple therapy.","TT:Patients with the TT genotype may have higher response rates (SVR) to triple therapy (telaprevir, peginterferon alfa-2a/b and ribavirin) in people with Hepatitis C genotype 1 as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence a patient''s response to HCV triple therapy."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (298, 'rs8175347', 'UGT1A1 (PA420)', '1A', 'Toxicity/ADR', 'atazanavir (PA10251),"ritonavir (PA451260)"', 'Infectious Diseases', 'HIV (PA447230),"HIV Infections (PA446213)"', '"(TA)6/(TA)6:Patients with the (TA)6/(TA)6 (UGT1A1 *1/*1) genotype and HIV may have 1) a decreased likelihood for hyperbilirubinemia (up to jaundice range), 2) a decreased risk for treatment discontinuation when treated with atazanavir (in most studies boosted with low dose of ritonavir) as compared to patients with the (TA)7/(TA)7 (*28/*28) genotype. Other genetic and clinical factors may also influence a patient''s response to atazanavir.,"(TA)6/(TA)7:Patients with the (TA)6/(TA)7 (UGT1A1 *1/*28) genotype and HIV may have increased levels of bilirubin leading to an increased likelihood for hyperbilirubinemia when treated with atazanavir (in most studies boosted with low dose of ritonavir) as compared to patients with the (TA)6/(TA)6 (*1/*1). However, contradictory findings exist. Other genetic and clinical factors may also influence a patient''s response to atazanavir.","(TA)7/(TA)7:Patients with the (TA)7/(TA)7 (UGT1A1 *28/*28) genotype and HIV may have 1) increased levels of bilirubin leading to an increased likelihood for hyperbilirubinemia (up to jaundice range), 2) an increased risk for treatment discontinuation when treated with atazanavir (in most studies boosted with low dose of ritonavir) as compared to patients with the (TA)6/(TA)6 (*1/*1) genotype. Other genetic and clinical factors may also influence a patient''s response to atazanavir."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (299, 'rs8175347', 'UGT1A1 (PA420)', '2A', 'Other', 'SN-38 (PA165110775)', 'Oncology', 'Neoplasms (PA445062)', '"(TA)6/(TA)6:Patients with the (TA)6/(TA)6 genotype and cancer may have increased metabolism of SN-38 when treated with irinotecan as compared to patients with the (TA)6/(TA)7 or (TA)7/(TA)7 genotype. SN-38 is the active metabolite of irinotecan, and is glucuronidated by UGT1A1. One in vitro study found that patients with the (TA)6/(TA)6 genotype had increased UGT1A1 enzyme activity compared to those with the (TA)6/(TA)7 or (TA)7/(TA)7 genotype. Other genetic and clinical factors may also influence metabolism of SN-38.,"(TA)6/(TA)7:Patients with the (TA)6/(TA)7 genotype and cancer may have decreased metabolism of SN-38 when treated with irinotecan as compared to patients with the (TA)6/(TA)6 genotype, or increased metabolism compared to patients with the (TA)7/(TA)7 genotype. SN-38 is the active metabolite of irinotecan, and is glucuronidated by UGT1A1. One in vitro study found that livers with the (TA)6/(TA)7 genotype had decreased UGT1A1 enzyme activity compared to livers with the (TA)6/(TA)6 genotype, and increased activity compared to livers with the (TA)7/(TA)7 genotype. Other genetic and clinical factors may also influence metabolism of SN-38.","(TA)7/(TA)7:Patients with the (TA)7/(TA)7 genotype and cancer may have decreased metabolism of SN-38 when treated with irinotecan as compared to patients with the (TA)6/(TA)7 or (TA)6/(TA)6 genotype. SN-38 is the active metabolite of irinotecan, and is glucuronidated by UGT1A1. One in vitro study found that patients with the (TA)7/(TA)7 genotype had decreased UGT1A1 enzyme activity compared to those with the (TA)6/(TA)6 or (TA)6/(TA)7 genotype. Other genetic and clinical factors may also influence metabolism of SN-38."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (300, 'rs885004', 'SLC28A3 (PA426)', '2B', 'Toxicity/ADR', 'anthracyclines and related substances (PA130620651)', 'Oncology', 'Neoplasms (PA445062)', '"AA:Patients with the AA genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient''s response to anthracyclines and related substance.,"AG:Patients with the AG genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient''s response to anthracyclines and related substance.","GG:Patients with the GG genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient''s response to anthracyclines and related substance."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (301, 'rs887829', 'UGT1A1 (PA420)', '1A', 'Other', 'atazanavir (PA10251)', 'Infectious Diseases', 'HIV (PA447230)', '"CC:Patients infected with the human immunodeficiency virus (HIV) and the CC genotype who are treated with atazanavir may have a decreased, but not absent, risk of hyperbilirubinemia and bilirubin-related drug discontinuation as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient''s risk for hyperbilirubinemia, or drug discontinuation.,"CT:Patients infected with the human immunodeficiency virus (HIV) and the CT genotype who are treated with atazanavir may have a decreased, but not absent, risk of hyperbilirubinemia and bilirubin-related drug discontinuation as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient''s risk for hyperbilirubinemia, or drug discontinuation.","TT:Patients infected with the human immunodeficiency virus (HIV) and the TT genotype who are treated with atazanavir may have an increased risk of hyperbilirubinemia and bilirubin-related drug discontinuation as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence a patient''s risk for hyperbilirubinemia, or drug discontinuation."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (302, 'rs924607', '.', '2B', 'Toxicity/ADR', 'vincristine (PA451879)', 'Oncology', 'Precursor Cell Lymphoblastic Leukemia-Lymphoma (PA446155)', '"CC:Patients with the CC genotype may have decreased, but not absent, risk of peripheral nervous system diseases when treated with vincristine may have as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient''s response to vincristine.,"CT:Patients with the CT genotype may have decreased, but not absent, risk of peripheral nervous system diseases when treated with vincristine may have as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient''s response to vincristine.","TT:Patients with the TT genotype may have increased risk of peripheral nervous system diseases when treated with vincristine may have as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient''s response to vincristine."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (303, 'rs9923231', 'VKORC1 (PA133787052)', '1A', 'Dosage', 'warfarin (PA451906)', 'variant implication on Dosing', '', '"CC:Patients with the CC genotype may require an increased dose of warfarin as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient''s warfarin dose requirement.,"CT:Patients with the CT genotype may require a decreased dose of warfarin as compared to patients with the CC genotype or an increased dose as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient''s warfarin dose requirement.","TT:Patients with the TT genotype may require a decerased dose of warfarin as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient''s warfarin dose requirement."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (304, 'rs9923231', 'VKORC1 (PA133787052)', '1B', 'Dosage', 'acenocoumarol (PA452632),"phenprocoumon (PA450921)"', 'variant implication on Dosing', '', '"CC:Patients with the CC genotype who are treated with acenocoumarol or phenprocoumon may require a higher dose as compared to patients with the TT and CT genotypes, although some suggest that it may only require a higher dose as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient''s acenocoumarol or phenprocoumon dose.,"CT:Patients with the CT genotype who are treated with acenocoumarol or phenprocoumon may require a lower dose as compared to patients with the CC genotype, although some suggest that the CT genotype may also require a higher dose as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient''s acenocoumarol or phenprocoumon dose.","TT:Patients with the TT genotype who are treated with acenocoumarol or phenprocoumon may require a lower dose as compared to patients with the CC genotype, although some suggest that it may also require a lower dose as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient''s acenocoumarol or phenprocoumon dose."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (305, 'rs9923231', 'VKORC1 (PA133787052)', '2A', 'Toxicity/ADR', 'acenocoumarol (PA452632),"phenprocoumon (PA450921)","warfarin (PA451906)"', 'Cardiovascular', 'Atrial Fibrillation (PA443459),"Stroke (PA447054)","venous thromboembolism (PA447298)"', '"CC:Patients with the CC genotype who are treated with warfarin or acenocoumarol may have a decreased risk of Hemorrhage as compared to the CT or TT genotypes, however this is contradicted in nearly half the studies. Other clinical and genetic factors may also influence risk of hemorrhage in patients administered warfarin or acenocoumarol. ,"CT:Patients with the CT genotype who are treated with warfarin or acenocoumarol may have an increased risk of Hemorrhage as compared to the CC genotypes, however this is contradicted in nearly half the studies. Other clinical and genetic factors may also influence risk of hemorrhage in patients administered warfarin or acenocoumarol. ","TT:Patients with the TT genotype who are treated with warfarin or acenocoumarol may have an increased risk of Hemorrhage as compared to the CC genotypes, however this is contradicted in nearly half the studies. Other clinical and genetic factors may also influence risk of hemorrhage in patients administered warfarin or acenocoumarol. "');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (306, 'rs9923231', 'VKORC1 (PA133787052)', '2A', 'Efficacy', 'warfarin (PA451906)', 'Drug Response effects/ toxicity', '', '"CC:Patients with genotype CC may require longer time to therapeutic INR when treated with warfarin as compared with patients with genotype TT or CT. Other genetic and clinical factors may also influence the response to warfarin. ,"CT:Patients with genotype CT may require shorter time to therapeutic INR when treated with warfarin as compared with patients with genotype CC. Other genetic and clinical factors may also influence the response to warfarin. ","TT:Patients with genotype TT may require shorter time to therapeutic INR when treated with warfarin as compared with patients with genotype CC. Other genetic and clinical factors may also influence the response to warfarin. "');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (307, 'rs9923231', 'VKORC1 (PA133787052)', '2A', 'Toxicity/ADR', 'warfarin (PA451906)', 'Hematology', 'over-anticoagulation (PA166123298)', '"CC:Patients with the CC genotype may have decreased risk of over-anticoagulation when treated with warfarin as compared with patients with genotype TT or CT. Other genetic and clinical factors may also influence the toxicity to warfarin.,"CT:Patients with the CT genotype may have increased risk of over-anticoagulation when treated with warfarin as compared with patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to warfarin.","TT:Patients with the TT genotype may have increased risk of over-anticoagulation when treated with warfarin as compared with patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to warfarin."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (308, 'rs9934438', 'VKORC1 (PA133787052)', '1B', 'Dosage', 'warfarin (PA451906)', 'Cardiovascular', 'Arteriosclerosis (PA443425),"Heart Diseases (PA444368)","Hemorrhage (PA444417)","Intracranial Hemorrhages (PA446997)","Myocardial Infarction (PA445019)","Peripheral Vascular Diseases (PA153619833)","Pulmonary Embolism (PA445465)","Stroke (PA447054)","Thro', '"AA:Patients with the AA genotype who are treated with warfarin may require a lower dose as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient''s required dose of warfarin.,"AG:Patients with the AG genotype who are treated with warfarin may require a lower dose as compared to patients with the GG genotype, and a higher dose as compared to patients with the AA genotype. Other clinical and genetic factors may also influence a patient?s required dose of warfarin. ","GG:Patients with the GG genotype who are treated with warfarin may require higher dose as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient''s required dose of warfarin."');
INSERT INTO "PGx" ("id", "rsid", "gene", "evidence", "clinical_annotation_types", "related_chemicals", "drug_response_category", "related_diseases", "annotation_text") VALUES (309, 'rs9934438', 'VKORC1 (PA133787052)', '2A', 'Dosage', 'acenocoumarol (PA452632),"phenprocoumon (PA450921)"', 'variant implication on Dosing', '', '"AA:Patients with the AA genotype may have decreased dose of acenocoumarol or phenprocoumon as compared to patients with genotype GG. Other genetic and clinical factors may also influence the dose of acenocoumarol or phenprocoumon.,"AG:Patients with the AG genotype may have decreased dose of acenocoumarol or phenprocoumon as compared to patients with genotype GG. Other genetic and clinical factors may also influence the dose of acenocoumarol or phenprocoumon.","GG:Patients with the GG genotype may have increased dose of acenocoumarol or phenprocoumon as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the dose of acenocoumarol or phenprocoumon."');